SNDL (SNDL) 20-F 18 Mar 21 2020 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Registrant Name	Sundial Growers Inc.
Entity Central Index Key	0001766600
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding	918,844,133
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Shares
Trading Symbol	SNDL
Security Exchange Name	NASDAQ
Entity File Number	001-39005
Entity Address, State or Province	AB
Entity Address, Address Line One	#300, 919
Entity Address, Address Line Two	11 Avenue SW
Entity Address, City or Town	Calgary
Entity Address, Postal Zip Code	T2R 1P3
Entity Address, Country	CA
Document Annual Report	true
Document Transition Report	false
Document Registration Statement	false
Document Shell Company Report	false
ICFR Auditor Attestation Flag	false
Document Accounting Standard	International Financial Reporting Standards
Business Contact
Document Information [Line Items]
City Area Code	403
Local Phone Number	948-5227

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current Assets
Cash and cash equivalents	$ 60,376	$ 45,337
Restricted cash	5,333	15,827
Accounts receivable	15,898	27,638
Biological assets	3,531	14,309
Inventory	25,613	59,942
Prepaid expenses and deposits	4,622	9,564
Assets held for sale	2,998
Current assets	118,371	172,617
Non-current assets
Long-term deposits	2,633
Property, plant and equipment	116,928	281,984
Intangible assets	5,063	43,995
Investments	51,876
Goodwill		11,440
Total assets	294,871	510,036
Current liabilities
Accounts payable and accrued liabilities	23,308	58,110
Current portion of long-term debt		177,913
Current portion of lease obligations	409	722
Derivative warrant liabilities	428
Contingent consideration		32,501
Current liabilities	24,145	269,246
Non-current liabilities
Lease obligations	1,031	16,227
Deferred tax liability		3,365
Total liabilities	25,176	288,838
Shareholders’ equity
Share capital	762,046	509,654
Warrants	6,138	27,831
Contributed surplus	59,344	30,192
Contingent consideration	2,279	2,279
Accumulated deficit	(564,565)	(360,338)
Accumulated other comprehensive income		6,866
Total shareholders’ equity	265,242	216,484
Non-controlling interest	4,453	4,714
Total liabilities and shareholders’ equity	$ 294,871	$ 510,036

Consolidated Statements of Loss

Consolidated Statements of Loss and Comprehensive Loss - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Statement Of Comprehensive Income [Abstract]
Gross revenue		$ 73,321	$ 66,927
Excise taxes		12,403	3,365
Net revenue		60,918	63,562
Cost of sales		51,740	46,721
Inventory obsolescence		45,913
Gross margin before fair value adjustments		(36,735)	16,841
Change in fair value of biological assets	$ (1,280)	5,432	30,340
Change in fair value realized through inventory		(18,566)	(10,685)
Gross margin	(1,280)	(49,869)	36,496
General and administrative	8,309	32,029	38,934
Sales and marketing	2,380	5,737	8,068
Research and development	275	488	2,410
Pre-production expenses	6,457
Depreciation and amortization	920	4,711	595
Share-based compensation	7,410	8,566	38,698
Restructuring costs		6,470
Asset impairment	523	79,191	162
Government subsidies		(4,128)
Loss on cancellation of contracts		2,471
Loss from operations	(27,554)	(185,404)	(52,371)
Transaction costs		(3,587)	(8,481)
Finance costs	(1,797)	(16,814)	(24,216)
Foreign exchange loss	(141)	(1,000)	(939)
Loss on financial obligation	(27,017)		(60,308)
Gain (loss) on disposition of PP&E	(17)	488	8
Loss before income tax	(56,526)	(206,317)	(146,307)
Income tax recovery			3,609
Net loss from continuing operations	(56,526)	(206,317)	(142,698)
Net loss from discontinued operations		(33,627)	(128,931)
Net loss	(56,526)	(239,944)	(271,629)
Gain on translation of foreign operations		600	6,866
Comprehensive loss	(56,526)	(239,344)	(264,763)
Net loss from continuing operations attributable to:
Sundial Growers Inc.	(56,526)	(206,056)	(142,533)
Non-controlling interest		(261)	(165)
Net loss from continuing operations	(56,526)	(206,317)	(142,698)
Net loss attributable to:
Sundial Growers Inc.	(56,526)	(239,683)	(271,464)
Non-controlling interest		(261)	(165)
Net loss	(56,526)	(239,944)	(271,629)
Comprehensive loss attributable to:
Sundial Growers Inc.	(56,526)	(239,083)	(264,598)
Non-controlling interest		(261)	(165)
Comprehensive loss	$ (56,526)	$ (239,344)	$ (264,763)
Net loss per common share attributable to Sundial Growers Inc.
Basic and diluted	$ (0.82)	$ (1.10)	$ (3.17)

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Equity - CAD ($) $ in Thousands	Total	Share Capital	Warrants	Contributed Surplus	Convertible Notes-Equity Components	Contingent Consideration	Accumulated Deficit	Accumulated Other Comprehensive Loss	Non-controlling Interest
Beginning balance at Feb. 28, 2018	$ 13,710	$ 25,769		$ 4,551			$ (16,610)
Net loss	(56,526)						(56,526)
Share issuances	20,452	20,452
Shares issued to related parties	16,474	16,474
Share issuance costs	(310)	(310)
Share repurchase	(16,565)	(827)					(15,738)
Fair value allocated to warrants		(3,108)	$ 3,108
Warrants exercised	2,182	2,182
Share-based compensation	7,410	521		6,889
Employee warrants exercised	2,033	3,980		(1,947)
Equity component of convertible notes	3,232				$ 3,232
Ending balance at Dec. 31, 2018	(7,908)	65,133	3,108	9,493	3,232		(88,874)
Net loss	(271,629)						(271,464)		$ (165)
Other comprehensive income	6,866							$ 6,866
Share issuances	198,378	198,378
Shares issued to related parties	69,293	63,460	5,833
Share issuance costs	(12,770)	(12,770)
Business acquisitions	47,007	39,849				$ 2,279			4,879
Convertible debt - conversions	117,025	113,526	6,731		$ (3,232)
Warrants reclassified from liability	16,091		16,091
Warrants exercised	17,950	21,882	(3,932)
Share-based compensation	39,524	2,515		37,009
Employee warrants exercised	1,371	17,681		(16,310)
Ending balance at Dec. 31, 2019	221,198	509,654	27,831	30,192		2,279	(360,338)	6,866	4,714
Net loss	(239,944)						(239,683)		(261)
Other comprehensive income	600							600
Share issuances	176,931	176,931
Share issuance costs	(5,593)	(5,593)
Convertible debt - conversions	63,002	63,002
Derivative warrants exercised	55,912	55,912
Warrants issued	306		306
Warrants expired			(21,999)	21,999
Dispositions	(10,457)	(38,447)					35,456	$ (7,466)
Share-based compensation	7,740	52		7,688
Employee warrants exercised		535		(535)
Ending balance at Dec. 31, 2020	$ 269,695	$ 762,046	$ 6,138	$ 59,344		$ 2,279	$ (564,565)		$ 4,453

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Operating activities
Net loss from continuing operations for the period	$ (56,526)	$ (206,317)	$ (142,698)
Items not involving cash:
Income tax recovery			(3,609)
Change in fair value of biological assets	1,280	(5,432)	(30,340)
Share-based compensation	7,410	8,566	38,698
Depreciation and amortization	920	11,582	6,296
(Gain) loss on disposition of PP&E	17	(488)	(8)
Inventory obsolescence		45,913
Transaction costs			1,279
Finance costs	917	9,261	11,070
Loss on cancellation of contracts		671
Loss on financial obligation	18,485		60,308
Unrealized foreign exchange loss (gain)		(757)	671
Restructuring costs		448
Warrants issued for services		306
Asset impairment	523	79,191	162
Change in non-cash working capital	1,217	(5,259)	(41,626)
Net cash used in operating activities from continuing operations	(25,757)	(62,315)	(99,797)
Net cash provided by operating activities from discontinued operations		4,820	(12,939)
Net cash used in operating activities	(25,757)	(57,495)	(112,736)
Investing activities
Additions to property, plant and equipment	(76,321)	(3,024)	(110,271)
Additions to intangible assets		(150)
Proceeds from disposal of PP&E		2,109	51
Additions to long-term investments		(51,876)
Acquisition of Bridge Farm			(77,023)
Change in non-cash working capital	10,282	(11,319)	1,659
Net cash used in investing activities from continuing operations	(66,039)	(64,260)	(185,584)
Net cash used in investing activities from discontinued operations		(6,617)	(27,560)
Net cash used in investing activities	(66,039)	(70,877)	(213,144)
Financing activities
Proceeds from convertible notes, net of costs	27,764	18,070	90,373
Change in restricted cash		10,494	(15,477)
(Repayment) proceeds from Syndicated Credit Agreement, net of costs		(84,493)	82,687
Payments on lease obligations	(34)	(420)	(292)
Proceeds from issuance of shares, net of costs	36,616	181,841	177,202
Proceeds from Term Debt Facility, net of costs			105,539
(Repayment) proceeds from other debt instruments	40,705		(89,044)
Proceeds from exercise of derivative warrant liabilities		20,391
Proceeds from exercise of equity classified warrants	2,182		17,950
Proceeds from exercise of employee warrants	2,033		1,371
Settlement of convertible notes			(4,190)
Settlement of financial obligation			(9,500)
Repurchase of shares	(9,634)
Change in non-cash working capital	(1,393)	(2,498)	2,147
Net cash provided by financing activities from continuing operations	98,239	143,385	358,766
Net cash used in financing activities from discontinued operations		(639)	(499)
Net cash provided by financing activities	98,239	142,746	358,267
Effect of exchange rate changes on cash held in foreign currency		665	(1,472)
Impact of foreign currency translation from discontinued operations			301
Change in cash and cash equivalents	6,443	15,039	31,216
Cash and cash equivalents, beginning of period	7,678	45,337	14,121
Cash and cash equivalents, end of period	$ 14,121	$ 60,376	$ 45,337

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2020
Description Of Business [Abstract]
Description of Business	1. Sundial Growers Inc. (“Sundial” or the “Company”) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. The Company’s head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada. The principal activities of the Company are the production, distribution and sale of cannabis in Canada. The production, distribution and sale of cannabis was regulated by the Access to Cannabis for Medical Purposes Regulations (“ACMPR”) in Canada, up to and including October 16, 2018. On October 17, 2018, the ACMPR was superseded by the Cannabis Act which regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company’s common shares trade on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “SNDL”. Sundial does not engage in any U.S. cannabis-related activities as defined in Canadian Securities Administrators Staff Notice 51-352. COVID -19 The global impact of COVID-19 has resulted in significant declines in global stock markets and has contributed to a great deal of uncertainty as to the health of the global economy. The Company has implemented several new pandemic-related procedures and protocols at its facilities, including enhanced screening measures, enhanced cleaning and sanitation processes and frequency, encouraging social distancing measures and directing employees to work from home if possible. The Company believes that it can maintain safe operations with these pandemic-related procedures and protocols in place. The potential impact that COVID-19 will have on the Company’s business or financial results cannot be reasonably estimated at this time. However, any shutdowns requested or mandated by government authorities in response to the outbreak of COVID-19 that may affect the Company, its suppliers, distribution channels or customers may have a material impact to the Company’s planned operations.

Basis of Presentation

Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Disclosure Of Basis Of Presentation [Abstract]
Basis of Presentation	2. Basis of presentation a) Statement of compliance These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International Accounting Standards Board (“IASB”) and interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”) in effect as of December 31, 2020. During 2018, the Company changed its fiscal year end from February 28 to December 31 and accordingly a ten-month period ended December 31, 2018 is presented in these consolidated financial statements. The change in fiscal year was made to better align the Company’s reporting calendar with other publicly listed companies. These consolidated financial statements were approved and authorized for issue by the Board of Directors (“Board”) on March 17, 2021. b) Basis of measurement These consolidated financial statements have been prepared on a historical cost basis, except for biological assets, cannabis inventory and certain financial instruments which are measured at fair value with changes in fair value recorded in earnings. c) Functional and presentation currency These consolidated financial statements are presented in Canadian dollars, which is the functional and presentation currency of the Company and its Canadian based subsidiaries. Sundial Deutschland GmbH and Sundial Portugal, Unipessoal LDA use the European Euro as their functional currency. Transactions in currencies other than the functional currency are translated at the rate prevailing at the date of transaction. Monetary assets and liabilities that are denominated in foreign currencies are translated at the rate prevailing at each reporting date. Income and expense amounts are translated at the dates of the transactions. In preparing the Company’s consolidated financial statements, the financial statements of foreign subsidiaries are translated into Canadian dollars, the functional currency of the Company. The assets and liabilities of foreign subsidiaries that do not have a functional currency of Canadian dollars, are translated into Canadian dollars using exchange rates at the reporting date. Revenues and expenses of foreign operations are translated into Canadian dollars using foreign exchange rates that approximate those on the date of the underlying transactions. Foreign exchange differences from the translation of foreign subsidiaries into Canadian dollars are recognized in Other Comprehensive Income. d) Basis of consolidation Subsidiaries are entities controlled by the Company. Control exists when the Company has the power, directly and indirectly, to govern the financial and operating policies of an entity and be exposed to the variable returns from its activities. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. Subsidiaries Jurisdiction of incorporation Percentage ownership Sprout Technologies Inc. Alberta, Canada 100 % KamCan Products Inc. British Columbia, Canada 100 % 2011296 Alberta Inc. Alberta, Canada 100 % Sundial Deutschland GmbH Germany 100 % Sundial Portugal, Unipessoal LDA Portugal 100 % Pathway Rx Inc. Alberta, Canada 50 % 2657408 Ontario Inc. Ontario, Canada 100 % NGBA-BC Holdings Ltd. British Columbia, Canada 100 %

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Disclosure Of Significant Accounting Policies [Abstract]
Significant Accounting Policies	3. Significant accounting policies The accounting policies set out below have been applied consistently to all periods presented in these consolidated financial statements. Cash and cash equivalents Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days. Restricted cash and cash equivalents Restricted cash is recorded as current assets representing the minimum balance required in accordance with the Syndicated Credit Agreement for interest coverage and funds held in trust by the Town of Olds, Alberta in accordance with municipal regulations related to the granting of a building permit. Biological assets The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour related costs, grow consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less cost to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with IAS 41 and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. Our method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices and several uncontrollable factors, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods. Inventory Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less cost to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labor related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Inventories for resale and cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value. The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. Property, plant, and equipment Property, plant and equipment are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of property, plant and equipment with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of property and equipment is capitalized, the carrying amount of the replaced component is derecognized. Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s license is granted. The assets’ residual values and useful lives are reviewed, and adjusted as appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates. Any gain or loss arising on the disposal or retirement of a component of property and equipment is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in the consolidated statements of loss and comprehensive loss. Property, plant and equipment are depreciated as they become available for use. Buildings are not depreciated until a producer’s license is obtained. For assets available for use, depreciation is computed using the straight-line method over the estimated useful life of the assets, as described below: Land n/a Production facilities 20 years Equipment 2 to 10 years Right-of-use assets Shorter of estimated useful life or lease term Construction in progress n/a Intangible assets Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with IAS 38. The Company’s intangible assets at December 31, 2020 are comprised of the following: • Intellectual property purchased from Sun 8 Holdings Inc. consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years. • Intellectual property acquired through the acquisition of Pathway RX Inc. consisting of proprietary rights to certain technology, copyrights and trademarks with a useful life of 20 years. Impairment of assets Management assesses and continually monitors internal and external indicators of impairment relating to our assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining future licenses from Health Canada, the demand for cannabis for medical and recreational purposes, the price of cannabis, and changes in market discount rates. (i) Financial assets We apply an expected credit loss, or ECL, model to all debt financial assets not held at fair value through profit and loss, or “FVTPL”, where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, we have applied the simplified approach under IFRS 9 and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECL’s are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow we expect to receive. ECL’s are discounted at the effective interest rate of the financial asset. (ii) Non-financial assets The carrying amounts of our property, plant and equipment and intangible assets, including goodwill, are assessed for impairment indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of assets estimated fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit, or CGU). Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset (or CGU) is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized for the asset (or CGU) previously. A reversal of an impairment loss is recognized immediately in the statements of loss and comprehensive loss. Financial instruments The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments: Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance. (i) Financial assets At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or Fair Value Through Other Comprehensive Income depending on the business model and contractual cash flows of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in earnings or loss. The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s long-term investment is measured at FVTPL. The Company has no financial assets measured at Fair Value Through Other Comprehensive Income. (ii) Financial liabilities Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method. Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in earnings or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt. The Company’s accounts payable and accrued liabilities and long-term debt are measured at amortized cost. The Company’s convertible notes were designated as FVTPL upon initial recognition as the notes contained multiple embedded derivatives. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition. The Company’s contingent consideration was designated as FVTPL. Non-monetary transactions All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value. Compound financial instruments The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. The Company’s compound financial instruments are comprised of convertible notes. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition. Interest and losses and gains relating to the financial liability are recognized in the consolidated statements of loss and comprehensive loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion. Revenue Under IFRS 15, to determine the amount and timing of revenue to be recognized, we follow a five-step model: 1. Identifying the contract with a customer 2. Identifying the performance obligations 3. Determining the transaction price 4. Allocating the transaction price to the performance obligations 5. Recognizing revenue when/as performance obligations are satisfied Gross revenue from the direct sale of cannabis for a fixed price is recognized when we transfer control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods. For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly. Gross revenue earned in Canada includes excise taxes, which we pay as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and certain promotional activities and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing. Research and development Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization of IAS 38 “Intangible Assets”. Research and development costs comprise consulting fees and license acquisition fees. No development costs have been capitalized as at December 31, 2020 or December 31, 2019. Share-based compensation The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted. Share-based compensation expense includes the expense for the issue of simple and performance warrants, stock options, restricted share units and deferred share units to employees, directors, and others at the discretion of our board of directors. Given the absence of an active trading market for the Company’s common shares prior to its initial public offering, determining the fair value of the Company’s common shares required our board of directors to make complex and subjective judgments. Our board of directors, with input from management, exercised significant judgment and considered numerous objective and subjective factors to determine the fair value of the Company’s common shares as of the date of each grant. For periods prior to January 1, 2019, the fair value of share-based compensation expense was primarily estimated using the value of the equity or convertible security issued to third parties for cash within a reasonable period of time of the grant to the employee. Subsequent to January 1, 2019, the fair value of share-based compensation expenses was estimated using the value of the equity or convertible security issued to third parties for cash within a reasonable period of time of the grant to the employee, as well as, other factors, including: the Company’s stage of development; the impact of significant corporate events, operational changes or milestones; material risks related to the business; the Company’s financial condition and operating results, including its revenue, history of net losses and levels of available capital resources; equity market conditions affecting comparable public companies; general U.S. market conditions; the likelihood and potential timing of achieving a liquidity event or completing an offering of common shares, such as an initial public offering; and the instruments involved illiquid securities of a private company. Subsequent to the Company’s IPO on August 6, 2019, the fair value of the Company’s shares is based on public trading data. Income taxes Income taxes are recognized in the consolidated statements of loss and comprehensive loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity. Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and includes any adjustment to income tax payable or recoverable in respect of previous periods. Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable. Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities, and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted by the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income (loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each consolidated statements of financial position date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized. Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously. Business combinations Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as cash paid and the fair value of assets given, equity instruments issued and liabilities incurred or assumed at the acquisition date. Any excess of the cost of acquisition over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net income. Transactions costs associated with business combinations are expensed as incurred. Goodwill The Company records goodwill relating to a business combination when the purchase price exceeds the fair value of the net identifiable assets and liabilities of the acquired business. The goodwill balance is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in net income. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed. Non-controlling interests The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis. leases A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease obligation at the lease commencement date. The right-of-use asset is initially measured at cost, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease obligation. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease obligation is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease obligation is subsequently increased by the interest cost on the lease obligation and decreased by lease payments made. Lease payments are allocated between the liability and interest expense. Interest expense is recognized on the lease obligation using the effective interest rate method and payments are applied against the lease obligation. The carrying amounts of the right-of-use assets, lease obligations, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgments including economic environment, term, and the underlying risk inherent to the asset. GOVERNMENT GRANTS Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred. New accounting standards The following accounting standards were effective for annual periods beginning on or after January 1, 2020 and did not have a material impact on the Company’s consolidated financial statements: • Interest Rate Benchmark Reform (Amendments to IFRS 9, IAS 39 and IFRS 7) There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2021 that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2020. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include: • Onerous contracts – Cost of Fulfilling a Contract (Amendments to IAS 37). • Interest Rate Benchmark Reform – Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16). • COVID-19 Related Rent Concessions (Amendments to IFRS 16).

Significant Accounting Estimate

Significant Accounting Estimates, Assumptions and Judgements	12 Months Ended
	Dec. 31, 2020
Disclosure Of Initial Application Of Standards Or Interpretations [Abstract]
Significant accounting estimates, assumptions and judgements	4. Significant accounting estimates, assumptions and judgements The preparation of these consolidated financial statements in accordance with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Judgement is used mainly in determining whether a balance or transaction should be recognized in the consolidated financial statements. Estimates and assumptions are mostly used in determining the measurement of recognized transactions and balances. However, judgements and estimates are often interrelated. Judgements, estimates and assumptions are continually evaluated and are based on factors including expectations of future events that are believed to be reasonable under the circumstances. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in future periods affected. Judgements, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment include the following: Impairments CGU’s are defined as the lowest grouping on integrated assets that generate identifiable cash inflows that are largely independent of the cash inflows of other assets or groups of assets. The classification of assets into CGU’s requires significant judgement and interpretations with respect to the integration between assets, the existence of active markets, external users, shared infrastructures and the way in which management monitors the Company’s operations. The recoverable amounts of CGU’s and individual assets have been determined as the higher of the CGU’s or the asset’s fair value less costs of disposal and its value in use. These calculations require the use of estimates and assumptions and are subject to changes as new information becomes available including information on the likelihood of obtaining future licenses from Health Canada, demand for cannabis for recreational and medical purposes, future selling prices, expected sales volumes, discount rates and future development and operating costs. Changes in assumptions used in determining the recoverable amount could affect the carrying value of the related assets and CGU’s. Biological assets and inventory Biological assets, comprising cannabis plants and agricultural product consisting of cannabis, are measured at fair value less costs to produce and sell up to the point of harvest. Determination of the fair values of the biological assets and the agricultural product requires the Company to make assumptions about how market participants assign fair values to these assets. These assumptions primarily relate to the level of effort required to bring the cannabis up to the point of harvest, costs to convert the harvested cannabis to finished goods, sales price, risk of loss, expected future yields from the cannabis plants and estimating values during the growth cycle. The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and thus any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory. The Company must also determine if the carrying value of any inventory exceeds its net realizable value, such as cases where prices have decreased, or inventory has spoiled or has otherwise been damaged. Revenue Government customers typically have a right of product return, and in some cases, the right to pricing adjustments for products that are subsequently discounted or sold for a lower price in another jurisdiction. Licensed Producers can, in some cases, have a right of product return or warranty period. The estimate of potential future returns and pricing adjustments includes the use of estimates and assumptions and are subject to change as new information becomes available. Deferred tax assets Deferred tax assets, including those arising from tax loss carry-forwards, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management’s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be affected. Share-based compensation The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the warrant, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of warrants granted. Convertible instruments Convertible notes are compound financial instruments which are accounted for separately by their components: a financial liability and an equity instrument. The financial liability, which represents the obligation to pay coupon interest on the convertible notes in the future, is initially measured at its fair value and subsequently measured at amortized cost. The residual amount is accounted for as an equity instrument at issuance. The identification of the components of convertible notes is based on interpretations of the substance of the contractual arrangement and therefore requires judgement from management. The separation of the components affects the initial recognition of the convertible debenture at issuance and the subsequent recognition of interest on the liability component. The determination of the fair value of the liability is also based on various assumptions, including contractual future cash flows, discount rates and the presence of any derivative financial instruments. The Secured Convertible Note and Unsecured Convertible Notes are financial liabilities measured at FVTPL. The determination of the fair value of the liabilities are estimated based on various assumptions, including future share price, volatility, discount rate and various probability factors. The derivative warrant liabilities are financial liabilities measured at FVTPL. The determination of the fair value of the liabilities are estimated based on various assumptions, including future share price, volatility, discount rate and various probability factors. Financial obligations The financial obligation arising pursuant to a royalty agreement, required management to make assumptions and use judgement in determining the generation of future revenues and an appropriate discount rate. Acquisitions The Company assesses whether an acquisition should be accounted for as an asset acquisition or a business combination under IFRS 3. This assessment requires management to make judgements on whether the assets acquired and liabilities assumed constitute a business as defined in IFRS 3 and if the integrated set of activities, including inputs and processes acquired, is capable of being conducted and managed as a business and the Company obtains control of the business inputs and processes. Fair value of assets acquired and liabilities assumed in a business combination The fair value of assets acquired and liabilities assumed in a business combination, including contingent consideration and goodwill, is estimated based on information available at the date of acquisition. Various valuation techniques are applied for measuring fair value including market comparables and discounted cash flows which rely on assumptions such as future selling prices, expected sales volumes, discount rates and future development and operating costs. Changes in these variables could significantly impact the carrying value of the net assets. Specific judgement is required in the identification of intangible assets.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2020
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Abstract]
Discontinued Operations	5. Discontinued operations On February 22, 2019, the Company, through its wholly owned subsidiary, Sundial UK Limited, signed a Sale and Purchase Agreement to acquire all the issued and outstanding shares of Project Seed Topco (“Bridge Farm”). The acquisition closed on July 2, 2019 (note 6). Bridge Farm was acquired to expand the Company’s business to cannabidiol (“CBD”) extraction and production, subject to certain regulatory, licensing and other restrictions, to launch CBD sales in the United Kingdom. At December 31, 2019, the Company recorded a goodwill impairment based on significant delays and uncertainties in the licensing and regulatory framework in the United Kingdom. As part of the negotiations with the Company’s senior lenders regarding a December 31, 2019 covenant breach and restructuring of its credit agreements, the Company was required to enter into a definitive sale and purchase agreement related to the sale of Bridge Farm. On May 15, 2020, the Company entered into an agreement to sell all of the outstanding shares of Bridge Farm to a company affiliated with the former management sellers that were parties to the original acquisition (the “Bridge Farm Purchaser”) in exchange for (i) the assumption by the Bridge Farm Purchaser of $45 million of the total $115 million principal amount outstanding under the Term Debt Facility (thereby reducing the Company’s obligations thereunder to $70 million), (ii) the assumption by the Bridge Farm Purchaser of contingent consideration liabilities related to the additional share obligation and remaining earn out obligation under the original Bridge Farm acquisition agreement dated July 2, 2019 (note 19), and (iii) the cancellation of approximately 2.7 million Sundial common shares (fair value of $3.0 million), representing all of the shares then held by the management sellers of Bridge Farm issued in connection with the original acquisition of Bridge Farm by the Company in 2019 (collectively, the “Bridge Farm Disposition”). The sale of Bridge Farm closed on June 5, 2020. The Bridge Farm operations comprised the Company’s entire Ornamental Flower segment located in the United Kingdom. The Ornamental Flower segment was not previously classified as held-for-sale or as a discontinued operation as it was not highly probable that the carrying amount of the disposal group would be recovered through a sale transaction rather than through continuing use. The comparative statement of loss and comprehensive loss and statement of cash flows has been re-presented to show the discontinued operation separately from continuing operations. With the disposition of the Ornamental Flower segment, the Company no longer has multiple segments. Accordingly, the Cannabis operations in Canada comprise the entire operations of the Company. Results of discontinued operations Year ended December 31 2020 (2) 2019 (1) Gross revenue 22,139 12,298 Net revenue 22,139 12,298 Cost of sales 15,633 9,426 Gross margin before fair value adjustments 6,506 2,872 Change in fair value of biological assets 1,064 386 Change in fair value realized through inventory (1,122 ) — Gross margin 6,448 3,258 General and administrative 8,585 5,515 Sales and marketing 1,418 820 Depreciation and amortization 2,752 3,482 Foreign exchange 1,057 (1,779 ) Share-based compensation (826 ) 826 Goodwill impairment — 100,305 Loss from operations (6,538 ) (105,911 ) Transaction costs — (1,588 ) Finance costs (10,083 ) (3,982 ) Loss on contingent consideration (2,252 ) (18,645 ) Gain on investment — 165 Gain (loss) on disposition of PP&E — 13 Loss on disposition of Bridge Farm (14,979 ) — Loss before income tax (33,852 ) (129,948 ) Income tax recovery 225 1,017 Net loss (3) (33,627 ) (128,931 ) (1) Period July 2, 2019 to December 31, 2019 (2) Period January 1, 2020 to June 5, 2020 (3) Net loss from the discontinued operations is attributable entirely to the owners of the Company. Effect of disposal on the financial position of the Company Cash and cash equivalents 2,963 Accounts receivable 15,641 Biological assets 2,831 Inventory 787 Property, plant and equipment 88,698 Goodwill 11,345 Intangible assets 23,884 Accounts payable and accrued liabilities (22,792 ) Lease obligation (14,894 ) Deferred tax liability (3,115 ) Accumulated other comprehensive income (7,466 ) Net assets and liabilities 97,882 Consideration received Term Debt Facility 45,000 Contingent consideration liability 34,912 Cancellation of common shares 2,991 Total consideration 82,903 Loss on disposition (14,979 )

Business Acquisitions

Business Acquisitions	12 Months Ended
	Dec. 31, 2020
Disclosure Of Business Combinations [Abstract]
Business Acquisitions	6 . Business acquisitions (a) Acquisition of Bridge Farm On February 22, 2019, the Company, through its wholly owned subsidiary, Sundial UK Limited, signed a Sale and Purchase Agreement to acquire all the issued and outstanding shares of Bridge Farm a private company located in the United Kingdom of Great Britain and Northern Ireland (“UK”). Bridge Farm was acquired to expand the Company’s business to CBD extraction and production, subject to certain regulatory, licensing and other restrictions, to launch CBD sales in the UK. The acquisition closed on July 2, 2019. The acquisition consideration was comprised of: (i) Cash consideration in the amount of $77.0 million (£45.0 million); (ii) The issuance of 2.4 million common shares valued at $37.2 million based on the fair value of a common share of the Company on the closing date and contingent consideration of $8.4 million representing the value of incremental shares potentially issuable on the one year anniversary of the closing date; and (iii) Contingent consideration valued at $7.2 million representing the fair value of earn-out payments ranging from nil to a maximum of an additional 1.6 million common shares of the Company based on a prescribed formula based on future earnings. The Company engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts. The fair value of the assets and liabilities acquired was as follows: December 31, 2019 Cash 77,023 Issuance of common shares 37,248 Contingent consideration 15,991 130,262 The purchase price was allocated as follows: December 31, 2019 Accounts receivable 7,403 Inventory 470 Biological assets 1,288 Property, plant and equipment 58,368 Intangible assets 25,471 Accounts payable (14,293 ) Long term debt (33,618 ) Lease obligations (15,179 ) Deferred income tax liability (4,355 ) Goodwill 104,707 130,262 The Company recorded adjustments to the fair value in the fourth quarter of 2019 to reflect facts and circumstances in existence at the date of the acquisition. These adjustments primarily related to changes in preliminary valuation assumptions, including refinement of biological assets, intangible assets and deferred income tax liability based on new information that became available that existed at the date of the acquisition. All measurement period adjustments were offset to goodwill. On October 10, 2019, the earn-out payment terms whereby the sellers would be entitled to earn from nil to a maximum of an additional 1.6 million common shares based on a prescribed formula based on future earnings were replaced with the following terms: Common shares of 320,000 earned upon the commissioning of the woodfired boilers at Lay Lake Phase 2 with confirmation that grant funding would be secured; Common shares of 320,000 earned upon completion of the Clay Lake Phase 2 facility before March 30, 2020; Common shares of 320,000 earned upon completing a budget for Clay Lake Phase 3; Common shares of 320,000 earned upon the acquisition of the minority interest in Zyon Plants and Flowers Limited; Common shares of 320,000 earned upon the passage of 18 months from the amendment date During the year ended December 31, 2019, the fair value of the incremental share portion of the contingent consideration was adjusted to $27.5 million and the fair value of the earn out portion was adjusted to $5.0 million. These adjustments resulted in a loss on contingent consideration of $18.6 million. (a) Acquisition of Pathway Rx On March 13, 2019, the Company acquired 50% of the issued and outstanding shares of Pathway RX Inc. (“Pathway”), which was a private company. Pathway was acquired to develop cannabis-based pharmaceutical drugs to treat symptoms associated with a wide range of medical conditions. The purchase price was as follows: Issuance of common shares 2,601 Contingent consideration ( i ) 2,279 4,880 (i) Contingent consideration valued at $2.3 million representing the granting of up to 280,000 warrants to purchase common shares of the Company at an exercise price of $1.81 per share, subject to the achievement of certain milestone gross revenue derived from the Pathway Royalty Activities, which has been presented on the consolidated statement of financial position as contingent consideration in the form of equity. The purchase price was allocated as follows: December 31, 2019 Intangible assets 13,552 Accounts payable and accrued liabilities ) (184 ) Deferred tax liability (3,609 ) Non-controlling interest (50%) (4,879 ) 4,880 The shares in Pathway were acquired by issuance of 296,800 common shares of the Company at a price of $8.76 per common share to the acquired company’s existing shareholders. In conjunction with the acquisition, the Company entered into a license agreement that provides for use of Pathway’s intellectual property in exchange for: (iv) A royalty of 3% of gross revenues derived from activities which use the intellectual property that is the subject matter of the license agreement (“Pathway Royalty Activities”), which royalty percentage is increased to 5% of gross revenues derived from Pathway Royalty Activities upon the achievement of certain gross revenue milestones in one calendar year; (v) 50% of net revenues received from the Company from the sale of certain of the licensed products or the use of certain licensed intellectual property; and (vi) A fixed payment of $1.4 million, payable in quarterly installments of $87,500 over the first four years of the term of the agreement. Pathway consisted solely of intellectual property comprising the identifiable net assets of the entity. The non-controlling interest recognized at the acquisition date was recorded at their proportionate 50% share of the fair value of the identifiable net assets. Subsequent to recording the purchase price allocation, the deferred tax liability was adjusted to nil with the offsetting adjustment to income tax recovery on the basis that both the Company and the acquired private company are subject to income tax under the same taxation authority. The Company recorded adjustments to the preliminary fair value to reflect facts and circumstances in existence as of the date of acquisition. These adjustments primarily related to accounts payable and accrued liabilities based on new information available that existed at the date of acquisition. These measurement adjustments were offset to the fair value of intangible assets.

Accounts Receivable

Accounts Receivable	12 Months Ended
	Dec. 31, 2020
Subclassifications Of Assets Liabilities And Equities [Abstract]
Accounts Receivable	7. Accounts receivable As at December 31, 2020 December 31, 2019 Trade receivables 15,786 24,684 Other receivables 112 2,954 15,898 27,638 The Company has calculated expected credit losses (“ECLs”) based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. The Company has evaluated the potential impact of COVID-19 on the collection of its trade receivables and concluded that it does not currently have a material impact. Refer to note 30 for credit risk disclosures.

Biological Assets

Biological Assets	12 Months Ended
	Dec. 31, 2020
Disclosure Of Reconciliation Of Changes In Biological Assets [Abstract]
Biological Assets	8. Biological assets The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets are as follows: As at December 31, 2020 December 31, 2019 Balance, beginning of year 14,309 876 Increase in biological assets due to capitalized costs 39,957 62,331 Net change in fair value of biological assets 6,496 30,726 Transferred to inventory upon harvest (54,388 ) (80,991 ) Acquisitions — 1,288 Disposition of Bridge Farm (note 5) (2,831 ) — Foreign currency translation (12 ) 79 Balance, end of year 3,531 14,309 Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company’s method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows: Assumption Input Weighted average input Effect of 10% change ($000s) December 31 2020 December 31 2019 December 31 2020 December 31 2019 Yield per square foot of growing space (1) Grams 45 47 347 1,183 Average net selling price (2) $/gram 5.13 5.47 1,022 3,021 After harvest cost to complete and sell $/gram 1.32 2.34 291 267 (1) Varies by strain; obtained through historical growing results or grower estimate if historical results are not available. (2) Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available. These estimates are subject to volatility in market prices and several uncontrollable factors, which could significantly affect the fair value of biological assets in future periods. The Company estimates the harvest yields for cannabis at various stages of growth. As at December 31, 2020, it is estimated that the Company’s biological assets will yield approximately 5,507 kilograms (December 31, 2019 - 10,455 kilograms) of dry cannabis when harvested. During the year ended December 31, 2020 the Company harvested 27,972 kilograms of dry cannabis (year ended December 31, 2019 – 34,012 kilograms). The Company’s estimates are, by their nature, subject to change and differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2020
Classes Of Inventories [Abstract]
Inventory	9. Inventory As at December 31, 2020 December 31, 2019 Harvested cannabis 20,358 50,403 Cannabis supplies and consumables 5,255 8,808 Ornamental flowers, supplies and consumables (note 5) — 731 25,613 59,942 At December 31, 2020, the Company held 10,335 kilograms of harvested cannabis (December 31, 2019 – 8,380 kilograms) in inventory. During the year ended December 31, 2020, inventories of $51.7 million were recognized as an expense (year ended December 31, 2019 - $46.7 million). The Company recognized inventory write downs of $56.9 million, of which $45.9 million was recognized as an excess and obsolete inventory provision, and $11.0 million was included in the change in fair value realized through inventory as the fair value component of the excess and obsolete inventory provision.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Property, Plant and Equipment	10. Property, plant and equipment Land and buildings Production facilities Equipment Right of use assets Construction in progress (“CIP”) Total Cost Balance at December 31, 2018 5,246 23,336 7,254 — 54,061 89,897 Adoption of IFRS 16 — — (327 ) 1,333 — 1,006 Acquisitions 15,860 21,294 247 14,648 6,360 58,409 Additions 1,517 283 3,393 687 134,183 140,063 Transfers from CIP 3,406 120,724 13,603 — (137,733 ) — Dispositions (31 ) — (159 ) (700 ) — (890 ) Foreign currency translation 608 805 10 541 1,160 3,124 Balance at December 31, 2019 26,606 166,442 24,021 16,509 58,031 291,609 Additions 8 213 2,886 763 4,319 8,189 Transfers from CIP 509 8,212 2,287 — (11,008 ) — Reclassification to assets held for sale (1,547 ) — — — (1,451 ) (2,998 ) Dispositions (499 ) (162 ) (50 ) (825 ) (991 ) (2,527 ) Disposition of Bridge Farm (note 5) (16,300 ) (21,587 ) (249 ) (14,431 ) (39,734 ) (92,301 ) Foreign currency translation (137 ) (181 ) (1 ) (122 ) (347 ) (788 ) Balance at December 31, 2020 8,640 152,937 28,894 1,894 8,819 201,184 Accumulated amortization and impairment Balance at December 31, 2018 — 312 1,094 — — 1,406 Adoption of IFRS 16 — — (100 ) — — (100 ) Depreciation 3 5,026 2,833 610 — 8,472 Impairment — — — — 162 162 Dispositions — — (130 ) (248 ) — (378 ) Foreign currency translation — 62 — 1 — 63 Balance at December 31, 2019 3 5,400 3,697 363 162 9,625 Depreciation 475 6,249 4,847 638 — 12,209 Impairment — 60,658 — — 5,659 66,317 Dispositions — (37 ) (44 ) (176 ) — (257 ) Disposition of Bridge Farm (note 5) (473 ) (2,879 ) — (251 ) — (3,603 ) Foreign currency translation (5 ) (27 ) — (3 ) — (35 ) Balance at December 31, 2020 — 69,364 8,500 571 5,821 84,256 Net book value Balance at December 31, 2019 26,603 161,042 20,324 16,146 57,869 281,984 Balance at December 31, 2020 8,640 83,573 20,394 1,323 2,998 116,928 During the year ended December 31, 2020, no salaries and benefits were capitalized. During the year ended December 31, 2019 – $0.6 million in salaries and benefits was capitalized, including $0.6 million associated with construction in progress. In addition, no interest associated with construction in progress was capitalized during the year ended December 31, 2020 (year ended December 31, 2019 – $1.3 million). Construction in progress relates to the construction of production facilities and related infrastructure. During the year ended December 31, 2020, depreciation expense of $6.9 million was capitalized to biological assets and inventory (year ended December 31, 2019 - $5.7 million). During the year ended December 31, 2020, the Company signed a purchase and sale agreement to sell certain non-core assets, consisting of land, building and equipment, located in Kamloops, British Columbia, for gross cash proceeds of $2.1 million. The sale closed on March 27, 2020. During the year ended December 31, 2020, the Company determined that indicators of impairment existed with respect to the Company’s B.C. cash generating unit (“CGU”) as a result of the Company’s disposition of its Kamloops property and decision to suspend further construction and development activities on its Merritt facility due to market conditions and available financing. Approximately $10.0 million had been invested into the Merritt facility which consisted of land and construction in progress. A test for impairment was performed at the CGU level by comparing the estimated recoverable amount to the carrying values of the assets. The estimated recoverable amount of the assets was determined to be their fair value less costs of disposal and an impairment of $5.7 million was recorded to write down the assets to their recoverable amount of $4.2 million. The fair value measurement is categorized within Level 3 of the fair value hierarchy. The recoverable amount of these assets was further reduced to $2.9 million due to the Company receiving utility deposits back resulting from the deferral of the facility. Management is committed to a plan to sell the Merritt facility and the asset is available for immediate sale, resulting in the reclassification to assets held for sale on the consolidated statement of financial position. During the three months ended September 30, 2020, the Company determined that indicators of impairment existed due to decreasing estimates for the size of the potential Canadian cannabis market, the Company curtailing the number of flowering rooms being used for cultivation at its Olds facility and the carrying amount of the Company’s total net assets significantly exceeded the Company’s market capitalization. The impairment test for the Company’s Alberta CGU used a value in use approach based on internal cash flow estimates and a discount rate of 25%. The discount rate was estimated based on the Company’s weighted average cost of capital, adjusted for risks specific to the CGU. The estimated cash flows were based on a 5-year model taking into account forecasted Canadian cannabis industry activity market size and Sundial’s forecasted market share. A terminal value thereafter was applied. Based on the analysis, the Company determined there was an impairment of the Company’s Alberta CGU of $60.0 million for the three months ended September 30, 2020 (2019 - nil), as the estimated recoverable amount for this CGU was lower than the respective carrying amount. The estimated value in use for the Company’s Alberta CGU was sensitive to an increase in the discount rate. An increase to the discount rate by 1% would increase impairment by approximately $9.2 million. At December 31, 2020, the Company determined that no indicators of impairment existed and no impairment test was required. On December 28, 2020, the Company announced a concentrates licensing agreement based out of its Rocky View facility. Within the agreement is a non-binding purchase agreement to sell the Rocky View facility for $5.0 million. The estimated recoverable amount of the Rocky View facility was determined to be its fair value less costs of disposal and an impairment of $0.7 million was recorded to write down the assets to their recoverable amount of $5.0 million. The fair value measurement is categorized within Level 3 of the fair value hierarchy.

Intangible assets

Intangible assets	12 Months Ended
	Dec. 31, 2020
Disclosure Of Intangible Assets [Abstract]
Intangible Assets	11. Intangible assets Brands and trademarks Patents Customer relationships Other Total Cost Balance at December 31, 2018 — — — — — Additions 5,295 — — — 5,295 Acquisitions 2,977 13,551 18,855 3,639 39,022 Foreign currency translation 114 — 723 139 976 Balance at December 31, 2019 8,386 13,551 19,578 3,778 45,293 Additions 150 — — — 150 Disposition of Bridge Farm (note 5) (3,066 ) — (19,415 ) (3,747 ) (26,228 ) Foreign currency translation (25 ) — (163 ) (31 ) (219 ) Balance at December 31, 2020 5,445 13,551 — — 18,996 Accumulated amortization Balance at December 31, 2018 — — — — — Depreciation 132 — 982 192 1,306 Foreign currency translation (1 ) — (6 ) (1 ) (8 ) Balance at December 31, 2019 131 — 976 191 1,298 Depreciation 441 677 842 165 2,125 Impairment — 12,874 — — 12,874 Disposition of Bridge Farm (note 5) (190 ) — (1,801 ) (353 ) (2,344 ) Foreign currency translation — — (17 ) (3 ) (20 ) Balance at December 31, 2020 382 13,551 — — 13,933 Net book value Balance at December 31, 2019 8,255 13,551 18,602 3,587 43,995 Balance at December 31, 2020 5,063 — — — 5,063 Brands and trademarks consist of intellectual property purchased from Sun 8 Holdings Inc. with a useful life of 15 years and other intellectual property with a useful life of 12 years. Patents consisted of intellectual property acquired through the acquisition of Pathway Rx Inc. which consisted of proprietary rights to certain technology, copyrights and trademarks with a useful life of 20 years. During the year ended December 31, 2020, the Company determined that indicators of impairment existed regarding the Pathway intellectual property due to the Company’s decision to reduce its focus on medical cannabis research. The estimated recoverable amount of the intangible assets was determined to be their fair value less costs of disposal and an impairment of $12.9 million was recorded to write down the assets to their recoverable amount of nil. Brands and trademarks consisting of intellectual property acquired as part of the Bridge Farm acquisition, customer relationships and other intangible assets consisting of non-compete clauses and energy credits were disposed of as part of the sale of Bridge Farm (note 5).

Investments

Investments	12 Months Ended
	Dec. 31, 2020
Disclosure Of Investments [Abstract]
Investments	12. Investments On December 30, 2020, the Company closed the acquisition of a special purpose vehicle (the “Zenabis Investment”). Consideration for the Zenabis Investment totaled $58.9 million in cash. The Zenabis Investment owned $58.9 million of aggregate principal amount of senior secured debt (the “Zenabis Senior Loan”) of Zenabis Investments Ltd. (“Zenabis”), a subsidiary of Zenabis Global Inc. Zenabis is a Canadian licensed producer of cannabis. The Zenabis Senior Loan bears interest at a rate of 14% per annum and has a maturity date of March 31, 2025, with principal repayments under certain circumstances over time including $7.0 million payable on December 31, 2020. The Zenabis Senior Loan is secured by the assets of Zenabis and its subsidiaries and is guaranteed by the Parent. Pursuant to the terms of the Zenabis Senior Loan, Zenabis will also pay the Company a royalty (the “Royalty”) based on quarterly sales revenue from its medical, recreational and wholesale cannabis lines net of value added or sales taxes (“Net Cannabis Revenue”), which will be payable each fiscal quarter as follows: i) 3.5% of Net Cannabis Revenue where Net Cannabis Revenue exceeds $20 million but not $25 million; ii) 3.0% of Net Cannabis Revenue where Net Cannabis Revenue exceeds $25 million but not $30 million; iii) 2.5% of Net Cannabis Revenue where Net Cannabis Revenue exceeds $30 million but not $37.5 million; and iv) 2.0% of Net Cannabis Revenue where Net Cannabis Revenue exceeds $37.5 million. The Royalty is payable for 32 fiscal quarters and is payable for quarters in which Zenabis accomplishes certain Net Cannabis Revenue targets and maintains certain debt service ratios. If those targets are not met, the Royalty is not payable for the applicable fiscal quarter but the term of the Royalty is extended another fiscal quarter. On December 31, 2020, the Company received the principal repayment of $7.0 million. The Zenabis Investment has been designated as Fair Value Through Profit or Loss (“FVTPL”) (note 30).

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2020
Goodwill [Abstract]
Goodwill	1 3 . Goodwill Net book value Balance at December 31, 2018 — Acquisitions through business combinations (note 6) 107,053 Foreign currency translation 4,692 Impairment (100,305 ) Balance at December 31, 2019 11,440 Disposition of Bridge Farm (note 5) (11,345 ) Foreign currency translation (95 ) Balance at December 31, 2020 — At December 31, 2019, the Company recorded a goodwill impairment of $100.3 million based on significant delays and uncertainties in the licensing and regulatory framework in the U.K. The goodwill impairment was recognized in the Bridge Farm CBD CGU and is the full amount of goodwill that was attributable to this CGU. The Bridge Farm CBD CGU was the business line focused on developing a CBD business in the U.K. The recoverable amount of the CGU was determined to be its fair value less costs of disposal and was categorized as level 3 in the fair value hierarchy. At December 31, 2019, goodwill was comprised of the goodwill in the Bridge Farm nursery business (flowers, plants and herbs) which was disposed of as part of the sale of Bridge Farm (note 5).

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	12 Months Ended
	Dec. 31, 2020
Subclassifications Of Assets Liabilities And Equities [Abstract]
Accounts Payable and Accrued Liabilities	1 4 . Accounts payable and accrued liabilities December 31, 2020 December 31, 2019 Trade payables 4,849 20,228 Accrued and other liabilities 18,459 37,882 23,308 58,110

Debt

Debt	12 Months Ended
	Dec. 31, 2020
Borrowings [Abstract]
Debt	1 5 . Debt Interest rate Maturity Principal December 31 2020 December 31 2019 Syndicated Credit Agreement (a) Syndicated facility Prime + 2.5% Aug 27, 2021 74,000 — 82,910 Operating facility Prime + 2.5% Aug 27, 2021 5,330 — — Term Debt Facility (b) First tranche 9.75% Jul 27, 2023 115,000 — 95,003 — 177,913 Current portion — 177,913 Long term — — (a) Syndicated Credit Agreement As at December 31, 2020 December 31, 2019 Principal value of debt — 84,000 Transaction costs — (1,313 ) Accretion — 223 — 82,910 At December 31, 2019, the Syndicated Credit Agreement, as written, contained certain financial covenants to maintain: (i) An available cash balance to March 31, 2020; (ii) An interest coverage ratio as at December 31, 2019; (iii) A senior funded debt to EBITDA ratio as at March 31, 2020 and as at the end of every fiscal quarter thereafter; and (iv) A fixed charge coverage ratio at March 31, 2020 and as at the end of every fiscal quarter thereafter. At December 31, 2019, the Company was not in compliance with the interest coverage ratio covenant under its Syndicated Credit Agreement, which caused a cross-default under the Term Debt Facility. As a result, as at December 31, 2019, the full principal amount of the Syndicated Credit Agreement and the Term Debt Facility were classified as current liabilities on the Company’s consolidated statement of financial position. The Company obtained a waiver under the Syndicated Credit Agreement for the December 31, 2019 interest coverage ratio covenant breach and a waiver for any corresponding breaches of the Term Debt Facility. Under the terms of the waivers, the Company agreed that on or before April 15, 2020 it would (i) enter into a definitive purchase agreement related to the sale of Bridge Farm and (ii) enter into term sheets with the each of the respective lenders under the Syndicated Credit Agreement and Term Debt Facility setting out a financing strategy for the Company. On April 15, 2020, the Company and its senior lenders agreed to amend the terms of the waiver by extending the date required to enter into a definitive purchase agreement related to the sale of Bridge Farm to April 30, 2020, and on May 1, 2020, the date was extended to May 11, 2020. On May 12, 2020, the Company announced that the previously extended waiver expired, however, on May 14, 2020, the Company obtained a new waiver for the December 31, 2019 covenant breach as described below. On May 14, 2020, the Company obtained a waiver under the Syndicated Credit Agreement for the December 31, 2019 interest coverage ratio covenant breach, the March 31, 2020 senior funded debt to EBITDA ratio covenant breach and any corresponding breaches of the Term Debt Facility. Under the terms of the waivers, the Company agreed that on or before June 1, 2020 it would (i) execute an amended and restated credit agreement under its Syndicated Facility, (ii) execute a refinancing transaction under its Term Debt Facility, (iii) execute an intercreditor agreement, and (iv) close the sale of Bridge Farm. On June 1, 2020, the Company’s senior lenders amended the terms of the May 14, 2020 waivers and agreements extending the required completion of defined milestones to June 5, 2020. On June 5, 2020, the Company entered into an amended and restated credit agreement, executed a refinancing transaction under its Term Debt Facility (note 15b), executed an intercreditor agreement and closed the sale of Bridge Farm (note 5). The amended and restated credit agreement included a waiver for the Company’s March 31, 2020 covenant non-compliance, elimination of financial covenants other than a minimum cash balance covenant of $2.5 million until December 31, 2020 or later and a covenant requiring the Company to raise capital of US$10 million by December 1, 2020 (which was satisfied as a result of the August 2020 Offering (note 21b)). Additionally, principal repayments of $2.1 million per quarter had been rescheduled to commence on September 30, 2020 and were paid on that date. Principal repayments of $2.1 million were scheduled to be paid every fiscal quarter with the remaining principal balance of $65.6 million due in August 2021. During December 2020, the Company voluntarily prepaid the outstanding principal balance of $71.9 million and cancelled the Syndicated Credit Agreement. (b) Term Debt Facility As at December 31, 2020 December 31, 2019 Principal value of debt — 115,000 Transaction costs — (9,461 ) Accretion — 3,397 Fair value assigned to warrants, at issuance — (13,933 ) — 95,003 At December 31, 2019, the Company was subject to three financial covenants under this facility, so long as the principal amount owing under the Term Debt Facility was greater than $75 million. On May 14, 2020, the Company obtained a waiver under the Syndicated Credit Agreement for the December 31, 2019 interest coverage ratio covenant breach, the March 31, 2020 senior funded debt to EBITDA ratio covenant breach and any corresponding breaches of the Term Debt Facility (note 15a). On June 5, 2020, the Company entered into a restructuring and novation agreement (the “Restructuring and Novation Agreement”) and a securities restructuring agreement (the “Securities Restructuring Agreement”) whereby $45.0 million of principal from the Term Debt Facility was assigned to the Bridge Farm Purchaser and the remaining $73.2 million of principal plus accrued interest was extinguished and replaced with $73.2 million senior second lien convertible notes of the Company (note 16a).

Convertible Notes

Convertible Notes	12 Months Ended
	Dec. 31, 2020
Convertible Notes [Abstract]
Convertible Notes	1 6 . Convertible notes (a) Secured convertible note December 31, 2020 December 31, 2019 Balance, beginning of year — — Secured Convertible Note - fair value on issuance 54,693 — Change in fair value recognized in profit or loss (5,075 ) Converted to common shares (49,618 ) — Balance, end of year — — On June 5, 2020, in connection with the Restructuring and Novation Agreement, the Company entered into the Securities Restructuring Agreement, pursuant to which the $73.2 million balance of the Term Debt Facility was extinguished and replaced with a $73.2 million senior second lien convertible note (the “Secured Convertible Note”), convertible into common shares at an initial conversion price of US$1.00 per common share. The Company also issued common share purchase warrants to acquire up to 17.5 million common shares at an initial exercise price of US$1.00 per warrant and common share purchase warrants to acquire up to 17.5 million common shares at an initial exercise price of US$1.20 per warrant (the “Secured Convertible Note Warrants”) (note 17a). The Secured Convertible Note was to mature on June 5, 2022 and did not bear interest, except upon the occurrence of defined triggering events. The Secured Convertible Note was secured by a second priority lien on the assets and property of the Company. The Secured Convertible Note could be converted into common shares at any time after the earlier of the date upon which the indebtedness under the Unsecured Convertible Notes was less than US$3.0 million (note 16b) and February 1, 2021. On September 30, 2020, the indebtedness under the Unsecured Convertible Notes was less than US$3.0 million and the Company subsequently filed a registration statement which allowed the holders to offer and sell the common shares issuable upon conversion or exercise of the Secured Convertible Note and Secured Convertible Note Warrants. The registration statement was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on October 22, 2020. Beginning on October 22, 2020, up to $10 million of principal of the Secured Convertible Note could be converted into common shares per month at an alternate conversion price equal to the lower of (i) the applicable conversion price in effect on such conversion date, and (ii) the greater of (a) US$0.1624 and (b) 92% of the volume weighted average price of the Company’s common shares during the eight consecutive trading day period ending and including the date of delivery of the conversion notice. The Secured Convertible Note and related warrants did not permit the holder to have beneficial ownership of the outstanding common shares in excess of 9.99%. The conversion or exercise price, as applicable, was subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issued, sold or entered into any agreement to issue or sell, any variable rate securities, the investors had the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable. The Secured Convertible Note has been designated as Fair Value Through Profit or Loss (“FVTPL”) (note 30). During the period October 22, 2020 to December 31, 2020, the entire $73.2 million aggregate principal of the Secured Convertible Note was converted into common shares at a weighted average conversion price of $0.2468 resulting in the issuance of 296.7 million common shares (note 21b). The following table presents the change in principal balance during the year: Principal balance December 31, 2020 Balance, beginning of year — Issued 73,227 Converted to common shares (73,227 ) Balance, end of year — (b) Unsecured convertible notes December 31, 2020 December 31, 2019 Balance, beginning of year — — Unsecured Convertible Notes - fair value on issuance 16,113 — Change in fair value recognized in profit or loss (2,066 ) Converted to common shares (13,943 ) — Unrealized foreign exchange loss (104 ) Balance, end of year — — On June 5, 2020, in connection with the debt restructuring transactions, the Company entered into a securities purchase agreement providing for the sale of a new series of unsecured senior subordinated convertible notes (the “Unsecured Convertible Notes”) in the aggregate principal amount of US$18.0 million, convertible into common shares at any time at the option of the holder at an initial conversion price of US$1.00, and common share purchase warrants to acquire up to 14.5 million common shares at an initial exercise price of US$0.9338 per common share (the “Unsecured Convertible Notes Warrants”) (note 17b). In connection with the securities purchase agreement, placement agents for the offering were issued common share purchase warrants to acquire up to 1,080,000 common shares at an initial exercise price of US$1.00 per common share (the “Agent Warrants”) (note 17c). The Unsecured Convertible Notes were to mature on June 5, 2022 and did not bear interest, except upon the occurrence of defined triggering events. The Unsecured Convertible Notes could be converted into common shares at any time. The terms of the Unsecured Convertible Notes were amended in August 2020 to allow the entire principal amount to be converted into common shares at an alternate conversion price equal to the lower of (i) the applicable conversion price in effect on such conversion date, and (ii) the greater of (a) US$0.1624 and (b) 88% of the lowest volume weighted average price of the Company’s common shares during the five consecutive trading day period ending and including the date of delivery of the conversion notice. The Unsecured Convertible Notes and related warrants did not permit the holder to have beneficial ownership of the outstanding common shares in excess of 9.99%. The conversion or exercise price, as applicable, was subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issued, sold or entered into any agreement to issue or sell, any variable rate securities, the investors had the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable. The Unsecured Convertible Notes have been designated as FVTPL (note 30). During the period July 16, 2020 to December 31, 2020, the entire US$18.0 million aggregate principal was converted into common shares at a weighted average exercise price of US$0.2348 resulting in the issuance of 76.7 million common shares (note 21b). The following table presents the change in principal balance during the year: Principal balance (USD) December 31, 2020 Balance, beginning of year — Issued 18,000 Converted to common shares (18,000 ) Balance, end of year — (c) Senior convertible notes December 31, 2020 December 31, 2019 Senior Convertible Notes issued — 93,192 Transaction costs — (2,819 ) Fair value attributable to conversion feature — (40,494 ) Balance attributable to debt portion upon issuance — 49,879 Accretion of note obligation — 1,223 Amortization of note issue costs — 93 Accrued interest — 1,903 Conversion to common shares — (53,098 ) Balance, end of year — — In May 2019, the Company closed a private placement of 8% senior unsecured convertible notes (“Senior Convertible Notes”) for gross proceeds of $92.6 million. In July 2019, an additional $0.6 million were issued. The Senior Convertible Notes bore interest at a rate of 8% per annum, compounded monthly. The Senior Convertible Notes and any accrued interest were repayable on the earlier of five years from date of issuance, the day the Company redeems the Senior Convertible Notes on certain conditions defined in the note agreement, or the day upon which the noteholder exercise their conversion rights as defined in the agreement. $0.1 million of the senior convertible notes were issued to a director of the Company. The Senior Convertible Notes were hybrid instruments consisting of a financial liability and an embedded conversion feature. The embedded conversion feature met the definition of an embedded derivative which was separated from the host contract and accounted for separately as the economic characteristics and risks of the host contract and the embedded derivative were not closely related. The conversion feature did not contain a fixed conversion price and was only exercisable in the event of an initial public offering and at the second anniversary following the closing date. Prior to the initial public offering and the subsequent conversion, the embedded conversion feature was carried at FVTPL. On August 14, 2019, Sundial received conversion notices from all holders of the 8% convertible notes. As a result, all principal and accrued interest was converted into 6.9 million common shares (note 21b) at a conversion price of $13.84 representing 80% of the initial public offering price converted to Canadian dollars. (d) convertible notes December 31, 2020 December 31, 2019 Balance, beginning of year — 25,449 Unrealized foreign exchange gain — (209 ) Accrued interest — (152 ) Accretion — 2,443 Amortization of note issue costs — 745 Conversion to common shares — (18,139 ) Conversion to warrants — (5,947 ) Repayments — (4,190 ) Balance, end of year — — In 2018, the Company closed three separate tranches of a private placement of 12% notes for gross proceeds of $28.9 million ($22.2 million from the CAD offering and $USD 5.0 from the USD offering), convertible into units consisting of 1.6 common shares and 0.8 of one common share purchase warrant at the option of the holder for up to twelve months. The Canadian dollar denominated offering was convertible into units at a price of $3.91 per unit. The U.S. dollar denominated offering was convertible into units at a price of $3.13 USD per unit. Interest was payable at 12% per annum, payable monthly, and maturing twelve months from the date of issuance. The convertible notes were segregated into their debt and equity components using the residual value approach, with $3.2 million being allocated to equity. $7 million of the convertible notes were issued to directors and officers. During the year ended December 31, 2019, principal of $21.2 million convertible notes and USD$2.5 million convertible notes were converted into equity units, at the option of the holders. Equity units issued consisted of 6.2 million common shares and 3.6 million warrants. During the year ended December 31, 2019, principal of $1.0 million convertible notes and USD$2.4 million convertible notes were repaid to unit holders.

Derivative Warrant Liabilities

Derivative Warrant Liabilities	12 Months Ended
	Dec. 31, 2020
Derivative Warrant Liabilities [Abstract]
Derivative Warrant Liabilities	1 7 . Derivative warrant liabilities December 31, 2020 December 31, 2019 Balance, beginning of year — — Secured Convertible Note Warrants - fair value on issuance (a) 6,683 — Unsecured Convertible Notes Warrants - fair value on issuance (b) 3,961 — Agent Warrants - fair value on issuance (c) 504 — Series A and Series B Warrants - fair value on issuance (d) 11,784 — Change in fair value recognized in profit or loss 12,995 — Converted to common shares (35,521 ) — Unrealized foreign exchange loss 22 — Balance, end of year 428 — (a) Secured Convertible Note Warrants The Secured Convertible Note Warrants were issued on June 5, 2020 and expired 36 months from the date of issuance. The Secured Convertible Note Warrants could be converted into common shares at any time after the earlier of the date upon which the indebtedness under the Unsecured Convertible Notes was less than US$3.0 million and February 1, 2021. On September 30, 2020, the indebtedness under the Unsecured Convertible Notes was less than US$3.0 million and the Company subsequently filed an F-3 registration statement with a date of effectiveness of October 22, 2020. In certain circumstances, the Secured Convertible Note Warrants were subject to forced exercise provisions whereby the Company could force exercise should the volume weighted average price of the Company’s common shares exceed US$2.00. During the period October 22, 2020 to December 31, 2020, 35.0 million Secured Convertible Note Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of $8.0 million (note 21b). As at December 31, 2020, nil Secured Convertible Note Warrants remained outstanding. (b) Unsecured Convertible Notes Warrants The Unsecured Convertible Notes Warrants were issued on June 5, 2020, are immediately exercisable, and expire 42 months from the date that the underlying common shares become freely tradeable, which was July 16, 2020. In certain circumstances, the Unsecured Convertible Notes Warrants are subject to forced exercise provisions whereby the Company can force exercise should the volume weighted average price of the Company’s common shares exceed US$2.8014. As a result of sales under the ATM Program, the exercise price of the Unsecured Convertible Notes Warrants was adjusted to US$0.1766 per common share. The foregoing exercise price may be further adjusted as the result of future sales under the ATM Program or other offerings, if any. During the period July 16, 2020 to December 31, 2020, 14.0 million Unsecured Convertible Notes Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 14.0 million common shares and gross proceeds to the Company of $3.2 million (note 21b). As at December 31, 2020, 0.5 million Unsecured Convertible Notes Warrants remained outstanding. (c) Agent Warrants The Agent Warrants were issued on June 5, 2020, are immediately exercisable, and expire on June 5, 2025. The Agent Warrants do not permit the holder to have beneficial ownership of the outstanding common shares in excess of 4.99%. During the year ended December 31, 2020, no Agent Warrants were exercised. Subsequent to December 31, 2020, 540,000 Agent Warrants were exercised at a weighted average exercise price of US$1.00 per warrant resulting in the issuance of 356,949 common shares. There were no gross proceeds to the Company as the exercise was cashless. (d) Series a and series b warrants On August 18, 2020, in connection with the August 2020 Offering, the Company issued 40.1 million Series A Warrants and 14.3 million Series B Warrants (note 21b). The Series A Warrants and Series B Warrants are exercisable immediately and have a term of five years commencing on the date of issuance. The exercise price of the Series A Warrants are US$0.75 per common share and the exercise price of the Series B Warrants are US$0.0001 per common share. On August 19, 2020, 9.2 million Series B Warrants were converted into common shares and on August 20, 2020, the remaining 5.1 million Series B Warrants were converted into common shares (note 21b). As a result of sales under the ATM Program, the exercise price of the Series A Warrants was adjusted to US$0.1766 per common share. The exercise price of the Series A Warrants may be further adjusted as the result of future sales under the ATM Program or other offerings, if any. During the period August 18, 2020 to December 31, 2020, 39.6 million Series A Warrants were exercised at a weighted average exercise price of US$0.1766 per warrant resulting in the issuance of 39.6 million common shares and gross proceeds to the Company of $9.1 million (note 21b). As at December 31, 2020, 0.5 million Series A Warrants remained outstanding. The following table summarizes outstanding derivative warrants as at December 31, 2020: Exercise price (USD) (1) Number of warrants Weighted average contractual life Series A Warrants 0.1766 500,000 4.6 Unsecured Convertible Notes Warrants 0.1766 500,000 3.0 Agent Warrants 1.00 1,080,000 4.4 2,080,000 3.0 (1) The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

Lease Obligations

Lease Obligations	12 Months Ended
	Dec. 31, 2020
Lease Liabilities [Abstract]
Lease Obligations	1 8 . Lease obligations December 31, 2020 December 31, 2019 Balance, beginning of year 16,949 214 Adoption of IFRS 16 — 1,119 Acquisitions — 15,179 Liabilities incurred 763 674 Lease payments (937 ) (778 ) Dispositions (735 ) (468 ) Interest expense 416 444 Disposition of Bridge Farm (note 5) (14,894 ) — Foreign currency translation (122 ) 565 Balance, end of year 1,440 16,949 Current portion 409 722 Long-term 1,031 16,227 The Company’s minimum lease payments are as follows: December 31, 2020 Less than one year 490 One to three years 895 Three to five years 222 Thereafter — Minimum lease payments 1,607 Amounts representing finance charges (167 ) Net minimum lease payments 1,440 The Company has short-term leases with lease terms of 12 months or less as well as low-value leases. As these costs are incurred, they are recognized as general and administrative expense. These costs were immaterial in 2020.

Contingent Consideration

Contingent Consideration	12 Months Ended
	Dec. 31, 2020
Disclosure Of Contingent Liabilities [Abstract]
Contingent Consideration	1 9 . Contingent Consideration December 31, 2020 December 31, 2019 Balance, beginning of year 32,501 — Acquisition of Bridge Farm — 15,991 Change in fair value recognized in profit or loss 2,252 18,645 Earn-out payments — (1,170 ) Unrealized foreign exchange loss 1,058 (1,779 ) Foreign currency translation (899 ) 814 Disposition of Bridge Farm (note 5) (34,912 ) — Balance, end of year — 32,501 Contingent consideration was comprised of the fair value of the incremental variable amount of shares potentially issuable in connection with the acquisition of Bridge Farm and the fair value of earn-out payments owed to the sellers of Bridge Farm. At June 5, 2020, the fair value of the incremental shares was $34.6 million and the fair value of the earn out shares was $0.3 million. On June 5, 2020, the total contingent consideration of $34.9 million was assumed by the Bridge Farm Purchaser as part of the consideration for the Bridge Farm Disposition (note 5).

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Major Components Of Tax Expense Income [Abstract]
Income Taxes	20 . Income taxes The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in the consolidated statements of loss and comprehensive loss for the years ended December 31, 2020, December 31, 2019 and ten months ended December 31, 2018: December 31, 2020 December 31, 2019 December 31, 2018 Loss before taxes (206,317 ) (146,307 ) (56,526 ) Statutory income tax rates 24.0 % 26.5 % 27.0 % Expected income tax recovery (49,516 ) (38,771 ) (15,262 ) Non-deductible share-based compensation 1,970 10,474 1,860 Non-deductible finance expense 2,130 15,981 2,304 Other non-deductible expenses 348 2,621 — Change in tax rates 1,528 3,305 — Deferred tax benefits not recognized 43,540 2,781 11,098 Income tax (recovery) expense — (3,609 ) — Details of the deferred tax assets (liabilities) are as follows: December 31, 2020 December 31, 2019 Deferred tax assets (liabilities): Property, plant and equipment — (3,490 ) Inventory 8,388 1,881 Biological assets (8,388 ) (7,170 ) Intangible assets — (7,355 ) Non-capital losses — 12,769 Net deferred tax asset (liability) — (3,365 ) Deferred tax assets have not been recognized for the following deductible temporary differences: December 31, 2020 December 31, 2019 Unrecognized deductible temporary differences: Property, plant and equipment 36,782 — Intangible assets 536 — Share issue costs 11,112 16,779 Financial obligations and other 1,054 1,726 Inventory and biological assets 34,781 — Non-capital losses 171,205 54,472 Unrecognized deductible temporary differences 255,470 72,977 The movement in deferred income tax liability is as follows: December 31, 2020 December 31, 2019 Balance, beginning of year 3,365 — Acquisition of Pathway Rx — 3,609 Acquisition of Bridge Farm — 4,355 Recognized in profit and loss — (3,609 ) Recognized in other comprehensive income (25 ) 27 Recognized in discontinued operations (note 5) (225 ) (1,017 ) Disposition of Bridge Farm (note 5) (3,115 ) — Balance, end of year — 3,365 The Company has $171.2 million (December 31, 2019 - $99.1 million) of non-capital losses available for future periods that will expire prior to 2038-2040. The loss on financial obligation in 2019 was not recognized as a deduction for deferred income taxes. If it was deducted, the amount would be considered as an unrecognized deferred tax asset as it is less likely than not that it would be utilized in the foreseeable future.

Share Capital and Warrants

Share Capital and Warrants	12 Months Ended
	Dec. 31, 2020
Share Capital And Warrants [Abstract]
Share Capital and Warrants	2 1 . Share capital and warrants (a) Authorized The authorized capital of the Company consists of an unlimited number of voting common shares and preferred shares with no par value. On July 12, 2019, the Company approved a 1.6 to 1 share split of the Company’s issued and outstanding common shares (the “Share Split”). Each shareholder of record of the Company as of the close of business on the record date on July 22, 2019 received 1.6 common shares for each share held on such date. All references to common shares, warrants, simple warrants and performance warrants have been retrospectively adjusted to reflect the Share Split. (b) Issued and outstanding December 31, 2020 December 31, 2019 Note Number of Shares Carrying Amount Number of Shares Carrying Amount Balance, beginning of year 107,180,423 509,654 68,648,984 65,133 Initial public offering — — 11,000,000 189,518 Shares issued for assets — — 797,952 6,537 Share issuances 337,696,867 176,931 394,926 2,323 Shares issued to related parties — — 3,730,963 63,460 Share issuance costs — (5,593 ) — (12,770 ) Business acquisitions — — 2,696,800 39,849 Disposition of Bridge Farm 5 (2,716,271 ) (38,447 ) — — Convertible debt - conversions 16 373,371,318 63,002 13,108,676 113,526 Derivative warrants exercised 17 102,836,429 55,912 — — Warrants exercised — — 4,551,082 21,882 Shares issued for services — — 164,080 2,320 RSUs exercised 22(c) 475,367 587 57,960 195 Employee warrants exercised — — 2,029,000 17,681 Balance, end of year 918,844,133 762,046 107,180,423 509,654 August 2020 Offering On August 18, 2020, the Company issued 25.8 million Series A Units (the “Series A Units”), each consisting of one common share and one Series A Warrant (collectively, the “Series A Warrants”) (note 17d) to purchase one common share and 14.3 million Series B Units (the “Series B Units”), each consisting of one pre-funded Series B Warrant (the “Series B Warrants”) to purchase one common share and one Series A Warrant to purchase one common share (note 17d). Each Series A Unit was sold at a price of US$0.50 per unit and each Series B Unit was sold at a price of US$0.50 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$20 million. The Series A Warrants and Series B Warrants were exercisable immediately and have a term of five years commencing on the date of issuance. The exercise price of the Series A Warrants was US$0.75 per common share and the exercise price of the Series B Warrants was US$0.0001 per common share. On August 19, 2020, 9.2 million Series B Warrants were exercised resulting in the issuance of 9.2 million common shares and on August 20, 2020, the remaining 5.1 million Series B Warrants were exercised resulting in the issuance of 5.1 million common shares. At-the-Market Offering Program On August 13, 2020, the Company entered into an equity distribution agreement to establish the ATM Program which allowed the Company to offer and sell common shares having an aggregate offering price of up to US$50 million. During the period from October 5, 2020 to December 4, 2020, the Company issued 153.5 million common shares at a weighted average exercise price of US$0.3250 for gross proceeds of US$49.9 million. On December 4, 2020, the Company entered into an equity distribution agreement to establish a new ATM Program which allowed the Company to offer and sell common shares having an aggregate offering price of up to US$150 million. During the period from December 14, 2020 to December 31, 2020, the Company issued 156.3 million common shares at a weighted average exercise price of US$0.4795 for gross proceeds of US$75.0 million. Subsequent to December 31, 2020, the Company issued 117.6 million common shares at a weighted average exercise price of $US0.6379 for gross proceeds of US$75.0 million. Subsequent to December 31, 2020, on January 11, 2021 the Company entered into an equity distribution agreement to establish a third ATM Program having an aggregate offering price of up to US$50.0 million. Under the third ATM Program, from January 11, 2021 to January 13, 2021 the Company issued 72.4 million common shares at a weighted average exercise price of US$0.6903 for gross proceeds of US$50.0 million. Subsequent to December 31, 2020, on January 20, 2021 the Company entered into an equity distribution agreement allowing it to issue common shares in an amount up to US$400 million at its discretion and established an ATM Program covering issuances of up to US$400 million. Under this ATM Program, the Company issued 237.7 million common shares at a weighted average exercise price of US$0.6325 for gross proceeds of US$150.3 million. Under this equity distribution agreement, the Company also completed two registered offerings (note 34). (c) Common share purchase warrants Number of Warrants Carrying Amount Balance at December 31, 2018 4,211,904 3,108 40% Warrants reclassified from derivative liability ( i ) 957,225 4,122 60% Warrants reclassified from derivative liability ( i ) 1,495,665 11,969 Warrants issued to related parties (ii) 480,000 5,833 Warrants issued on conversion of convertible notes (iii) 3,572,274 6,731 Warrants exercised (4,551,082 ) (3,931 ) Warrants expired (662 ) (1 ) Balance at December 31, 2019 6,165,324 27,831 Warrants issued 544,000 306 Warrants expired (3,232,434 ) (5,908 ) Warrants cancelled (2,452,890 ) (16,091 ) Balance at December 31, 2020 1,024,000 6,138 (i) On August 1, 2019, the 40% and 60% warrants issued as part of the term debt financing and initially classified as derivative liabilities as at June 30, 2019, were reclassified to equity as the number of warrants issuable and the exercise price for each tranche of warrants became fixed in conjunction with the initial public offering date. The exercise price for the 40% and 60% warrants were $21.63 and $20.76 respectively. (ii) 480,000 warrants with an exercise price of $15.94 were issued to a director of the Company in relation to the acquisition of the financial obligation. (iii) Equity units issued upon conversion of CAD denominated convertible notes included 3,095,386 warrants with an exercise price of $4.38 and vested immediately. Equity units issued upon conversion of USD denominated notes included 476,888 warrants with an exercise price of USD$3.75 and vested immediately. During the year ended December 31, 2020, the warrants issued upon conversion of the CAD and USD denominated convertible notes expired, and the 40% Warrants and 60% Warrants issued as part of the term debt financing were surrendered and cancelled. The following table summarizes outstanding warrants as at December 31, 2020: Warrants outstanding and exercisable Issued in relation to Weighted average exercise price Number of warrants Weighted average contractual life (years) Acquisition of financial obligation 15.94 480,000 1.5 Financial services 4.60 544,000 8.6 9.91 1,024,000 5.3 During the year ended December 31, 2019, a total of 4,551,082 warrants were exercised consisting of 4,211,242 warrants exercised at a price of $3.91 for gross proceeds of $16.5 million, 307,840 exercised for gross proceeds of $1.3 million of the warrants issued upon conversion of the CAD denominated convertible notes and 32,000 warrants exercised for gross proceeds of USD$120 thousand of the warrants issued upon conversion of the USD denominated convertible notes. 662 warrants expired unexercised in April 2019. The carrying value of the exercised warrants of $3.9 million was adjusted from warrants to share capital. The following table summarizes outstanding warrants as at December 31, 2019: Warrants outstanding and exercisable Issued in relation to Weighted average exercise price Number of warrants Weighted average contractual life (years) Convertible notes (USD) USD 3.75 444,888 0.8 Convertible notes (CAD) 4.38 2,787,546 0.7 Acquisition of financial obligation 15.94 480,000 2.5 Term debt financing (60%) 20.76 1,495,665 2.6 Term debt financing (40%) 21.63 957,225 2.6 11.97 6,165,324 1.6

Share-based Compensation

Share-based Compensation	12 Months Ended
	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Share-based Compensation	2 2 . Share-based compensation The Company has a number of equity-settled share-based compensation plans which include simple and performance warrants, stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”). Further detail on each of these plans is outlined below. Subsequent to the Company’s initial public offering, the Company established the stock option, RSU and DSU plans to replace the granting of simple warrants and performance warrants. The components of share-based compensation expense are as follows: Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Simple warrants (a) 1,539 23,918 5,029 Performance warrants (a) (42 ) 11,023 1,860 Stock options (b) 651 98 — Restricted share units (c) 4,069 220 — Deferred share units (c) 2,349 1,119 — Shares issued for services — 2,320 521 8,566 38,698 7,410 In determining the amount of share-based compensation, the Company used the Black-Scholes option pricing model to estimate the fair value of units granted during the year ended December 31, 2020, December 31, 2019 and ten months ended December 31, 2018 through application of the following assumptions: December 31, 2020 December 31, 2019 December 31, 2018 Risk-free interest rate 0.28% - 0.29% 1.41% - 1.88% 1.65% - 2.05% Expected life of units (years) 10 2 - 10 0.5 – 14 Expected annualized volatility 143% 97% - 116% 80% - 106% Expected dividend yield Nil Nil Nil Weighted average Black-Scholes value of each unit $1.13 - $1.17 $0.67 - $23.55 $1.76 - $3.81 Volatility was estimated by using the historical volatility of peer companies that the Company considers comparable, which have trading and volatility history. The expected life in years represents the period of time that the units granted are expected to be outstanding. The risk-free rate was based on Government of Canada bond rates of comparable duration. a) Simple and performance warrants The Company issued simple warrants and performance warrants to employees, directors and others at the discretion of the Board. Simple and performance warrants granted generally vest annually in thirds over a three-year period and simple warrants expire five years after the grant date. The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2020: Simple warrants outstanding Weighted average exercise price Performance warrants outstanding Weighted average exercise price Balance at December 31, 2019 9,815,000 $ 4.01 5,798,822 $ 2.66 Forfeited (6,390,400 ) 3.79 (4,126,822 ) 2.04 Balance at December 31, 2020 3,424,600 $ 4.41 1,672,000 $ 4.19 The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2019: Simple warrants outstanding Weighted average exercise price Performance warrants outstanding Weighted average exercise price Balance at December 31, 2018 6,129,866 $ 1.80 7,094,822 $ 2.04 Granted 4,795,200 6.32 723,200 12.23 Forfeited (733,866 ) 2.32 (366,400 ) 1.21 Exercised (376,200 ) 0.85 (1,652,800 ) 0.63 Balance at December 31, 2019 9,815,000 $ 4.01 5,798,822 $ 2.66 The following table summarizes outstanding simple and performance warrants as at December 31, 2020: Warrants outstanding Warrants exercisable Range of exercise prices Number of warrants Weighted average exercise price Weighted average contractual life (years) Number of warrants Weighted average exercise price Weighted average contractual life (years) Simple warrants $0.63 - $0.94 1,009,400 0.74 3.54 1,009,400 0.74 3.54 $1.25 - $1.88 400,000 1.56 3.59 400,000 1.56 3.59 $2.97 - $4.53 527,200 3.05 3.64 455,200 3.01 3.54 $6.25 - $9.38 1,318,400 6.33 5.18 275,200 6.61 5.10 $12.50 - $37.50 169,600 22.28 6.49 16,000 20.60 4.50 3,424,600 $ 4.41 4.34 2,155,800 $ 2.27 3.76 Performance warrants $0.63 - $0.94 498,667 0.70 n/a 370,667 0.72 n/a $1.25 - $1.88 282,133 1.42 n/a 247,467 1.40 n/a $2.97 - $4.53 624,000 3.13 n/a 397,333 3.10 n/a $6.25 - $9.38 150,933 7.32 n/a 38,400 6.25 n/a $12.50 - $37.50 116,267 27.52 n/a — — n/a 1,672,000 $ 4.19 n/a 1,053,867 $ 1.98 n/a The following table summarizes outstanding simple and performance warrants as at December 31, 2019: Warrants outstanding Warrants exercisable Range of exercise prices Number of warrants Weighted average exercise price Weighted average contractual life (years) Number of warrants Weighted average exercise price Weighted average contractual life (years) Simple warrants $0.63 - $0.94 4,019,000 0.68 5.62 3,635,000 0.68 5.62 $1.25 - $1.88 560,000 1.50 10.18 560,000 1.50 10.18 $2.97 - $4.53 1,232,000 3.18 5.62 848,000 3.10 5.11 $6.25 - $9.38 3,462,400 6.37 4.50 80,000 6.25 4.44 $12.50 - $37.50 541,600 18.08 7.87 9,600 21.88 9.05 9,815,000 $ 4.01 5.61 5,132,600 $ 1.29 6.02 Performance warrants $0.63 - $0.94 3,700,690 0.64 n/a 3,546,022 0.64 n/a $1.25 - $1.88 646,933 1.52 n/a 381,334 1.48 n/a $2.97 - $4.53 788,000 3.09 n/a 490,666 3.08 n/a $6.25 - $9.38 362,933 6.97 n/a 38,400 6.25 n/a $12.50 - $37.50 300,266 23.72 n/a — — n/a 5,798,822 $ 2.66 n/a 4,456,422 $ 1.02 n/a b) Stock options The Company issues stock options to employees and others at the discretion of the Board. Stock options granted generally vest annually in thirds over a three-year period and expire ten years after the grant date. The following table summarizes changes in stock options during the year ended December 31, 2020: Stock options outstanding Weighted average exercise price Balance at December 31, 2019 623,850 $ 4.33 Granted 481,600 1.16 Forfeited (384,850 ) 4.96 Balance at December 31, 2020 720,600 $ 1.82 The following table summarizes changes in the stock options during the year ended December 31, 2019: Stock options outstanding Weighted average exercise price Balance at December 31, 2018 — $ — Granted 623,850 4.33 Balance at December 31, 2019 623,850 $ 4.33 The following table summarizes outstanding stock options as at December 31, 2020: Stock options outstanding Stock options exercisable Exercise prices Number of options Weighted average contractual life (years) Number of options Weighted average contractual life (years) $1.15 400,000 9.41 — — $1.19 81,600 9.49 81,600 9.49 $3.15 239,000 8.68 77,417 8.63 720,600 9.18 159,017 9.07 The following table summarizes outstanding stock options as at December 31, 2019: Stock options outstanding Stock options exercisable Exercise prices Number of options Weighted average contractual life (years) Number of options Weighted average contractual life (years) $3.15 373,850 9.21 22,500 4.97 $5.93 250,000 6.37 — — 623,850 7.97 22,500 4.97 c) Restricted and deferred share units RSUs are granted to employees and the vesting requirements and maximum term are at the discretion of the Board. DSUs are granted to directors and generally vest in equal quarterly instalments over a one year. RSUs and DSUs are exchangeable for an equal number of common shares. The following table summarizes changes in RSUs and DSUs as at December 31, 2020: RSUs outstanding DSUs outstanding Balance at December 31, 2019 48,883 367,924 Granted 3,002,213 3,265,503 Forfeited (43,813 ) (310,164 ) Exercised (1,350,367 ) — Balance at December 31, 2020 1,656,916 3,323,263 The following table summarizes changes in RSUs and DSUs as at December 31, 2019: RSUs outstanding DSUs outstanding Balance at December 31, 2018 — — Granted 107,543 378,080 Forfeited (700 ) (7,617 ) Settled — (2,539 ) Exercised (57,960 ) — Balance at December 31, 2019 48,883 367,924 Subsequent to December 31, 2020, the Company granted 11.9 million RSUs to employees as part of its long-term incentive program.

Revenue

Revenue	12 Months Ended
	Dec. 31, 2020
Revenue [Abstract]
Revenue	2 3 . Revenue The Company’s revenue is solely from contracts with customers and is comprised of revenue from the sale of cannabis. Cannabis revenue is comprised of sales to Provincial boards that sell cannabis through their respective distribution models, sales to licensed producers for further processing, and sales to medical customers. Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Provincial boards 55,315 13,386 — Medical 32 24 — Licensed producers 17,974 53,517 — Gross revenue (1) 73,321 66,927 — (1) The Company had four major customers each with revenue in excess of 10% of total cannabis revenue. Sales to major customers totaled $43.9 million for the year ended December 31, 2020 (December 31, 2019 – four major customers with sales of $40.7 million). Only one major customer had sales exceeding 10% of total cannabis revenue for both periods. The following table disaggregates revenue by form for the periods noted: Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Revenue from dried flower 51,424 58,246 — Revenue from vapes 18,447 504 — Revenue from oil 3,145 8,177 — Revenue from edibles 263 — — Revenue from concentrates 42 — — Gross revenue 73,321 66,927 — The Company has recognized the following receivables from contracts with customers: December 31, 2020 December 31, 2019 December 31, 2018 Receivables, included in 'trade receivables' (note 7) 15,786 20,281 209 Receivables from contracts with customers are typically settled within 30 days. As at December 31, 2020, an impairment reversal of $0.5 million (December 31, 2019 - $0.6 million loss) has been recognized on receivables from contracts with customers (note 30).

Other Operating Expenses

Other Operating Expenses	12 Months Ended
	Dec. 31, 2020
Expense By Nature [Abstract]
Other Operating Expenses	2 4 . Other operating expenses a) General and administrative Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Salaries and wages 11,634 15,262 3,847 Consulting fees 2,193 6,896 1,647 Office and general 9,843 9,533 1,738 Professional fees 4,658 3,559 877 Director fees 365 188 30 Other 3,336 3,496 170 32,029 38,934 8,309 b) Sales and marketing Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Marketing 4,839 3,093 1,733 Events 393 2,961 — Research 57 199 24 Media 448 1,815 623 5,737 8,068 2,380

Government Subsidies

Government Subsidies	12 Months Ended
	Dec. 31, 2020
Government Subsidies [Abstract]
Government Subsidies	2 5 . Government subsidies In March 2020, the federal government launched the Canadian Emergency Wage Subsidy (“CEWS”) to help businesses impacted by the COVID-19 pandemic keep and rehire employees. The CEWS delivered a 75 percent wage subsidy to eligible employers for an initial period of 12 weeks, from March 15, 2020 to July 4, 2020. Eligibility was based on meeting a minimum requirement for decreased revenue. The CEWS was extended to November 21, 2020 and amended to change the eligibility requirements from meeting a certain threshold to being variable based on how much an employer’s revenue decreased. The CEWS has further been extended to June 2021 and includes changes to the rates and the top-up calculation. The Company became eligible for the CEWS based on decreases in revenue and has received the subsidy for certain periods. The subsidy of $4.0 million has been recognized in the consolidated statement of loss and comprehensive loss. There are no unfulfilled conditions or contingencies attached to the CEWS. In October 2020, the federal government launched the Canadian Emergency Rent Subsidy (“CERS”) to help businesses impacted by the COVID-19 pandemic cover part of their commercial rent or property taxes. The CERS program provides a base rent subsidy that is available to organizations that continue to see decreasing revenues and an additional top up for organizations that must either close or significantly restrict their activities due to a public health order. CERS is available from September 27, 2020 until June 2021. The Company became eligible for CERS based on decreases in revenue and has received the subsidy for certain periods. The subsidy of $0.1 million has been recognized in the consolidated statement of loss and comprehensive loss. There are no unfulfilled conditions or contingencies attached to the CERS.

Finance Costs

Finance Costs	12 Months Ended
	Dec. 31, 2020
Disclosure Of Finance Cost [Abstract]
Finance Costs	2 6 . Finance costs Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Cash finance expense Interest on Syndicated Credit Agreement 4,546 1,746 — Interest on Credit Facilities — 1,818 437 Interest on Term Debt Facility 2,936 3,478 — Interest on Senior Convertible Notes — 375 — Interest on Convertible Notes — 2,574 421 Interest on other debt — 1,526 1,659 Other finance costs 286 2,909 399 7,768 14,426 2,916 Non-cash finance expense (income) Accretion 1,622 5,511 594 Amortization of debt issue costs 1,782 1,586 172 Change in fair value of convertible notes (note 16) (7,141 ) — — Change in fair value of derivative warrant liabilities (note 17) 12,995 — — Interest on Senior Convertible Notes — 1,903 — Loss on derivative liabilities — 1,649 — Loss on extinguishment of debt — 488 — Other 3 (67 ) 151 9,261 11,070 917 Less: interest capitalized relating to CIP (note 10) — (1,280 ) (2,036 ) Interest income (215 ) — — 16,814 24,216 1,797

Loss On Financial Obligations

Loss On Financial Obligations	12 Months Ended
	Dec. 31, 2020
Financial Obligations [Abstract]
Loss on Financial Obligations	27. Loss on financial obligations On January 15, 2018, the Company entered into the Investment and Royalty Agreement with a company controlled by the former Executive Chairman of the Company (the “Purchaser”). The Investment and Royalty Agreement was amended on August 16, 2018. Under the amended agreement, the Purchaser agreed to provide up to $11.0 million of equity financing for the construction of a portion of the Company’s facility in Olds, Alberta. As at December 31, 2018, a total of $10.9 million had been advanced under the amended agreement and was converted into 7,149,035 common shares. The difference between the estimated fair value of the shares at the time of issue and the amount based on the price per share as outlined in the credit agreement of $8.5 million was charged to finance expense in 2018. The Investment and Royalty Agreement was subject to various non-financial covenants, with which the Company was in compliance as a December 31, 2018, except for the growing capacity covenant. This covenant required that at least 25,000 square feet of defined space at the Olds facility be dedicated exclusively to and capable of producing flower. This covenant was waived by the Purchaser for the period from August 16, 2018 to October 1, 2019, as the use of that facility space for clones and vegetation plants was determined to be a superior allocation of productive capacity. In addition, pursuant to the terms of the Investment and Royalty Agreement, the Purchaser was entitled to quarterly royalty payments calculated based on the Company’s revenue from the facilities subject to the amended agreement for each fiscal quarter multiplied by 6.5% (the “Royalty Payment”). The Royalty Payments accrued beginning October 1, 2019 and were to be paid on the first business day of every subsequent fiscal quarter until September 30, 2028. The Company had estimated the present value of these payments at December 31, 2018 to be $18.5 million assuming a discount rate of 18%. The Company used a discounted cash flow methodology to estimate the value the royalty component of the financial obligation. The material assumptions used by the Company to estimate the valuation for the royalty and held constant for the 10-year term of the royalty payments, and assuming a discount rate of 18%, were as follows: December 31, 2018 Growing space related to royalty square feet 44,403 Average yield grams/square feet 45 Total cannabis production million grams/year 12.0 Average price $/gram 5.50 On July 17, 2019, the Company issued 50,963 shares to the Company’s former Executive Chairman in consideration for advancing the remaining funds available to be advanced under the financial obligation. In addition, the Company agreed to indirectly acquire the Investment and Royalty Agreement pursuant to a purchase agreement whereby the Company would purchase all of the outstanding shares of the Purchaser from the Company’s former Executive Chairman for aggregate consideration of 3,680,000 common shares, 480,000 share purchase warrants (each exercisable for one common share at an exercise price of $15.94 for a period of three years from the date of issue) and a cash payment of $9.5 million. Upon completion of the Company’s initial public offering, the Purchaser was acquired on August 6, 2019 resulting in a loss on financial obligation of $59.6 million based on the initial public offering price of $US13.00. The cash payment of $9.5 million under the purchase agreement was paid prior to September 30, 2019.

Supplemental Cash Flow Disclosu

Supplemental Cash Flow Disclosures	12 Months Ended
	Dec. 31, 2020
Supplemental Cash Flow Disclosure [Abstract]
Supplemental Cash Flow Disclosures	2 8 . Supplemental cash flow disclosures Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Cash provided by (used in): Accounts receivable (2,037 ) (19,625 ) (2,469 ) Biological assets 13,789 19,328 (2,102 ) Inventory (12,315 ) (57,977 ) (923 ) Prepaid expenses and deposits 2,280 (7,213 ) 1,072 Accounts payable and accrued liabilities (20,793 ) 27,819 14,421 Convertible notes — (152 ) — Lease obligations — — 107 (19,076 ) (37,820 ) 10,106 Changes in non-cash working capital relating to: Operating (5,259 ) (41,626 ) 1,217 Investing (11,319 ) 1,659 10,282 Financing (2,498 ) 2,147 (1,393 ) (19,076 ) (37,820 ) 10,106 Cash interest paid 6,094 13,753 919 The following table reconciles long-term debt to cash flows arising from financing activities: Long-term debt (1) Balance at February 28, 2018 7,000 Cash changes: Proceeds from Credit Facilities 32,159 Proceeds from other debt instruments 8,546 Non-cash changes: Promissory Note issued to repurchase shares 6,931 Balance at December 31, 2018 54,636 Cash changes: Proceeds from Syndicated Credit Agreement, net of costs 82,687 Repayment of Credit Facilities (32,871 ) Proceeds from Term Debt Facility, net of costs 105,539 Repayment of other debt instruments (56,173 ) Debt acquired through acquisitions 33,618 Non-cash changes: Accretion 3,030 Amortization of debt issue costs 892 Extinguishment of debt issue costs 488 Reclassification to derivative liability (13,933 ) Balance at December 31, 2019 177,913 Cash changes: Repayment of Syndicated Credit Agreement (84,000 ) Syndicated Credit Agreement costs (493 ) Non-cash changes: Term Debt Facility extinguished (59,649 ) Term Debt Facility disposed of as part of Bridge Farm consideration (38,346 ) Accretion 2,665 Amortization of debt issue costs 1,910 Balance at December 31, 2020 — (1) Long-term debt, including the current portion of long-term debt

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Loss Per Share	2 9 . Loss per share Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Weighted average shares outstanding (000s) Basic and dilutive (1) 218,645 85,750 69,203 Continuing operations Net loss attributable to Sundial Growers Inc. (206,056 ) (142,533 ) (56,526 ) Per share - basic and diluted $ (0.95 ) $ (1.67 ) $ (0.82 ) Discontinued operations Net loss attributable to Sundial Growers Inc. (33,627 ) (128,931 ) — Per share - basic and diluted $ (0.15 ) $ (1.50 ) $ — Net loss attributable to Sundial Growers Inc. (239,683 ) (271,464 ) (56,526 ) Per share - basic and diluted $ (1.10 ) $ (3.17 ) $ (0.82 ) (1) For the year ended December 31, 2020, there were 1.0 million warrants exercisable, 2.2 million simple warrants exercisable and 1.1 million performance warrants exercisable that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2019 – 6.2 million warrants, 5.1 million simple warrants and 4.5 million performance warrants, ten months ended December 31, 2018 – 2.2 million simple warrants and 2.0 million performance warrants).

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2020
Disclosure Of Financial Instruments [Abstract]
Financial Instruments	30 . Financial instruments The financial instruments recognized on the consolidated statement of financial position are comprised of cash and cash equivalents, restricted cash, accounts receivable, long-term investments, accounts payable and accrued liabilities, long-term debt, derivative warrant liabilities and contingent consideration. (a) Fair value The carrying value of cash and cash equivalents, restricted cash, accounts receivable and accounts payable and accrued liabilities approximate the fair value of the respective assets and liabilities due to the short-term nature of those instruments. The carrying value of the long-term investment approximates its fair value of the cash consideration paid due to proximity of the transaction date to the year-end date. Fair value measurements of long-term debt, derivative warrant liabilities and contingent consideration are as follows: Fair value measurements using December 31, 2020 Carrying amount Level 1 Level 2 Level 3 Recurring measurements: Financial liabilities Derivative warrant liabilities 428 — — 428 Fair value measurements using December 31, 2019 Carrying amount Level 1 Level 2 Level 3 Recurring measurements: Financial liabilities Contingent consideration 32,501 — — 32,501 Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. As at December 31, 2020, the Company did not have any financial instruments measured at Level 1 fair value. Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. As at December 31, 2020, the Company did not have any financial instruments measured at Level 2 fair value. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Derivative warrant liabilities are designated as FVTPL. The fair value of derivative warrant liabilities is re-measured each reporting period with changes in fair value recognized in the consolidated statement of loss within finance income (costs). The fair value of derivative warrant liabilities is estimated by using a 50% weighting of two different valuation models. Assumptions used in these calculations include expected future share price, volatility, discount rate and various probability factors. At December 31, 2020, a 10% change in the material assumptions would change the fair value of derivative warrant liabilities by approximately $0.1 million. Contingent consideration classified as liabilities was part of the consideration paid for Bridge Farm and was a Level 3 financial liability that was re-measured each reporting period. Contingent consideration was estimated by discounting to present value the probability-weighted contingent payments expected to be made. Assumptions used in these calculations included expected future share price, discount rate and various probability factors. There were no transfers between Levels 1, 2 and 3 inputs during the period. (b) Interest rate risk management The Company was exposed to interest rate risk in that changes in market interest rates would cause fluctuations in the fair value of future cash flows. The Company was exposed to interest rate risk through its Syndicated Credit Agreement which had a variable interest rate. The Syndicated Credit Agreement was repaid in full and cancelled in December 2020 (note 15a). (c) Credit risk management Credit risk is the risk of financial loss if the counterparty to a financial transaction fails to meet its obligations. The Company manages risk over its accounts receivable by issuing credit only to credit worthy counterparties. The Company limits its exposure to credit risk over its long-term investments by ensuring the agreements governing the long-term investments are secured in the event of counterparty default. The Company considers financial instruments to have low credit risk when its credit risk rating is equivalent to investment grade. The Company assumes that the credit risk on a financial asset has increased significantly if it is outstanding past the contractual payment terms. The Company considers a financial asset to be in default when the debtor is unlikely to pay its credit obligations to the Company. The Company applies the simplified approach under IFRS 9 and has calculated expected credit losses (“ECLs”) based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. Impairment losses on accounts receivable recognized in profit or loss were as follows: As at December 31, 2020 December 31, 2019 Impairment loss (reversal) on trade receivables (506 ) 582 Impairment loss (reversal) on other receivables (126 ) 170 (632 ) 752 The movement in the allowance for impairment in respect of accounts receivable during the year was as follows: December 31, 2020 December 31, 2019 Balance, beginning of year 752 — Net remeasurement of impairment loss allowance (632 ) 752 Balance, end of year 120 752 The change in the impairment loss allowance during the year ended December 31, 2020, was mainly attributable to a decrease in trade receivables that were subject to a higher credit risk assessment. The maximum amount of the Company’s credit risk exposure is the carrying amounts of cash and cash equivalents, accounts receivable and long-term investments. The Company attempts to mitigate such exposure to its cash by investing only in financial institutions with investment grade credit ratings or secured investments. (d) Foreign currency risk management The Company is exposed to risks arising from fluctuations in currency exchange rates between the Canadian dollar and United States dollar. At December 31, 2020, the Company’s primary currency exposure related to the United States dollar (“USD”) balances. The following table summarizes the Company’s foreign currency balances subject to exchange risk for the currencies indicated: As at December 31, 2020 USD Cash and cash equivalents 1 Accounts payable and accrued liabilities (206 ) Net foreign exchange exposure (205 ) Translation to CAD 1.2732 CAD equivalent at period end exchange rate (261 ) As at December 31, 2019 USD Cash and cash equivalents 22,088 Accounts payable and accrued liabilities (2,150 ) Net foreign exchange exposure 19,938 Translation to CAD 1.2988 CAD equivalent at period end exchange rate 25,895 Based on the net foreign exchange exposure at the end of the year, if these currencies had strengthened or weakened by 10% compared to the Canadian dollar and all other variables were held constant, the after-tax earnings would have decreased or increased by approximately the following amounts: Year ended December 31 Year ended December 31 2020 2019 Impact on profit (loss) (26 ) 2,590 (e) Liquidity risk management Liquidity risk is the risk that the Company cannot meet its financial obligations when due. The Company manages liquidity risk by monitoring operating and growth requirements. Management believes its current capital resources and its ability to manage cash flow and working capital levels will be sufficient to satisfy cash requirements associated with funding the Company’s operating expenses to maintain capacity and fund future development activities for at least the next 12 months. However, no assurance can be given that this will be the case or that future sources of capital will not be necessary. The timing of expected cash outflows relating to financial liabilities at December 31, 2020 is as follows: Less than one year One to three years Three to five years Thereafter Total Accounts payable and accrued liabilities 23,308 — — — 23,308 Lease obligations 409 818 213 — 1,440 Balance, end of period 23,717 818 213 — 24,748

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Transactions	3 1 . Related party transactions a) Loan receivable agreements The Company has entered into separate shareholder loan agreements with two (December 31, 2019 – two) employees of the Company. The loans bear interest at rates ranging from 0-1.5% per annum and are secured by each employee’s shareholdings in the Company. The loans are each repayable in full upon the departure of an individual employee from employment, a change in control of the Company or sale of the Company. During the year ended December 31, 2020, $61 thousand was repaid by one of the employees. As at December 31, 2020, $0.1 million (December 31, 2019 - $0.2 million), had been advanced under these loan agreements. b) Related party transactions and balances Transactions Balance outstanding Year ended December 31 Year ended December 31 December 31 December 31 2020 2019 2020 2019 Marketing, brand research and development (a) 1,144 3,117 — (265 ) Legal services (b) 2,462 3,895 (510 ) (397 ) 3,606 7,012 (510 ) (662 ) (a) A former member of the Board of Directors controls a company that provides marketing, brand research and development services. (b) A member of the Board of Directors was a partner at a law firm prior to his departure which provides legal services to the Company. All transactions were conducted at the exchange amount agreed to with the related parties. a) Compensation of key management personnel The Company considers directors and officers of the Company as key management personnel. Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Salaries and short-term benefits 1,944 3,295 1,237 Share-based compensation 7,629 23,715 2,414 9,573 27,010 3,651

Capital Management

Capital Management	12 Months Ended
	Dec. 31, 2020
Disclosure Of Objectives Policies And Processes For Managing Capital Abstract
Capital Management	3 2 . Capital management The Company defines its capital as its shareholder’s equity and debt. Except as otherwise disclosed in these consolidated financial statements, there are no restrictions on the Company’s capital. The Company’s objectives with respect to the management of capital are to: • Maintain financial flexibility in order to preserve its ability to meet financial obligations; • Deploy capital to provide an appropriate investment return to its shareholders; and, • Maintain a capital structure that allows various financing alternatives to the Company as required.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Disclosure Of Commitments And Contingencies [Abstract]
Commitments and contingencies	3 3 . Commitments and contingencies (a) Commitments The Company has entered into certain supply agreements to provide dried cannabis and cannabis products to third parties. The contracts require the provision of various amounts of dried cannabis on or before certain dates. Should the Company not deliver the product in the agreed timeframe, financial penalties apply which may be paid either in product in-kind or cash. Under these agreements, the Company has accrued financial penalties payable as at December 31, 2020 of $1.5 million (December 31, 2019 - $1.5 million). (b) Contingencies From time to time, the Company is involved in various claims and legal actions which occurred in the ordinary course of operations, the losses from which, if any, are not anticipated to be material to the financial statements.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Disclosure Of Nonadjusting Events After Reporting Period [Abstract]
Subsequent events	3 4 . Subsequent events Registered Offerings On February 2, 2021, the Company issued 100.0 million series A units (the “Series A Units”), each consisting of one common share and one-half series A warrant (collectively, the “Series A Warrants”) to purchase one common share and 33.3 million series B units (the “Series B Units”), each consisting of one pre-funded series B warrant (the “Series B Warrants”) to purchase one common share and one-half Series A Warrant to purchase one common share (collectively, the “January 2021 Units Offering”). Each Series A Unit was sold at a price of US$0.75 per unit and each Series B Unit was sold at a price of US$0.75 per unit, less US$0.0001 per unit. Gross proceeds from this offering were US$100.0 million. The Series A Warrants and Series B Warrants are exercisable immediately and have a term of five years commencing on the date of issuance. The exercise price of the Series A Warrants is US$0.80 per common share and the exercise price of the Series B Warrants is US$0.0001 per common share. On February 2, 2021, the entire 33.3 million Series B Warrants were exercised resulting in the issuance of 33.3 million common shares. On February 10, 2021, 3.3 million Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 3.3 million common shares and gross proceeds to the Company of US$2.7 million. On February 4, 2021, the Company issued 60.5 million additional series A units (the “Additional Series A Units”), each consisting of one common share and one-half additional series A warrant (collectively, the “Additional Series A Warrants”) to purchase one common share and 14.0 million additional On February 4, 2021, the entire 14.0 million Additional Series B Warrants were exercised resulting in the issuance of 14.0 million common shares. On February 10, 2021, 2.3 million Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 2.3 million common shares and gross proceeds to the Company of US$2.5 million. On February 22, 2021, (i) the remaining 63.3 million Series A Warrants were exercised at a weighted average exercise price of US$0.80 per warrant resulting in the issuance of 63.3 million common shares and gross proceeds to the Company of US$50.7 million and (ii) the remaining 35.0 million Additional Series A Warrants were exercised at a weighted average exercise price of US$1.10 per warrant resulting in the issuance of 35.0 million common shares and gross proceeds to the Company of US$38.5 million. In connection with this exercise, the Company issued 98.3 million new warrants (the “New Warrants”), each entitling the holder to purchase one common share at an exercise price of US$1.50, subject to customary anti-dilution adjustments. The Company has granted the holders rights to have the common shares issuable upon exercise of the New Warrants registered pursuant to a registration statement filed with the SEC. The New Warrants are immediately exercisable and have a term of 42 months from the effective date of the registration statement. Nasdaq minimum bid requirement As previously reported, the Company was notified by Nasdaq on May 12, 2020 that the bid price for its common shares was not in compliance with the Nasdaq minimum bid price requirement. At that time, the Company had until December 28, 2020 to regain compliance. On December 11, 2020, the Company announced that it had received approval to transfer the listing of its common shares to the Nasdaq Capital Market. The transfer allows the Company to take advantage of the additional 180 calendar day compliance period offered by the Nasdaq Capital Market, which extended the period that the Company had to regain compliance with Nasdaq’s minimum bid price requirement. On February 12, 2021, the Company was notified by Nasdaq that the Company had regained compliance with the minimum bid requirement as the bid price for its common shares closed at or above US$1.00 per share for the 10 consecutive business days between February 1, 2021, and February 12, 2021. Indiva investment On February 16, 2021, the Company announced a $22 million strategic investment (the “Indiva Investment”) into Indiva Limited (“Indiva”). Indiva is a leading Canadian producer of cannabis edibles. The Indiva Investment closed on February 23, 2021. The Indiva Investment was completed in the form of a brokered private placement of 25 million common shares of Indiva at a price of $0.44 per common share, to raise gross proceeds of $11 million, and a non-revolving term loan to Indiva in the principal amount of $11 million. Strategic capital partnership On March 15, 2021, the Company and SAF Opportunities LP, a member of the SAF Group (“SAF”) announced they had entered into an agreement to form a 50/50 joint venture (the “Joint Venture”) through a new corporation, SunStream Bancorp Inc. (“SunStream”). The Joint Venture will leverage a strategic financial and operational partnership to generate asymmetrically enhanced risk-return opportunities in the cannabis industry to provide exposure to a portfolio of attractive debt, equity and hybrid investments. The Joint Venture will focus on cannabis-related verticals, seeking both Canadian and international opportunities and investments. The Joint Venture’s first mandate is the formation of a special opportunities fund with commitments from third party limited partners alongside an initial commitment from Sundial of $100 million. The Joint Venture expects to pursue additional potential mandates, including a Canadian SPAC and other investments.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Significant Accounting Policies [Abstract]
Cash and cash equivalents	Cash and cash equivalents Cash and cash equivalents include cash on hand, deposits held with banks and other short-term liquid investments with maturities of less than 90 days.
Restricted cash and cash equivalents	Restricted cash and cash equivalents Restricted cash is recorded as current assets representing the minimum balance required in accordance with the Syndicated Credit Agreement for interest coverage and funds held in trust by the Town of Olds, Alberta in accordance with municipal regulations related to the granting of a building permit.
Biological assets	Biological assets The Company’s biological assets consist of cannabis plants. The Company capitalizes all direct and indirect costs related to the biological transformation of the biological assets between the point of initial recognition and the point of harvest, including labour related costs, grow consumables, materials, utilities, facilities costs, depreciation and quality and testing costs. Biological assets are then recorded at fair value and consist of cannabis plants in various stages of vegetation, including cannabis clones which have not been harvested. Net unrealized changes in fair value of biological assets less cost to sell during the period are included in the results of operations for the related period. Biological assets are valued in accordance with IAS 41 and are presented at their fair values less costs to sell up to the point of harvest. The fair values are determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts the amount for the expected selling price less costs to produce and sell per gram. The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. Our method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest. The estimated expected harvest yield is based on assumptions of the estimated yield per plant and the weighted average number of growing weeks completed as a percentage of total expected growing weeks as at year end. These estimates are subject to volatility in market prices and several uncontrollable factors, which could significantly affect the fair value of biological assets in future periods. Differences from the anticipated yield will be reflected in the net change in fair value of biological assets in future periods.
Inventory	Inventory Inventories of harvested cannabis are valued at the lower of cost and net realizable value. Inventories of harvested cannabis are transferred from biological assets at their fair value less cost to sell up to the point of harvest, which becomes the initial deemed cost. All subsequent direct and indirect post-harvest costs are capitalized to inventory as incurred, including labor related costs, consumables, materials, packaging supplies, utilities, facilities costs, as well as quality and testing costs. Net realizable value is determined as the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale. Inventories for resale and cannabis supplies and consumables are initially valued at cost and subsequently at the lower of cost and net realizable value. The valuation of biological assets at the point of harvest is used as the measurement basis for all cannabis-based inventory and, thus, any critical estimates and judgements related to the valuation of biological assets are also applicable to inventory. The valuation of work-in-progress and finished goods also requires the estimate of conversion costs incurred, which become part of the carrying amount of the inventory.
Property, plant, and equipment	Property, plant, and equipment Property, plant and equipment are carried at cost less accumulated depreciation, less any recognized impairment losses. The cost of additions, betterments, renewals, and interest during construction is capitalized. Each part of a component of property, plant and equipment with a cost that is significant in relation to the total cost of the component is depreciated separately. When the cost of replacing a portion of a component of property and equipment is capitalized, the carrying amount of the replaced component is derecognized. Depreciation of construction in progress assets commences when the assets are ready for their intended use or when a Health Canada producer’s license is granted. The assets’ residual values and useful lives are reviewed, and adjusted as appropriate, at the end of each reporting period. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are accounted for by adjusting the depreciation period or method, as appropriate, and are treated as changes in accounting estimates. Any gain or loss arising on the disposal or retirement of a component of property and equipment is determined as the difference between the sale proceeds and the carrying amount of the asset and is recognized in the consolidated statements of loss and comprehensive loss. Property, plant and equipment are depreciated as they become available for use. Buildings are not depreciated until a producer’s license is obtained. For assets available for use, depreciation is computed using the straight-line method over the estimated useful life of the assets, as described below: Land n/a Production facilities 20 years Equipment 2 to 10 years Right-of-use assets Shorter of estimated useful life or lease term Construction in progress n/a
Intangible assets	Intangible assets Intangible assets are recorded at cost less accumulated amortization and impairment losses, if any. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Amortization of definite life intangibles is provided on a straight-line basis over their estimated useful lives, once the intangible asset is available for use, as described below. If the intangible asset is not yet available for use it will be tested for impairment on an annual basis in accordance with IAS 38. The Company’s intangible assets at December 31, 2020 are comprised of the following: • Intellectual property purchased from Sun 8 Holdings Inc. consisting of world-wide proprietary rights to certain cannabis brands, including patents, copyrights and trademarks with a useful life of 15 years. • Intellectual property acquired through the acquisition of Pathway RX Inc. consisting of proprietary rights to certain technology, copyrights and trademarks with a useful life of 20 years.
Impairment of assets	Impairment of assets Management assesses and continually monitors internal and external indicators of impairment relating to our assets. The assessment of indicators of impairment takes into account various factors including the likelihood of obtaining future licenses from Health Canada, the demand for cannabis for medical and recreational purposes, the price of cannabis, and changes in market discount rates. (i) Financial assets We apply an expected credit loss, or ECL, model to all debt financial assets not held at fair value through profit and loss, or “FVTPL”, where credit losses that are expected to transpire in futures years are provided for, irrespective of whether a loss event has occurred or not as at the statement of financial position date. For trade receivables, we have applied the simplified approach under IFRS 9 and have calculated ECLs based on lifetime expected credit losses, taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. ECL’s are a probability-weighted estimate of credit losses. Credit losses are measured as the present value of the difference between the cash flows due in accordance with the contract and the cash flow we expect to receive. ECL’s are discounted at the effective interest rate of the financial asset. (ii) Non-financial assets The carrying amounts of our property, plant and equipment and intangible assets, including goodwill, are assessed for impairment indicators at each reporting period end to determine whether there is an indication that such assets have experienced impairment. If such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss, if any. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s or group of assets estimated fair value less costs to sell and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable independent cash inflows (a cash generating unit, or CGU). Where an impairment loss is subsequently determined to have reversed, the carrying amount of the asset (or CGU) is adjusted to the revised estimate of its recoverable amount but limited to the carrying amount that would have been determined had no impairment loss been recognized for the asset (or CGU) previously. A reversal of an impairment loss is recognized immediately in the statements of loss and comprehensive loss.
Financial instruments	Financial instruments The Company classifies the fair value of financial instruments according to the following hierarchy based on the amount of observable inputs used to value the instruments: Level 1 – unadjusted quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2 – quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Financial assets and liabilities are recognized when the Company becomes a party to the contractual provisions of the instrument. A financial asset or liability is measured initially at fair value plus, for an item not measured at FVTPL, transaction costs that are directly attributable to its acquisition or issuance. (i) Financial assets At initial recognition, a financial asset is classified and measured at: amortized cost, FVTPL or Fair Value Through Other Comprehensive Income depending on the business model and contractual cash flows of the instrument. Financial assets are derecognized when the rights to receive cash flows from the assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership. A substantial modification to the terms of an existing financial asset results in the derecognition of the financial asset and the recognition of a new financial asset at fair value. In the event that the modification to the terms of an existing financial asset do not result in a substantial difference in the contractual cash flows the gross carrying amount of the financial asset is recalculated and the difference resulting from the adjustment in the gross carrying amount is recognized in earnings or loss. The Company’s cash and cash equivalents, restricted cash and accounts receivable are measured at amortized cost. The Company’s long-term investment is measured at FVTPL. The Company has no financial assets measured at Fair Value Through Other Comprehensive Income. (ii) Financial liabilities Financial liabilities are initially measured at amortized cost or FVTPL. Accounts payable and accrued liabilities are initially recognized at the amount required to be paid less any required discount to reduce the payables to fair value. Long-term debt is recognized initially at fair value, net of any transaction costs incurred, and subsequently at amortized cost using the effective interest method. Financial liabilities are derecognized when the liability is extinguished. A substantial modification of the terms of an existing financial liability is recorded as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of a financial liability extinguished and the consideration paid is recognized in earnings or loss. Where a financial liability is modified in a way that does not constitute an extinguishment, the modified cash flows are discounted at the liability’s original effective interest rate. Transaction costs paid to third parties in a modification are amortized over the remaining term of the modified debt. The Company’s accounts payable and accrued liabilities and long-term debt are measured at amortized cost. The Company’s convertible notes were designated as FVTPL upon initial recognition as the notes contained multiple embedded derivatives. The Company’s derivative warrant liabilities were designated as FVTPL upon initial recognition. The Company’s contingent consideration was designated as FVTPL.
Non-monetary transactions	Non-monetary transactions All non-monetary transactions are measured at the fair value of the asset surrendered or the asset received, whichever is more reliable, unless the transaction lacks commercial substance, or the fair value cannot be reliably established. The lack of commercial substance requirement is met when the future cash flows are expected to change significantly as a result of the transaction. When the fair value of a non-monetary transaction cannot be reliably measured, it is recorded at the carrying amount (after reduction, when appropriate, for impairment) of the asset given up, adjusted by the fair value of any monetary consideration received or given. When the asset received or the consideration given consists of shares in an actively traded market, the value of those shares will be considered fair value.
Compound financial instruments	Compound financial instruments The liability component of a compound financial instrument is recognized initially at the fair value of a similar liability which does not have an equity conversion option. The equity component is recognized initially as the difference between the fair value of the compound financial instrument taken as a whole and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. The Company’s compound financial instruments are comprised of convertible notes. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is not re-measured subsequent to initial recognition. Interest and losses and gains relating to the financial liability are recognized in the consolidated statements of loss and comprehensive loss. On conversion, the financial liability is reclassified to equity; no gain or loss is recognized on conversion.
Revenue	Revenue Under IFRS 15, to determine the amount and timing of revenue to be recognized, we follow a five-step model: 1. Identifying the contract with a customer 2. Identifying the performance obligations 3. Determining the transaction price 4. Allocating the transaction price to the performance obligations 5. Recognizing revenue when/as performance obligations are satisfied Gross revenue from the direct sale of cannabis for a fixed price is recognized when we transfer control of the goods to the customer. The transfer of control is specific to each contract and can range from the point of delivery to a specified length of time for the customer to accept the goods. For contracts that permit the customer to return goods, revenue is recognized to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Therefore, the amount of revenue recognized is adjusted for expected returns, which are estimated based on historical data and management’s expectation of future returns. In these circumstances, a refund liability and a right to recover returned goods asset are recognized. The right to recover returned goods asset is measured at the former carrying amount of the inventory less any expected costs to recover goods. The refund liability is included in accounts payable and accrued liabilities and the right to recover returned goods is included in inventory. The Company reviews its estimate of expected returns at each reporting date and updates the amounts of the asset and liability accordingly. Gross revenue earned in Canada includes excise taxes, which we pay as principal, but excludes duties and taxes collected on behalf of third parties. Net revenue is gross revenue less excise taxes. Gross revenue is recognized to the extent that it is highly probable that a significant reversal will not occur. Therefore, gross revenue is stated net of expected price discounts, allowances for customer returns and certain promotional activities and similar items. Generally, payment of the transaction price is due within credit terms that are consistent with industry practices, with no element of financing.
Research and development	Research and development Research costs are expensed in the period incurred. Development costs are expensed in the period incurred unless the Company believes a development project meets the generally accepted criteria for deferral and amortization of IAS 38 “Intangible Assets”. Research and development costs comprise consulting fees and license acquisition fees. No development costs have been capitalized as at December 31, 2020 or December 31, 2019.
Share-based compensation	Share-based compensation The fair value of share-based compensation expenses is estimated using the Black-Scholes pricing model and relies on a number of estimates, such as the expected life of the award, the volatility of the underlying share price, the risk-free rate of return and the estimated rate of forfeiture of awards granted. Share-based compensation expense includes the expense for the issue of simple and performance warrants, stock options, restricted share units and deferred share units to employees, directors, and others at the discretion of our board of directors. Given the absence of an active trading market for the Company’s common shares prior to its initial public offering, determining the fair value of the Company’s common shares required our board of directors to make complex and subjective judgments. Our board of directors, with input from management, exercised significant judgment and considered numerous objective and subjective factors to determine the fair value of the Company’s common shares as of the date of each grant. For periods prior to January 1, 2019, the fair value of share-based compensation expense was primarily estimated using the value of the equity or convertible security issued to third parties for cash within a reasonable period of time of the grant to the employee. Subsequent to January 1, 2019, the fair value of share-based compensation expenses was estimated using the value of the equity or convertible security issued to third parties for cash within a reasonable period of time of the grant to the employee, as well as, other factors, including: the Company’s stage of development; the impact of significant corporate events, operational changes or milestones; material risks related to the business; the Company’s financial condition and operating results, including its revenue, history of net losses and levels of available capital resources; equity market conditions affecting comparable public companies; general U.S. market conditions; the likelihood and potential timing of achieving a liquidity event or completing an offering of common shares, such as an initial public offering; and the instruments involved illiquid securities of a private company. Subsequent to the Company’s IPO on August 6, 2019, the fair value of the Company’s shares is based on public trading data.
Income taxes	Income taxes Income taxes are recognized in the consolidated statements of loss and comprehensive loss, except to the extent that they relate to items recognized directly in equity, in which case the tax is recognized in equity. Current taxes are generally the expected income tax payable on taxable income for the reporting period, calculated using rates enacted or substantively enacted at the consolidated statements of financial position dates, and includes any adjustment to income tax payable or recoverable in respect of previous periods. Uncertain income tax positions are accounted for using the standards applicable to current income tax assets and liabilities. Liabilities and assets are recorded to the extent they are deemed to be probable. Deferred tax is recognized using the asset and liability method, based on temporary differences between financial statement carrying amounts of assets and liabilities, and their respective income tax bases. Deferred tax is determined using tax rates that have been enacted or substantively enacted by the consolidated statements of financial position date and are expected to apply when the related deferred tax asset is realized, or the deferred tax liability is settled. Deferred tax is not accounted for where it arises from initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the transaction, affects neither accounting nor taxable income (loss). The amount of deferred tax recognized is based on the expected manner and timing of realization or settlement of the carrying amount of assets and liabilities. Deferred tax assets are recognized only to the extent that it is probable that future taxable income will be available for which the temporary differences can be utilized. Deferred tax assets are reviewed at each consolidated statements of financial position date and adjusted to the extent that it is no longer probable that the related tax benefit will be realized. Tax assets and liabilities are offset when the Company has a legally enforceable right to offset the recognized amounts and intends either to settle on a net basis or to realize the asset and settle the liability simultaneously.
Business combinations	Business combinations Business combinations are accounted for using the acquisition method of accounting when the acquired assets meet the definition of a business. The acquired identifiable assets and liabilities and contingent liabilities assumed in a business combination are measured at their fair values at the acquisition date. The cost of an acquisition is measured as cash paid and the fair value of assets given, equity instruments issued and liabilities incurred or assumed at the acquisition date. Any excess of the cost of acquisition over the fair value of the identifiable assets, liabilities and contingent liabilities acquired is recorded as goodwill. If the cost of the acquisition is less than the fair value of the net assets acquired, the difference is recognized immediately in net income. Transactions costs associated with business combinations are expensed as incurred.
Goodwill	Goodwill The Company records goodwill relating to a business combination when the purchase price exceeds the fair value of the net identifiable assets and liabilities of the acquired business. The goodwill balance is assessed for impairment annually or when facts and circumstances indicate that it is impaired. Goodwill is tested for impairment at a CGU level by comparing the carrying amount to the recoverable amount, which is determined as the greater of fair value less costs of disposal and value in use. Any excess of the carrying amount over the recoverable amount is the impaired amount. The recoverable amount estimates are categorized as Level 3 according to the fair value hierarchy. Impairment charges are recognized in net income. Goodwill is reported at cost less any accumulated impairment. Goodwill impairments are not reversed.
Non-controlling Interests	Non-controlling interests The Company recognizes non-controlling interests in an acquired entity either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets, determined on an acquisition-by-acquisition basis.
Leases	leases A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease obligation at the lease commencement date. The right-of-use asset is initially measured at cost, and subsequently at cost less any accumulated depreciation and impairment losses and adjusted for certain remeasurements of the lease obligation. Depreciation is recognized on the lease asset over the shorter of the estimated useful life of the asset or the lease term. The lease obligation is initially measured at the present value of the lease payments that have not been paid at the commencement date, discounted at the rate implicit in the lease or, if that rate cannot be readily determined, the Company’s incremental borrowing rate. The lease obligation is subsequently increased by the interest cost on the lease obligation and decreased by lease payments made. Lease payments are allocated between the liability and interest expense. Interest expense is recognized on the lease obligation using the effective interest rate method and payments are applied against the lease obligation. The carrying amounts of the right-of-use assets, lease obligations, and the resulting interest and depreciation expense are based on the implicit interest rate within the lease arrangement or, if this information is unavailable, the incremental borrowing rate. Incremental borrowing rates are based on judgments including economic environment, term, and the underlying risk inherent to the asset.
Government grants	GOVERNMENT GRANTS Government grants are recognized when there is reasonable assurance that the grant will be received, and all attached conditions will be complied with. If a grant is received but reasonable assurance and compliance with conditions is not achieved, the grant is recognized as a deferred liability until such conditions are fulfilled. When the grant relates to an expense item in nature, it is recognized as “government subsidies” in profit or loss on a systematic basis in the period in which the costs are incurred.
New accounting standards	New accounting standards The following accounting standards were effective for annual periods beginning on or after January 1, 2020 and did not have a material impact on the Company’s consolidated financial statements: • Interest Rate Benchmark Reform (Amendments to IFRS 9, IAS 39 and IFRS 7) There are new accounting standards, amendments to accounting standards and interpretations that are effective for annual periods beginning on or after January 1, 2021 that have not been applied in preparing the consolidated financial statements for the year ended December 31, 2020. These standards and interpretations are not expected to have a material impact on the Company’s consolidated financial statements and include: • Onerous contracts – Cost of Fulfilling a Contract (Amendments to IAS 37). • Interest Rate Benchmark Reform – Phase 2 (Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4 and IFRS 16). • COVID-19 Related Rent Concessions (Amendments to IFRS 16).

Basis of Presentation (Tables)

Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Basis Of Presentation [Abstract]
Summary of Subsidiaries	Subsidiaries Jurisdiction of incorporation Percentage ownership Sprout Technologies Inc. Alberta, Canada 100 % KamCan Products Inc. British Columbia, Canada 100 % 2011296 Alberta Inc. Alberta, Canada 100 % Sundial Deutschland GmbH Germany 100 % Sundial Portugal, Unipessoal LDA Portugal 100 % Pathway Rx Inc. Alberta, Canada 50 % 2657408 Ontario Inc. Ontario, Canada 100 % NGBA-BC Holdings Ltd. British Columbia, Canada 100 %

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Significant Accounting Policies [Abstract]
Summary of Estimated Use Full Life of Asset	For assets available for use, depreciation is computed using the straight-line method over the estimated useful life of the assets, as described below: Land n/a Production facilities 20 years Equipment 2 to 10 years Right-of-use assets Shorter of estimated useful life or lease term Construction in progress n/a

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Abstract]
Summary Results of Discontinued Operations	Results of discontinued operations Year ended December 31 2020 (2) 2019 (1) Gross revenue 22,139 12,298 Net revenue 22,139 12,298 Cost of sales 15,633 9,426 Gross margin before fair value adjustments 6,506 2,872 Change in fair value of biological assets 1,064 386 Change in fair value realized through inventory (1,122 ) — Gross margin 6,448 3,258 General and administrative 8,585 5,515 Sales and marketing 1,418 820 Depreciation and amortization 2,752 3,482 Foreign exchange 1,057 (1,779 ) Share-based compensation (826 ) 826 Goodwill impairment — 100,305 Loss from operations (6,538 ) (105,911 ) Transaction costs — (1,588 ) Finance costs (10,083 ) (3,982 ) Loss on contingent consideration (2,252 ) (18,645 ) Gain on investment — 165 Gain (loss) on disposition of PP&E — 13 Loss on disposition of Bridge Farm (14,979 ) — Loss before income tax (33,852 ) (129,948 ) Income tax recovery 225 1,017 Net loss (3) (33,627 ) (128,931 ) (1) Period July 2, 2019 to December 31, 2019 (2) Period January 1, 2020 to June 5, 2020 (3) Net loss from the discontinued operations is attributable entirely to the owners of the Company.
Summary of Effect of Disposal on Financial Position	Effect of disposal on the financial position of the Company Cash and cash equivalents 2,963 Accounts receivable 15,641 Biological assets 2,831 Inventory 787 Property, plant and equipment 88,698 Goodwill 11,345 Intangible assets 23,884 Accounts payable and accrued liabilities (22,792 ) Lease obligation (14,894 ) Deferred tax liability (3,115 ) Accumulated other comprehensive income (7,466 ) Net assets and liabilities 97,882 Consideration received Term Debt Facility 45,000 Contingent consideration liability 34,912 Cancellation of common shares 2,991 Total consideration 82,903 Loss on disposition (14,979 )

Business Acquisitions (Tables)

Business Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Business Combinations [Line Items]
Summary of Fair Value of Assets and Liabilities Acquired	The purchase price was as follows: Issuance of common shares 2,601 Contingent consideration ( i ) 2,279 4,880 (i) Contingent consideration valued at $2.3 million representing the granting of up to 280,000 warrants to purchase common shares of the Company at an exercise price of $1.81 per share, subject to the achievement of certain milestone gross revenue derived from the Pathway Royalty Activities, which has been presented on the consolidated statement of financial position as contingent consideration in the form of equity.
Pathway Rx Inc
Disclosure Of Business Combinations [Line Items]
Summary of Purchase Price Allocated	The purchase price was allocated as follows: December 31, 2019 Intangible assets 13,552 Accounts payable and accrued liabilities ) (184 ) Deferred tax liability (3,609 ) Non-controlling interest (50%) (4,879 ) 4,880
Sundial U K Limited | Bridge Farm
Disclosure Of Business Combinations [Line Items]
Summary of Fair Value of Assets and Liabilities Acquired	The fair value of the assets and liabilities acquired was as follows: December 31, 2019 Cash 77,023 Issuance of common shares 37,248 Contingent consideration 15,991 130,262
Summary of Purchase Price Allocated	The purchase price was allocated as follows: December 31, 2019 Accounts receivable 7,403 Inventory 470 Biological assets 1,288 Property, plant and equipment 58,368 Intangible assets 25,471 Accounts payable (14,293 ) Long term debt (33,618 ) Lease obligations (15,179 ) Deferred income tax liability (4,355 ) Goodwill 104,707 130,262

Accounts Receivable (Tables)

Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2020
Subclassifications Of Assets Liabilities And Equities [Abstract]
Summary of Accounts Receivable	As at December 31, 2020 December 31, 2019 Trade receivables 15,786 24,684 Other receivables 112 2,954 15,898 27,638

Biological Assets (Tables)

Biological Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Changes In Biological Assets [Abstract]
Summary of Change in Carrying Value of Biological Assets	The Company’s biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets are as follows: As at December 31, 2020 December 31, 2019 Balance, beginning of year 14,309 876 Increase in biological assets due to capitalized costs 39,957 62,331 Net change in fair value of biological assets 6,496 30,726 Transferred to inventory upon harvest (54,388 ) (80,991 ) Acquisitions — 1,288 Disposition of Bridge Farm (note 5) (2,831 ) — Foreign currency translation (12 ) 79 Balance, end of year 3,531 14,309
Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets	Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows: Assumption Input Weighted average input Effect of 10% change ($000s) December 31 2020 December 31 2019 December 31 2020 December 31 2019 Yield per square foot of growing space (1) Grams 45 47 347 1,183 Average net selling price (2) $/gram 5.13 5.47 1,022 3,021 After harvest cost to complete and sell $/gram 1.32 2.34 291 267 (1) Varies by strain; obtained through historical growing results or grower estimate if historical results are not available. (2) Varies by strain and sales market; obtained through average selling prices or estimated future selling prices if historical results are not available.

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2020
Classes Of Inventories [Abstract]
Summary of Inventories	As at December 31, 2020 December 31, 2019 Harvested cannabis 20,358 50,403 Cannabis supplies and consumables 5,255 8,808 Ornamental flowers, supplies and consumables (note 5) — 731 25,613 59,942

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Schedule of Property Plant and Equipment	Land and buildings Production facilities Equipment Right of use assets Construction in progress (“CIP”) Total Cost Balance at December 31, 2018 5,246 23,336 7,254 — 54,061 89,897 Adoption of IFRS 16 — — (327 ) 1,333 — 1,006 Acquisitions 15,860 21,294 247 14,648 6,360 58,409 Additions 1,517 283 3,393 687 134,183 140,063 Transfers from CIP 3,406 120,724 13,603 — (137,733 ) — Dispositions (31 ) — (159 ) (700 ) — (890 ) Foreign currency translation 608 805 10 541 1,160 3,124 Balance at December 31, 2019 26,606 166,442 24,021 16,509 58,031 291,609 Additions 8 213 2,886 763 4,319 8,189 Transfers from CIP 509 8,212 2,287 — (11,008 ) — Reclassification to assets held for sale (1,547 ) — — — (1,451 ) (2,998 ) Dispositions (499 ) (162 ) (50 ) (825 ) (991 ) (2,527 ) Disposition of Bridge Farm (note 5) (16,300 ) (21,587 ) (249 ) (14,431 ) (39,734 ) (92,301 ) Foreign currency translation (137 ) (181 ) (1 ) (122 ) (347 ) (788 ) Balance at December 31, 2020 8,640 152,937 28,894 1,894 8,819 201,184 Accumulated amortization and impairment Balance at December 31, 2018 — 312 1,094 — — 1,406 Adoption of IFRS 16 — — (100 ) — — (100 ) Depreciation 3 5,026 2,833 610 — 8,472 Impairment — — — — 162 162 Dispositions — — (130 ) (248 ) — (378 ) Foreign currency translation — 62 — 1 — 63 Balance at December 31, 2019 3 5,400 3,697 363 162 9,625 Depreciation 475 6,249 4,847 638 — 12,209 Impairment — 60,658 — — 5,659 66,317 Dispositions — (37 ) (44 ) (176 ) — (257 ) Disposition of Bridge Farm (note 5) (473 ) (2,879 ) — (251 ) — (3,603 ) Foreign currency translation (5 ) (27 ) — (3 ) — (35 ) Balance at December 31, 2020 — 69,364 8,500 571 5,821 84,256 Net book value Balance at December 31, 2019 26,603 161,042 20,324 16,146 57,869 281,984 Balance at December 31, 2020 8,640 83,573 20,394 1,323 2,998 116,928

Intangible assets (Tables)

Intangible assets (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Intangible Assets [Abstract]
Summary of Reconciliation of Changes in Intangible Assets and Goodwill	Brands and trademarks Patents Customer relationships Other Total Cost Balance at December 31, 2018 — — — — — Additions 5,295 — — — 5,295 Acquisitions 2,977 13,551 18,855 3,639 39,022 Foreign currency translation 114 — 723 139 976 Balance at December 31, 2019 8,386 13,551 19,578 3,778 45,293 Additions 150 — — — 150 Disposition of Bridge Farm (note 5) (3,066 ) — (19,415 ) (3,747 ) (26,228 ) Foreign currency translation (25 ) — (163 ) (31 ) (219 ) Balance at December 31, 2020 5,445 13,551 — — 18,996 Accumulated amortization Balance at December 31, 2018 — — — — — Depreciation 132 — 982 192 1,306 Foreign currency translation (1 ) — (6 ) (1 ) (8 ) Balance at December 31, 2019 131 — 976 191 1,298 Depreciation 441 677 842 165 2,125 Impairment — 12,874 — — 12,874 Disposition of Bridge Farm (note 5) (190 ) — (1,801 ) (353 ) (2,344 ) Foreign currency translation — — (17 ) (3 ) (20 ) Balance at December 31, 2020 382 13,551 — — 13,933 Net book value Balance at December 31, 2019 8,255 13,551 18,602 3,587 43,995 Balance at December 31, 2020 5,063 — — — 5,063

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill [Abstract]
Summary of Reconciliation of Changes in Goodwill	Net book value Balance at December 31, 2018 — Acquisitions through business combinations (note 6) 107,053 Foreign currency translation 4,692 Impairment (100,305 ) Balance at December 31, 2019 11,440 Disposition of Bridge Farm (note 5) (11,345 ) Foreign currency translation (95 ) Balance at December 31, 2020 —

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Subclassifications Of Assets Liabilities And Equities [Abstract]
Summary of Accounts Payable and Accrued Liabilities	December 31, 2020 December 31, 2019 Trade payables 4,849 20,228 Accrued and other liabilities 18,459 37,882 23,308 58,110

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2020
Borrowings [Abstract]
Summary of Debt	Interest rate Maturity Principal December 31 2020 December 31 2019 Syndicated Credit Agreement (a) Syndicated facility Prime + 2.5% Aug 27, 2021 74,000 — 82,910 Operating facility Prime + 2.5% Aug 27, 2021 5,330 — — Term Debt Facility (b) First tranche 9.75% Jul 27, 2023 115,000 — 95,003 — 177,913 Current portion — 177,913 Long term — —
Summary of Syndicated Credit Agreement	As at December 31, 2020 December 31, 2019 Principal value of debt — 84,000 Transaction costs — (1,313 ) Accretion — 223 — 82,910
Summary of Term Debt Facility	As at December 31, 2020 December 31, 2019 Principal value of debt — 115,000 Transaction costs — (9,461 ) Accretion — 3,397 Fair value assigned to warrants, at issuance — (13,933 ) — 95,003

Convertible Notes (Tables)

Convertible Notes (Tables)	12 Months Ended
	Dec. 31, 2020
Convertible Notes [Abstract]
Schedule of Secured Convertible Note	(a) Secured convertible note December 31, 2020 December 31, 2019 Balance, beginning of year — — Secured Convertible Note - fair value on issuance 54,693 — Change in fair value recognized in profit or loss (5,075 ) Converted to common shares (49,618 ) — Balance, end of year — —
Schedule of Change in Principal Balance of Secured Convertible Note	The following table presents the change in principal balance during the year: Principal balance December 31, 2020 Balance, beginning of year — Issued 73,227 Converted to common shares (73,227 ) Balance, end of year —
Schedule of Unsecured Convertible Note	(b) Unsecured convertible notes December 31, 2020 December 31, 2019 Balance, beginning of year — — Unsecured Convertible Notes - fair value on issuance 16,113 — Change in fair value recognized in profit or loss (2,066 ) Converted to common shares (13,943 ) — Unrealized foreign exchange loss (104 ) Balance, end of year — —
Schedule of Change in Principal Balance of Unsecured Convertible Note	The following table presents the change in principal balance during the year: Principal balance (USD) December 31, 2020 Balance, beginning of year — Issued 18,000 Converted to common shares (18,000 ) Balance, end of year —
Summary of Senior Convertible Notes	(c) Senior convertible notes December 31, 2020 December 31, 2019 Senior Convertible Notes issued — 93,192 Transaction costs — (2,819 ) Fair value attributable to conversion feature — (40,494 ) Balance attributable to debt portion upon issuance — 49,879 Accretion of note obligation — 1,223 Amortization of note issue costs — 93 Accrued interest — 1,903 Conversion to common shares — (53,098 ) Balance, end of year — —
Summary of Convertible Notes	(d) convertible notes December 31, 2020 December 31, 2019 Balance, beginning of year — 25,449 Unrealized foreign exchange gain — (209 ) Accrued interest — (152 ) Accretion — 2,443 Amortization of note issue costs — 745 Conversion to common shares — (18,139 ) Conversion to warrants — (5,947 ) Repayments — (4,190 ) Balance, end of year — —

Derivative Warrant Liabilities

Derivative Warrant Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Warrant Liabilities [Abstract]
Summary of Derivative Warrant Liabilities	December 31, 2020 December 31, 2019 Balance, beginning of year — — Secured Convertible Note Warrants - fair value on issuance (a) 6,683 — Unsecured Convertible Notes Warrants - fair value on issuance (b) 3,961 — Agent Warrants - fair value on issuance (c) 504 — Series A and Series B Warrants - fair value on issuance (d) 11,784 — Change in fair value recognized in profit or loss 12,995 — Converted to common shares (35,521 ) — Unrealized foreign exchange loss 22 — Balance, end of year 428 —
Summary of Outstanding Derivative Warrants	The following table summarizes outstanding derivative warrants as at December 31, 2020: Exercise price (USD) (1) Number of warrants Weighted average contractual life Series A Warrants 0.1766 500,000 4.6 Unsecured Convertible Notes Warrants 0.1766 500,000 3.0 Agent Warrants 1.00 1,080,000 4.4 2,080,000 3.0 (1) The conversion or exercise price, as applicable, is subject to full ratchet antidilution protection upon any subsequent transaction at a price lower than the price then in effect and standard adjustments in the event of any share split, share dividend, share combination, recapitalization or other similar transaction. If the Company issues, sells or enters into any agreement to issue or sell, any variable rate securities, the investors have the additional right to substitute the variable price (or formula) of such securities for the conversion or exercise price, as applicable.

Lease Obligations (Tables)

Lease Obligations (Tables)	12 Months Ended
	Dec. 31, 2020
Lease Liabilities [Abstract]
Summary of Lease Obligations	December 31, 2020 December 31, 2019 Balance, beginning of year 16,949 214 Adoption of IFRS 16 — 1,119 Acquisitions — 15,179 Liabilities incurred 763 674 Lease payments (937 ) (778 ) Dispositions (735 ) (468 ) Interest expense 416 444 Disposition of Bridge Farm (note 5) (14,894 ) — Foreign currency translation (122 ) 565 Balance, end of year 1,440 16,949 Current portion 409 722 Long-term 1,031 16,227
Summary of Minimum Lease Payments	The Company’s minimum lease payments are as follows: December 31, 2020 Less than one year 490 One to three years 895 Three to five years 222 Thereafter — Minimum lease payments 1,607 Amounts representing finance charges (167 ) Net minimum lease payments 1,440

Contingent Consideration (Table

Contingent Consideration (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Contingent Liabilities [Abstract]
Reconciliation of Contingent Consideration	December 31, 2020 December 31, 2019 Balance, beginning of year 32,501 — Acquisition of Bridge Farm — 15,991 Change in fair value recognized in profit or loss 2,252 18,645 Earn-out payments — (1,170 ) Unrealized foreign exchange loss 1,058 (1,779 ) Foreign currency translation (899 ) 814 Disposition of Bridge Farm (note 5) (34,912 ) — Balance, end of year — 32,501

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Major Components Of Tax Expense Income [Abstract]
Summary of Income Tax Expense (Recovery)	The following table reconciles the expected income tax expense (recovery) at the Canadian federal and provincial statutory income tax rates to the amounts recognized in the consolidated statements of loss and comprehensive loss for the years ended December 31, 2020, December 31, 2019 and ten months ended December 31, 2018: December 31, 2020 December 31, 2019 December 31, 2018 Loss before taxes (206,317 ) (146,307 ) (56,526 ) Statutory income tax rates 24.0 % 26.5 % 27.0 % Expected income tax recovery (49,516 ) (38,771 ) (15,262 ) Non-deductible share-based compensation 1,970 10,474 1,860 Non-deductible finance expense 2,130 15,981 2,304 Other non-deductible expenses 348 2,621 — Change in tax rates 1,528 3,305 — Deferred tax benefits not recognized 43,540 2,781 11,098 Income tax (recovery) expense — (3,609 ) —
Summary of Deferred Tax Assets (Liabilities)	Details of the deferred tax assets (liabilities) are as follows: December 31, 2020 December 31, 2019 Deferred tax assets (liabilities): Property, plant and equipment — (3,490 ) Inventory 8,388 1,881 Biological assets (8,388 ) (7,170 ) Intangible assets — (7,355 ) Non-capital losses — 12,769 Net deferred tax asset (liability) — (3,365 )
Summary of Unrecognized Deductible Temporary Differences	Deferred tax assets have not been recognized for the following deductible temporary differences: December 31, 2020 December 31, 2019 Unrecognized deductible temporary differences: Property, plant and equipment 36,782 — Intangible assets 536 — Share issue costs 11,112 16,779 Financial obligations and other 1,054 1,726 Inventory and biological assets 34,781 — Non-capital losses 171,205 54,472 Unrecognized deductible temporary differences 255,470 72,977
Summary of Movement in Deferred Income Tax Liability	The movement in deferred income tax liability is as follows: December 31, 2020 December 31, 2019 Balance, beginning of year 3,365 — Acquisition of Pathway Rx — 3,609 Acquisition of Bridge Farm — 4,355 Recognized in profit and loss — (3,609 ) Recognized in other comprehensive income (25 ) 27 Recognized in discontinued operations (note 5) (225 ) (1,017 ) Disposition of Bridge Farm (note 5) (3,115 ) — Balance, end of year — 3,365

Share Capital and Warrants (Tab

Share Capital and Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Share Capital And Warrants [Abstract]
Summary of Issued and Outstanding	(b) Issued and outstanding December 31, 2020 December 31, 2019 Note Number of Shares Carrying Amount Number of Shares Carrying Amount Balance, beginning of year 107,180,423 509,654 68,648,984 65,133 Initial public offering — — 11,000,000 189,518 Shares issued for assets — — 797,952 6,537 Share issuances 337,696,867 176,931 394,926 2,323 Shares issued to related parties — — 3,730,963 63,460 Share issuance costs — (5,593 ) — (12,770 ) Business acquisitions — — 2,696,800 39,849 Disposition of Bridge Farm 5 (2,716,271 ) (38,447 ) — — Convertible debt - conversions 16 373,371,318 63,002 13,108,676 113,526 Derivative warrants exercised 17 102,836,429 55,912 — — Warrants exercised — — 4,551,082 21,882 Shares issued for services — — 164,080 2,320 RSUs exercised 22(c) 475,367 587 57,960 195 Employee warrants exercised — — 2,029,000 17,681 Balance, end of year 918,844,133 762,046 107,180,423 509,654
Summary of Common Share Purchase Warrants	(c) Common share purchase warrants Number of Warrants Carrying Amount Balance at December 31, 2018 4,211,904 3,108 40% Warrants reclassified from derivative liability ( i ) 957,225 4,122 60% Warrants reclassified from derivative liability ( i ) 1,495,665 11,969 Warrants issued to related parties (ii) 480,000 5,833 Warrants issued on conversion of convertible notes (iii) 3,572,274 6,731 Warrants exercised (4,551,082 ) (3,931 ) Warrants expired (662 ) (1 ) Balance at December 31, 2019 6,165,324 27,831 Warrants issued 544,000 306 Warrants expired (3,232,434 ) (5,908 ) Warrants cancelled (2,452,890 ) (16,091 ) Balance at December 31, 2020 1,024,000 6,138 (i) On August 1, 2019, the 40% and 60% warrants issued as part of the term debt financing and initially classified as derivative liabilities as at June 30, 2019, were reclassified to equity as the number of warrants issuable and the exercise price for each tranche of warrants became fixed in conjunction with the initial public offering date. The exercise price for the 40% and 60% warrants were $21.63 and $20.76 respectively. (ii) 480,000 warrants with an exercise price of $15.94 were issued to a director of the Company in relation to the acquisition of the financial obligation. (iii) Equity units issued upon conversion of CAD denominated convertible notes included 3,095,386 warrants with an exercise price of $4.38 and vested immediately. Equity units issued upon conversion of USD denominated notes included 476,888 warrants with an exercise price of USD$3.75 and vested immediately.
Summary of Outstanding Warrants	The following table summarizes outstanding warrants as at December 31, 2020: Warrants outstanding and exercisable Issued in relation to Weighted average exercise price Number of warrants Weighted average contractual life (years) Acquisition of financial obligation 15.94 480,000 1.5 Financial services 4.60 544,000 8.6 9.91 1,024,000 5.3 The following table summarizes outstanding warrants as at December 31, 2019: Warrants outstanding and exercisable Issued in relation to Weighted average exercise price Number of warrants Weighted average contractual life (years) Convertible notes (USD) USD 3.75 444,888 0.8 Convertible notes (CAD) 4.38 2,787,546 0.7 Acquisition of financial obligation 15.94 480,000 2.5 Term debt financing (60%) 20.76 1,495,665 2.6 Term debt financing (40%) 21.63 957,225 2.6 11.97 6,165,324 1.6

Share-based Compensation (Table

Share-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Abstract]
Components of Share-based Compensation Expense	The components of share-based compensation expense are as follows: Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Simple warrants (a) 1,539 23,918 5,029 Performance warrants (a) (42 ) 11,023 1,860 Stock options (b) 651 98 — Restricted share units (c) 4,069 220 — Deferred share units (c) 2,349 1,119 — Shares issued for services — 2,320 521 8,566 38,698 7,410
Black-Scholes Option Pricing Model to Estimate the Fair Value of Units Granted	In determining the amount of share-based compensation, the Company used the Black-Scholes option pricing model to estimate the fair value of units granted during the year ended December 31, 2020, December 31, 2019 and ten months ended December 31, 2018 through application of the following assumptions: December 31, 2020 December 31, 2019 December 31, 2018 Risk-free interest rate 0.28% - 0.29% 1.41% - 1.88% 1.65% - 2.05% Expected life of units (years) 10 2 - 10 0.5 – 14 Expected annualized volatility 143% 97% - 116% 80% - 106% Expected dividend yield Nil Nil Nil Weighted average Black-Scholes value of each unit $1.13 - $1.17 $0.67 - $23.55 $1.76 - $3.81
Summary of Changes in Simple and Performance Warrants	The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2020: Simple warrants outstanding Weighted average exercise price Performance warrants outstanding Weighted average exercise price Balance at December 31, 2019 9,815,000 $ 4.01 5,798,822 $ 2.66 Forfeited (6,390,400 ) 3.79 (4,126,822 ) 2.04 Balance at December 31, 2020 3,424,600 $ 4.41 1,672,000 $ 4.19 The following table summarizes changes in the simple and performance warrants during the year ended December 31, 2019: Simple warrants outstanding Weighted average exercise price Performance warrants outstanding Weighted average exercise price Balance at December 31, 2018 6,129,866 $ 1.80 7,094,822 $ 2.04 Granted 4,795,200 6.32 723,200 12.23 Forfeited (733,866 ) 2.32 (366,400 ) 1.21 Exercised (376,200 ) 0.85 (1,652,800 ) 0.63 Balance at December 31, 2019 9,815,000 $ 4.01 5,798,822 $ 2.66
Summarizes Outstanding Simple and Performance Warrants	The following table summarizes outstanding simple and performance warrants as at December 31, 2020: Warrants outstanding Warrants exercisable Range of exercise prices Number of warrants Weighted average exercise price Weighted average contractual life (years) Number of warrants Weighted average exercise price Weighted average contractual life (years) Simple warrants $0.63 - $0.94 1,009,400 0.74 3.54 1,009,400 0.74 3.54 $1.25 - $1.88 400,000 1.56 3.59 400,000 1.56 3.59 $2.97 - $4.53 527,200 3.05 3.64 455,200 3.01 3.54 $6.25 - $9.38 1,318,400 6.33 5.18 275,200 6.61 5.10 $12.50 - $37.50 169,600 22.28 6.49 16,000 20.60 4.50 3,424,600 $ 4.41 4.34 2,155,800 $ 2.27 3.76 Performance warrants $0.63 - $0.94 498,667 0.70 n/a 370,667 0.72 n/a $1.25 - $1.88 282,133 1.42 n/a 247,467 1.40 n/a $2.97 - $4.53 624,000 3.13 n/a 397,333 3.10 n/a $6.25 - $9.38 150,933 7.32 n/a 38,400 6.25 n/a $12.50 - $37.50 116,267 27.52 n/a — — n/a 1,672,000 $ 4.19 n/a 1,053,867 $ 1.98 n/a The following table summarizes outstanding simple and performance warrants as at December 31, 2019: Warrants outstanding Warrants exercisable Range of exercise prices Number of warrants Weighted average exercise price Weighted average contractual life (years) Number of warrants Weighted average exercise price Weighted average contractual life (years) Simple warrants $0.63 - $0.94 4,019,000 0.68 5.62 3,635,000 0.68 5.62 $1.25 - $1.88 560,000 1.50 10.18 560,000 1.50 10.18 $2.97 - $4.53 1,232,000 3.18 5.62 848,000 3.10 5.11 $6.25 - $9.38 3,462,400 6.37 4.50 80,000 6.25 4.44 $12.50 - $37.50 541,600 18.08 7.87 9,600 21.88 9.05 9,815,000 $ 4.01 5.61 5,132,600 $ 1.29 6.02 Performance warrants $0.63 - $0.94 3,700,690 0.64 n/a 3,546,022 0.64 n/a $1.25 - $1.88 646,933 1.52 n/a 381,334 1.48 n/a $2.97 - $4.53 788,000 3.09 n/a 490,666 3.08 n/a $6.25 - $9.38 362,933 6.97 n/a 38,400 6.25 n/a $12.50 - $37.50 300,266 23.72 n/a — — n/a 5,798,822 $ 2.66 n/a 4,456,422 $ 1.02 n/a
Summary of Changes in Stock Options	The following table summarizes changes in stock options during the year ended December 31, 2020: Stock options outstanding Weighted average exercise price Balance at December 31, 2019 623,850 $ 4.33 Granted 481,600 1.16 Forfeited (384,850 ) 4.96 Balance at December 31, 2020 720,600 $ 1.82 The following table summarizes changes in the stock options during the year ended December 31, 2019: Stock options outstanding Weighted average exercise price Balance at December 31, 2018 — $ — Granted 623,850 4.33 Balance at December 31, 2019 623,850 $ 4.33
Summary of Outstanding Stock Options	The following table summarizes outstanding stock options as at December 31, 2020: Stock options outstanding Stock options exercisable Exercise prices Number of options Weighted average contractual life (years) Number of options Weighted average contractual life (years) $1.15 400,000 9.41 — — $1.19 81,600 9.49 81,600 9.49 $3.15 239,000 8.68 77,417 8.63 720,600 9.18 159,017 9.07 The following table summarizes outstanding stock options as at December 31, 2019: Stock options outstanding Stock options exercisable Exercise prices Number of options Weighted average contractual life (years) Number of options Weighted average contractual life (years) $3.15 373,850 9.21 22,500 4.97 $5.93 250,000 6.37 — — 623,850 7.97 22,500 4.97
Summary of Changes in RSUs and DSUs	The following table summarizes changes in RSUs and DSUs as at December 31, 2020: RSUs outstanding DSUs outstanding Balance at December 31, 2019 48,883 367,924 Granted 3,002,213 3,265,503 Forfeited (43,813 ) (310,164 ) Exercised (1,350,367 ) — Balance at December 31, 2020 1,656,916 3,323,263 The following table summarizes changes in RSUs and DSUs as at December 31, 2019: RSUs outstanding DSUs outstanding Balance at December 31, 2018 — — Granted 107,543 378,080 Forfeited (700 ) (7,617 ) Settled — (2,539 ) Exercised (57,960 ) — Balance at December 31, 2019 48,883 367,924

Revenue (Tables)

Revenue (Tables)	12 Months Ended
	Dec. 31, 2020
Revenue [Abstract]
Disaggregation of Revenue from Contracts with Customers	Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Provincial boards 55,315 13,386 — Medical 32 24 — Licensed producers 17,974 53,517 — Gross revenue (1) 73,321 66,927 — (1) The Company had four major customers each with revenue in excess of 10% of total cannabis revenue. Sales to major customers totaled $43.9 million for the year ended December 31, 2020 (December 31, 2019 – four major customers with sales of $40.7 million). Only one major customer had sales exceeding 10% of total cannabis revenue for both periods. The following table disaggregates revenue by form for the periods noted: Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Revenue from dried flower 51,424 58,246 — Revenue from vapes 18,447 504 — Revenue from oil 3,145 8,177 — Revenue from edibles 263 — — Revenue from concentrates 42 — — Gross revenue 73,321 66,927 —
Summary of Receivables from Contracts with Customers	The Company has recognized the following receivables from contracts with customers: December 31, 2020 December 31, 2019 December 31, 2018 Receivables, included in 'trade receivables' (note 7) 15,786 20,281 209

Other Operating Expenses (Table

Other Operating Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Expense By Nature [Abstract]
Summary of General and Administrative Expense	a) General and administrative Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Salaries and wages 11,634 15,262 3,847 Consulting fees 2,193 6,896 1,647 Office and general 9,843 9,533 1,738 Professional fees 4,658 3,559 877 Director fees 365 188 30 Other 3,336 3,496 170 32,029 38,934 8,309
Summary of Sales and Marketing Expense	b) Sales and marketing Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Marketing 4,839 3,093 1,733 Events 393 2,961 — Research 57 199 24 Media 448 1,815 623 5,737 8,068 2,380

Finance Costs (Tables)

Finance Costs (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Finance Cost [Abstract]
Summary of Finance Costs	Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Cash finance expense Interest on Syndicated Credit Agreement 4,546 1,746 — Interest on Credit Facilities — 1,818 437 Interest on Term Debt Facility 2,936 3,478 — Interest on Senior Convertible Notes — 375 — Interest on Convertible Notes — 2,574 421 Interest on other debt — 1,526 1,659 Other finance costs 286 2,909 399 7,768 14,426 2,916 Non-cash finance expense (income) Accretion 1,622 5,511 594 Amortization of debt issue costs 1,782 1,586 172 Change in fair value of convertible notes (note 16) (7,141 ) — — Change in fair value of derivative warrant liabilities (note 17) 12,995 — — Interest on Senior Convertible Notes — 1,903 — Loss on derivative liabilities — 1,649 — Loss on extinguishment of debt — 488 — Other 3 (67 ) 151 9,261 11,070 917 Less: interest capitalized relating to CIP (note 10) — (1,280 ) (2,036 ) Interest income (215 ) — — 16,814 24,216 1,797

Loss On Financial Obligations (

Loss On Financial Obligations (Tables)	12 Months Ended
	Dec. 31, 2020
Financial Obligations [Abstract]
Summary of Valuation of Royalty Payments	The Company used a discounted cash flow methodology to estimate the value the royalty component of the financial obligation. The material assumptions used by the Company to estimate the valuation for the royalty and held constant for the 10-year term of the royalty payments, and assuming a discount rate of 18%, were as follows: December 31, 2018 Growing space related to royalty square feet 44,403 Average yield grams/square feet 45 Total cannabis production million grams/year 12.0 Average price $/gram 5.50

Supplemental Cash Flow Disclo_2

Supplemental Cash Flow Disclosures (Tables)	12 Months Ended
	Dec. 31, 2020
Supplemental Cash Flow Disclosure [Abstract]
Summary of Changes in Non-cash Working Capital	Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Cash provided by (used in): Accounts receivable (2,037 ) (19,625 ) (2,469 ) Biological assets 13,789 19,328 (2,102 ) Inventory (12,315 ) (57,977 ) (923 ) Prepaid expenses and deposits 2,280 (7,213 ) 1,072 Accounts payable and accrued liabilities (20,793 ) 27,819 14,421 Convertible notes — (152 ) — Lease obligations — — 107 (19,076 ) (37,820 ) 10,106 Changes in non-cash working capital relating to: Operating (5,259 ) (41,626 ) 1,217 Investing (11,319 ) 1,659 10,282 Financing (2,498 ) 2,147 (1,393 ) (19,076 ) (37,820 ) 10,106 Cash interest paid 6,094 13,753 919
Summary of Reconciliation of Long Term Debt to Cash Flows Arising from Financing Activities	The following table reconciles long-term debt to cash flows arising from financing activities: Long-term debt (1) Balance at February 28, 2018 7,000 Cash changes: Proceeds from Credit Facilities 32,159 Proceeds from other debt instruments 8,546 Non-cash changes: Promissory Note issued to repurchase shares 6,931 Balance at December 31, 2018 54,636 Cash changes: Proceeds from Syndicated Credit Agreement, net of costs 82,687 Repayment of Credit Facilities (32,871 ) Proceeds from Term Debt Facility, net of costs 105,539 Repayment of other debt instruments (56,173 ) Debt acquired through acquisitions 33,618 Non-cash changes: Accretion 3,030 Amortization of debt issue costs 892 Extinguishment of debt issue costs 488 Reclassification to derivative liability (13,933 ) Balance at December 31, 2019 177,913 Cash changes: Repayment of Syndicated Credit Agreement (84,000 ) Syndicated Credit Agreement costs (493 ) Non-cash changes: Term Debt Facility extinguished (59,649 ) Term Debt Facility disposed of as part of Bridge Farm consideration (38,346 ) Accretion 2,665 Amortization of debt issue costs 1,910 Balance at December 31, 2020 — (1) Long-term debt, including the current portion of long-term debt

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Summary of Loss Per Share	Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Weighted average shares outstanding (000s) Basic and dilutive (1) 218,645 85,750 69,203 Continuing operations Net loss attributable to Sundial Growers Inc. (206,056 ) (142,533 ) (56,526 ) Per share - basic and diluted $ (0.95 ) $ (1.67 ) $ (0.82 ) Discontinued operations Net loss attributable to Sundial Growers Inc. (33,627 ) (128,931 ) — Per share - basic and diluted $ (0.15 ) $ (1.50 ) $ — Net loss attributable to Sundial Growers Inc. (239,683 ) (271,464 ) (56,526 ) Per share - basic and diluted $ (1.10 ) $ (3.17 ) $ (0.82 ) (1) For the year ended December 31, 2020, there were 1.0 million warrants exercisable, 2.2 million simple warrants exercisable and 1.1 million performance warrants exercisable that were excluded from the calculation as the impact was anti-dilutive (year ended December 31, 2019 – 6.2 million warrants, 5.1 million simple warrants and 4.5 million performance warrants, ten months ended December 31, 2018 – 2.2 million simple warrants and 2.0 million performance warrants).

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure Of Financial Instruments [Abstract]
Summary of Fair Value Measurements of Long-term Debt, Convertible Notes and Contingent Consideration	Fair value measurements of long-term debt, derivative warrant liabilities and contingent consideration are as follows: Fair value measurements using December 31, 2020 Carrying amount Level 1 Level 2 Level 3 Recurring measurements: Financial liabilities Derivative warrant liabilities 428 — — 428 Fair value measurements using December 31, 2019 Carrying amount Level 1 Level 2 Level 3 Recurring measurements: Financial liabilities Contingent consideration 32,501 — — 32,501
Summary of Impairment Losses on Accounts Receivable Recognized in Profit or Loss	Impairment losses on accounts receivable recognized in profit or loss were as follows: As at December 31, 2020 December 31, 2019 Impairment loss (reversal) on trade receivables (506 ) 582 Impairment loss (reversal) on other receivables (126 ) 170 (632 ) 752
Summary of Movement in Allowance for Impairment in Respect of Accounts Receivable	The movement in the allowance for impairment in respect of accounts receivable during the year was as follows: December 31, 2020 December 31, 2019 Balance, beginning of year 752 — Net remeasurement of impairment loss allowance (632 ) 752 Balance, end of year 120 752
Summary of Company's Foreign Currency Balances Subject to Exchange Risk	The following table summarizes the Company’s foreign currency balances subject to exchange risk for the currencies indicated: As at December 31, 2020 USD Cash and cash equivalents 1 Accounts payable and accrued liabilities (206 ) Net foreign exchange exposure (205 ) Translation to CAD 1.2732 CAD equivalent at period end exchange rate (261 ) As at December 31, 2019 USD Cash and cash equivalents 22,088 Accounts payable and accrued liabilities (2,150 ) Net foreign exchange exposure 19,938 Translation to CAD 1.2988 CAD equivalent at period end exchange rate 25,895
Schedule of Net Foreign Exchange Exposure at End of Year After-tax Earnings Decreased or Increased by Approximately the Following Amounts	Based on the net foreign exchange exposure at the end of the year, if these currencies had strengthened or weakened by 10% compared to the Canadian dollar and all other variables were held constant, the after-tax earnings would have decreased or increased by approximately the following amounts: Year ended December 31 Year ended December 31 2020 2019 Impact on profit (loss) (26 ) 2,590
Timing of Expected Cash Outflows Relating to Financial Liabilities	The timing of expected cash outflows relating to financial liabilities at December 31, 2020 is as follows: Less than one year One to three years Three to five years Thereafter Total Accounts payable and accrued liabilities 23,308 — — — 23,308 Lease obligations 409 818 213 — 1,440 Balance, end of period 23,717 818 213 — 24,748

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Summary of Related Party Transactions and Balances	b) Related party transactions and balances Transactions Balance outstanding Year ended December 31 Year ended December 31 December 31 December 31 2020 2019 2020 2019 Marketing, brand research and development (a) 1,144 3,117 — (265 ) Legal services (b) 2,462 3,895 (510 ) (397 ) 3,606 7,012 (510 ) (662 ) (a) A former member of the Board of Directors controls a company that provides marketing, brand research and development services. (b) A member of the Board of Directors was a partner at a law firm prior to his departure which provides legal services to the Company.
Compensation of Key Management Personnel	The Company considers directors and officers of the Company as key management personnel. Year ended December 31 Year ended December 31 Ten months ended December 31 2020 2019 2018 Salaries and short-term benefits 1,944 3,295 1,237 Share-based compensation 7,629 23,715 2,414 9,573 27,010 3,651

Basis of Presentation - Summary

Basis of Presentation - Summary of Subsidiaries (Details)	12 Months Ended
	Dec. 31, 2020
Sprout Technologies Inc.
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Sprout Technologies Inc.
Jurisdiction of incorporation	Alberta, Canada
Percentage ownership	100.00%
KamCan Products Inc.
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	KamCan Products Inc.
Jurisdiction of incorporation	British Columbia, Canada
Percentage ownership	100.00%
2011296 Alberta Inc.
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	2011296 Alberta Inc.
Jurisdiction of incorporation	Alberta, Canada
Percentage ownership	100.00%
Sundial Deutschland GmbH
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Sundial Deutschland GmbH
Jurisdiction of incorporation	Germany
Percentage ownership	100.00%
Sundial Portugal, Unipessoal LDA
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Sundial Portugal, Unipessoal LDA
Jurisdiction of incorporation	Portugal
Percentage ownership	100.00%
Pathway Rx Inc
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	Pathway Rx Inc.
Jurisdiction of incorporation	Alberta, Canada
Percentage ownership	50.00%
2657408 Ontario Inc.
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	2657408 Ontario Inc.
Jurisdiction of incorporation	Ontario, Canada
Percentage ownership	100.00%
NGBA-BC Holdings Ltd.
Disclosure of Basis of Presentation [Line Items]
Subsidiaries	NGBA-BC Holdings Ltd.
Jurisdiction of incorporation	British Columbia, Canada
Percentage ownership	100.00%

Significant Accounting Polici_4

Significant Accounting Policies - Additional Information (Details) - CAD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Significant Accounting Policies [Line Items]
Depreciation method, property, plant and equipment	straight-line method
Gain loss on conversion of financial liability reclassified to equity	$ 0
Development costs capitalized	$ 0	$ 0
Sun 8 Holdings Inc
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	15 years
Pathway Rx Inc
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets	20 years
Top of Range
Disclosure Of Significant Accounting Policies [Line Items]
Cash and cash equivalents maturities period	90 days

Significant Accounting Polici_5

Significant Accounting Policies - Schedule of Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2020
Land
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	n/a
Production Facilities
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	20 years
Equipment | Bottom of Range
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	2 years
Equipment | Top of Range
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	10 years
Right of Use Assets
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	Shorter of estimated useful life or lease term
Construction in Progress
Disclosure Of Significant Accounting Policies [Line Items]
Estimated useful life of property plant and equipment	n/a

Discontinued Operations - Addit

Discontinued Operations - Additional Information (Details) - CAD ($) $ in Thousands	May 15, 2020	Jul. 02, 2019	Dec. 31, 2019
Term Debt Facility
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Principal amount			$ 115,000
Bridge Farm
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Debt transferred to purchaser as sale consideration	$ 45,000
Cancellation of common shares	2,991	$ 2,700
Equity instruments held		$ 3,000
Bridge Farm | Term Debt Facility
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Principal amount	115,000
Reducing borrowing obligations	$ 70,000

Discontinued Operations - Summa

Discontinued Operations - Summary Results of Discontinued Operations (Details) - CAD ($) $ in Thousands	May 15, 2020	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Gross revenue			$ 73,321	$ 66,927
Net revenue			60,918	63,562
Cost of sales			51,740	46,721
Gross margin before fair value adjustments			(36,735)	16,841
Change in fair value of biological assets		$ (1,280)	5,432	30,340
Gross margin		(1,280)	(49,869)	36,496
General and administrative		8,309	32,029	38,934
Sales and marketing		2,380	5,737	8,068
Depreciation and amortization		920	4,711	595
Share-based compensation		7,410	8,566	38,698
Goodwill impairment				100,305
Loss from operations		(27,554)	(185,404)	(52,371)
Transaction costs			(3,587)	(8,481)
Finance costs		(1,797)	(16,814)	(24,216)
Gain (loss) on disposition of PP&E		(17)	488	8
Loss on disposition of Bridge Farm			(33,627)	(128,931)
Loss before income tax		(56,526)	(206,317)	(146,307)
Income tax recovery				3,609
Net loss		$ (56,526)	(239,944)	(271,629)
Bridge Farm
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Loss on disposition of Bridge Farm	$ (14,979)
Discontinued Operations | Bridge Farm
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Gross revenue			22,139	12,298
Net revenue			22,139	12,298
Cost of sales			15,633	9,426
Gross margin before fair value adjustments			6,506	2,872
Change in fair value of biological assets			1,064	386
Change in fair value realized through inventory			(1,122)
Gross margin			6,448	3,258
General and administrative			8,585	5,515
Sales and marketing			1,418	820
Depreciation and amortization			2,752	3,482
Foreign exchange			1,057	(1,779)
Share-based compensation			(826)	826
Goodwill impairment				100,305
Loss from operations			(6,538)	(105,911)
Transaction costs				(1,588)
Finance costs			(10,083)	(3,982)
Loss on contingent consideration			(2,252)	(18,645)
Gain on investment				165
Gain (loss) on disposition of PP&E				13
Loss on disposition of Bridge Farm			(14,979)
Loss before income tax			(33,852)	(129,948)
Income tax recovery			225	1,017
Net loss			$ (33,627)	$ (128,931)

Discontinued Operations - Sum_2

Discontinued Operations - Summary of Effect of Disposal on Financial Position (Details) - CAD ($) $ in Thousands	May 15, 2020	Jul. 02, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Feb. 28, 2018
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash and cash equivalents			$ 60,376	$ 45,337	$ 14,121	$ 7,678
Accounts receivable			15,898	27,638
Biological assets			3,531	14,309	$ 876
Inventory			25,613	59,942
Property, plant and equipment			116,928	281,984
Goodwill				11,440
Intangible assets			5,063	43,995
Accounts payable and accrued liabilities			(23,308)	(58,110)
Lease obligation			(1,031)	(16,227)
Deferred tax liability				(3,365)
Accumulated other comprehensive income				(6,866)
Consideration received
Net loss from discontinued operations			$ (33,627)	$ (128,931)
Bridge Farm
Disclosure Of Analysis Of Single Amount Of Discontinued Operations [Line Items]
Cash and cash equivalents	$ 2,963
Accounts receivable	15,641
Biological assets	2,831
Inventory	787
Property, plant and equipment	88,698
Goodwill	11,345
Intangible assets	23,884
Accounts payable and accrued liabilities	(22,792)
Lease obligation	(14,894)
Deferred tax liability	(3,115)
Accumulated other comprehensive income	(7,466)
Net assets and liabilities	97,882
Consideration received
Term Debt Facility	45,000
Contingent consideration liability	34,912
Cancellation of common shares	2,991	$ 2,700
Total consideration	82,903
Net loss from discontinued operations	$ (14,979)

Business Acquisitions - Additio

Business Acquisitions - Additional Information (Details) $ / shares in Units, $ in Thousands, £ in Millions	Oct. 10, 2019shares	Mar. 13, 2019CAD ($)shares$ / shares	Feb. 22, 2019CAD ($)shares	Dec. 31, 2019CAD ($)	Feb. 22, 2019GBP (£)shares
Disclosure Of Business Combinations [Line Items]
Contingent consideration		$ 2,300
Quarterly installments payable		$ 87,500
Pathway Rx Inc
Disclosure Of Business Combinations [Line Items]
Percentage of voting equity interests acquired		50.00%		50.00%
Issuance of common shares | shares		296,800
Issuance of common shares, value		$ 2,601
Contingent consideration		$ 2,279
Issuance of common shares, fair value per share | $ / shares		$ 8.76
Royalty percentage on gross revenue rate of increase		5.00%
Royalty payments for acquisition		$ 4,880		$ 4,880
Proportion of ownership interests held by non-controlling interests		50.00%
Pathway Rx Inc | Sale of Licensed Products
Disclosure Of Business Combinations [Line Items]
Percentage of net revenue		50.00%
Pathway Rx Inc | License Agreement
Disclosure Of Business Combinations [Line Items]
Royalty percentage on gross revenue		3.00%
Royalty payments for acquisition		$ 1,400
Period of royalty payments		4 years
Bridge Farm | Sundial U K Limited
Disclosure Of Business Combinations [Line Items]
Date of acquisition			Feb. 22, 2019
Cash consideration			$ 77,000	77,023	£ 45
Issuance of common shares | shares			2,400,000		2,400,000
Issuance of common shares, value			$ 37,200	37,248
Contingent consideration				15,991
Fair value of incremental share portion of contingent consideration, adjusted value				27,500
Contingent consideration earn out, adjusted fair value				5,000
Gain (loss) on contingent consideration				18,600
Royalty payments for acquisition				$ 130,262
Bridge Farm | Sundial U K Limited | Potential Incremental Common Shares
Disclosure Of Business Combinations [Line Items]
Contingent consideration			8,400
Bridge Farm | Sundial U K Limited | Earnout Payments
Disclosure Of Business Combinations [Line Items]
Contingent consideration			$ 7,200
Bridge Farm | Sundial U K Limited | Lay Lake Phase Two
Disclosure Of Business Combinations [Line Items]
Earn-out payments | shares	320,000
Bridge Farm | Sundial U K Limited | Clay Lake Phase Two
Disclosure Of Business Combinations [Line Items]
Earn-out payments | shares	320,000
Bridge Farm | Sundial U K Limited | Clay Lake Phase Three
Disclosure Of Business Combinations [Line Items]
Earn-out payments | shares	320,000
Bridge Farm | Sundial U K Limited | Zyon Plants And Flowers Limited
Disclosure Of Business Combinations [Line Items]
Earn-out payments | shares	320,000
Bridge Farm | Sundial U K Limited | 18 Months from Passage of Amendment date
Disclosure Of Business Combinations [Line Items]
Earn-out payments | shares	320,000
Bridge Farm | Sundial U K Limited | Top of Range
Disclosure Of Business Combinations [Line Items]
Earn-out payments | shares	1,600,000		1,600,000

Business Acquisitions - Summary

Business Acquisitions - Summary of Fair Value of Assets and Liabilities Acquired (Details) $ in Thousands, £ in Millions	Dec. 31, 2019CAD ($)	Mar. 13, 2019CAD ($)	Feb. 22, 2019CAD ($)	Feb. 22, 2019GBP (£)
Disclosure Of Business Combinations [Line Items]
Contingent consideration		$ 2,300
Sundial U K Limited | Bridge Farm
Disclosure Of Business Combinations [Line Items]
Cash consideration	$ 77,023		$ 77,000	£ 45
Issuance of common shares	37,248		$ 37,200
Contingent consideration	15,991
Total Purchase Price	$ 130,262

Business Acquisitions - Summa_2

Business Acquisitions - Summary of Purchase Price Allocated (Details) - CAD ($) $ in Thousands	Dec. 31, 2019	Mar. 13, 2019
Pathway Rx Inc
Disclosure Of Business Combinations [Line Items]
Intangible assets	$ 13,552
Accounts payable and accrued liabilities	(184)
Deferred income tax liability	(3,609)
Non-controlling interest (50%)	(4,879)
Total Purchase Price	4,880	$ 4,880
Sundial U K Limited | Bridge Farm
Disclosure Of Business Combinations [Line Items]
Accounts receivable	7,403
Inventory	470
Biological assets	1,288
Property, plant and equipment	58,368
Intangible assets	25,471
Accounts payable	(14,293)
Long term debt	(33,618)
Lease obligations	(15,179)
Deferred income tax liability	(4,355)
Goodwill	104,707
Total Purchase Price	$ 130,262

Business Acquisitions - Summa_3

Business Acquisitions - Summary of Preliminary Value Allocated to Purchase Price (Details) - CAD ($) $ in Thousands	Dec. 31, 2019	Mar. 13, 2019
Disclosure Of Business Combinations [Line Items]
Contingent consideration		$ 2,300
Pathway Rx Inc
Disclosure Of Business Combinations [Line Items]
Issuance of common shares		2,601
Contingent consideration		2,279
Total Purchase Price	$ 4,880	$ 4,880

Business Acquisitions - Summa_4

Business Acquisitions - Summary of Preliminary Value Allocated to Purchase Price (Parenthetical) (Details) $ / shares in Units, $ in Millions	Mar. 13, 2019CAD ($)$ / sharesshares
Disclosure Of Business Combinations [Abstract]
Contingent consideration | $	$ 2.3
Warrants to purchase common shares | shares	280,000
Exercise price of common shares | $ / shares	$ 1.81

Business Acquisitions - Summa_5

Business Acquisitions - Summary of Purchase Price Allocated (Parenthetical) (Details)	Dec. 31, 2019	Mar. 13, 2019
Pathway Rx Inc
Disclosure Of Business Combinations [Line Items]
Percentage of voting equity interests acquired	50.00%	50.00%

Accounts Receivable - Summary o

Accounts Receivable - Summary of Accounts Receivable (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Subclassifications Of Assets Liabilities And Equities [Abstract]
Trade receivables	$ 15,786	$ 24,684
Other receivables	112	2,954
Accounts receivable	$ 15,898	$ 27,638

Biological Assets - Summary of

Biological Assets - Summary of Change in Carrying Value of Biological Assets (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Changes In Biological Assets [Abstract]
Balance, beginning of year	$ 14,309	$ 876
Increase in biological assets due to capitalized costs	39,957	62,331
Net change in fair value of biological assets	6,496	30,726
Transferred to inventory upon harvest	(54,388)	(80,991)
Acquisitions		1,288
Disposition of Bridge Farm (note 5)	(2,831)
Foreign currency translation	(12)	79
Balance, end of year	$ 3,531	$ 14,309

Biological Assets - Summary o_2

Biological Assets - Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020CAD ($)g$ / kg	Dec. 31, 2019CAD ($)g$ / kg
Yield per Square Foot of Growing Space
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change	$ 347	$ 1,183
Average Net Selling Price
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change	1,022	3,021
After Harvest Cost to Complete and Sell
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Effect of change	$ 291	$ 267
Weighted Average Input
Disclosure Of Reconciliation Of Changes In Biological Assets [Line Items]
Yield per square foot of growing space | g	45	47
Average net selling price | $ / kg	5.13	5.47
After harvest cost to complete and sell | $ / kg	1.32	2.34

Biological Assets - Summary o_3

Biological Assets - Summary of Significant Unobservable Inputs and Impact on Fair Value of Biological Assets (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2020
Changes In Biological Assets [Abstract]
Percentage of assumption of effect change	10.00%

Biological Assets - Additional

Biological Assets - Additional Information (Details) - kg	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Changes In Biological Assets [Abstract]
Estimated biological assets to be harvested	5,507	10,455
Harvested biological assets	27,972	34,012

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Inventories [Line Items]
Inventory	$ 25,613	$ 59,942
Harvested Cannabis
Disclosure Of Inventories [Line Items]
Inventory	20,358	50,403
Cannabis Supplies and Consumables
Disclosure Of Inventories [Line Items]
Inventory	$ 5,255	8,808
Ornamental Flowers Supplies and Consumables
Disclosure Of Inventories [Line Items]
Inventory		$ 731

Inventory - Additional Informat

Inventory - Additional Information (Details) gram in Thousands, $ in Millions	12 Months Ended
	Dec. 31, 2020CAD ($)gram	Dec. 31, 2019CAD ($)gram
Classes Of Inventories [Abstract]
Harvested cannabis stock, quantity | gram	10,335	8,380
Inventories recognized as expense	$ 51.7	$ 46.7
Inventory write downs	56.9
Excess and obsolete inventory provision	45.9
Fair value component of excess and obsolete inventory provision	$ 11

Property Plant and Equipment -

Property Plant and Equipment - Schedule of Property Plant and Equipment (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	$ 281,984
Net book value	116,928	$ 281,984
Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	291,609	89,897
Adoption of IFRS 16		1,006
Acquisitions		58,409
Additions	8,189	140,063
Reclassification to assets held for sale	(2,998)
Dispositions	2,527	890
Disposition of Bridge Farm (note 5)	(92,301)
Foreign currency translation	(788)	3,124
Net book value	201,184	291,609
Accumulated Amortization
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	(9,625)	(1,406)
Adoption of IFRS 16		(100)
Impairment	66,317	162
Dispositions	(257)	(378)
Disposition of Bridge Farm (note 5)	(3,603)
Foreign currency translation	(35)	63
Net book value	(84,256)	(9,625)
Depreciation	12,209	8,472
Right of Use Assets
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	16,146
Net book value	1,323	16,146
Right of Use Assets | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	16,509
Adoption of IFRS 16		1,333
Acquisitions		14,648
Additions	763	687
Dispositions	825	700
Disposition of Bridge Farm (note 5)	(14,431)
Foreign currency translation	(122)	541
Net book value	1,894	16,509
Right of Use Assets | Accumulated Amortization
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	(363)
Dispositions	(176)	(248)
Disposition of Bridge Farm (note 5)	(251)
Foreign currency translation	(3)	1
Net book value	(571)	(363)
Depreciation	638	610
Land and Buildings
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	26,603
Net book value	8,640	26,603
Land and Buildings | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	26,606	5,246
Acquisitions		15,860
Additions	8	1,517
Transfers from CIP	509	3,406
Reclassification to assets held for sale	(1,547)
Dispositions	499	31
Disposition of Bridge Farm (note 5)	(16,300)
Foreign currency translation	(137)	608
Net book value	8,640	26,606
Land and Buildings | Accumulated Amortization
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	(3)
Disposition of Bridge Farm (note 5)	(473)
Foreign currency translation	(5)
Net book value		(3)
Depreciation	475	3
Production Facilities
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	161,042
Net book value	83,573	161,042
Production Facilities | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	166,442	23,336
Acquisitions		21,294
Additions	213	283
Transfers from CIP	8,212	120,724
Dispositions	162
Disposition of Bridge Farm (note 5)	(21,587)
Foreign currency translation	(181)	805
Net book value	152,937	166,442
Production Facilities | Accumulated Amortization
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	(5,400)	(312)
Impairment	60,658
Dispositions	(37)
Disposition of Bridge Farm (note 5)	(2,879)
Foreign currency translation	(27)	62
Net book value	(69,364)	(5,400)
Depreciation	6,249	5,026
Equipment
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	20,324
Net book value	20,394	20,324
Equipment | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	24,021	7,254
Adoption of IFRS 16		(327)
Acquisitions		247
Additions	2,886	3,393
Transfers from CIP	2,287	13,603
Dispositions	50	159
Disposition of Bridge Farm (note 5)	(249)
Foreign currency translation	(1)	10
Net book value	28,894	24,021
Equipment | Accumulated Amortization
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	(3,697)	(1,094)
Adoption of IFRS 16		(100)
Dispositions	(44)	(130)
Net book value	(8,500)	(3,697)
Depreciation	4,847	2,833
Construction in Progress
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	57,869
Net book value	2,998	57,869
Construction in Progress | Cost
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	58,031	54,061
Acquisitions		6,360
Additions	4,319	134,183
Transfers from CIP	(11,008)	(137,733)
Reclassification to assets held for sale	(1,451)
Dispositions	991
Disposition of Bridge Farm (note 5)	(39,734)
Foreign currency translation	(347)	1,160
Net book value	8,819	58,031
Construction in Progress | Accumulated Amortization
Disclosure Of Property Plant And Equipment [Line Items]
Net book value	(162)
Impairment	5,659	162
Net book value	$ (5,821)	$ (162)

Property Plant and Equipment _2

Property Plant and Equipment - Additional Information (Details) - CAD ($)	Dec. 28, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Property Plant And Equipment [Line Items]
Capitalized salaries and benefits					$ 0	$ 600,000
Construction in progress						600,000
Interest associated with construction in progress					0	1,300,000
Depreciation, capitalized to biological assets and inventory					6,900,000	5,700,000
Asset impairment				$ 523,000	$ 79,191,000	$ 162,000
Alberta CGU
Disclosure Of Property Plant And Equipment [Line Items]
Impairment discount rate					25.00%
Estimated cash flow term					5 years
Asset impairment		$ 60,000,000
Increase impairment discount rate					1.00%
Increase of Impairment on Assets					$ 9,200,000
Rocky View Facility | Non-Binding Purchase Agreement
Disclosure Of Property Plant And Equipment [Line Items]
Fair value less costs of disposal and impairment	$ 5,000,000
Write down assets to recoverable amount	700,000
Recoverable amount reduced due to receiving utility deposits	$ 5,000,000
Kamloops Property | Merritt Facility
Disclosure Of Property Plant And Equipment [Line Items]
Investment of land and construction in progress in Merritt facility					10,000,000
Kamloops Property | Merritt Facility | B.C. Cash Generating Unit
Disclosure Of Property Plant And Equipment [Line Items]
Fair value less costs of disposal and impairment					5,700,000
Write down assets to recoverable amount					4,200,000
Recoverable amount reduced due to receiving utility deposits					2,900,000
Other Disposals of Assets | Cannabis
Disclosure Of Property Plant And Equipment [Line Items]
Proceeds from sales of non-core assets					$ 2,100,000
Sale of property closing date					Mar. 27, 2020

Intangible Assets - Summary of

Intangible Assets - Summary of Reconciliation of Changes in Intangible Assets and Goodwill (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		$ 43,995
Depreciation	$ 920	4,711	$ 595
Impairment		12,900
Ending Balance		5,063	43,995
Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		45,293
Additions		150	5,295
Acquisitions			39,022
Foreign currency translation		(219)	976
Ending Balance		18,996	45,293
Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition		26,228
Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		(1,298)
Depreciation		2,125	1,306
Impairment		12,874
Foreign currency translation		(20)	(8)
Ending Balance		(13,933)	(1,298)
Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition		(2,344)
Brands and Trademarks
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		8,255
Ending Balance		5,063	8,255
Brands and Trademarks | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		8,386
Additions		150	5,295
Acquisitions			2,977
Foreign currency translation		(25)	114
Ending Balance		5,445	8,386
Brands and Trademarks | Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition		3,066
Brands and Trademarks | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		(131)
Depreciation		441	132
Foreign currency translation			(1)
Ending Balance		(382)	(131)
Brands and Trademarks | Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition		(190)
Patents
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		13,551
Ending Balance			13,551
Patents | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		13,551
Acquisitions			13,551
Ending Balance		13,551	13,551
Patents | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Depreciation		677
Impairment		12,874
Ending Balance		(13,551)
Customer Relationships
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		18,602
Ending Balance			18,602
Customer Relationships | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		19,578
Acquisitions			18,855
Foreign currency translation		(163)	723
Ending Balance			19,578
Customer Relationships | Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition		19,415
Customer Relationships | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		(976)
Depreciation		842	982
Foreign currency translation		(17)	(6)
Ending Balance			(976)
Customer Relationships | Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition		(1,801)
Other
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		3,587
Ending Balance			3,587
Other | Cost
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		3,778
Acquisitions			3,639
Foreign currency translation		(31)	139
Ending Balance			3,778
Other | Cost | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition		3,747
Other | Accumulated Amortization
Disclosure Of Intangible Assets [Line Items]
Beginning Balance		(191)
Depreciation		165	192
Foreign currency translation		(3)	(1)
Ending Balance			$ (191)
Other | Accumulated Amortization | Bridge Farm
Disclosure Of Intangible Assets [Line Items]
Disposition		$ (353)

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020CAD ($)
Disclosure Of Intangible Assets [Line Items]
Impairment	$ 12.9
Pathway Rx Inc
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets	20 years
Sun 8 Holdings Inc
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets	15 years
Other Intellectual Property
Disclosure Of Intangible Assets [Line Items]
Estimated useful life of intangible assets	12 years

Investments - Additional Inform

Investments - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020CAD ($)Quarter	Dec. 31, 2019CAD ($)
Disclosure Of Transactions Between Related Parties [Line Items]
Net revenue	$ 60,918	$ 63,562
Zenabis
Disclosure Of Transactions Between Related Parties [Line Items]
Cash transferred	58,900
Principal amount of senior secured debt	$ 58,900
Rate of interest on investments.	14.00%
Maturity date of investments	Mar. 31, 2025
Scheduled repayments of principle over time	$ 7,000
Number of royalty payable quarters | Quarter	32
Proceeds form principal repayments	$ 7,000
Zenabis | Net revenue in between 20 million and 25 millions | Cannabis
Disclosure Of Transactions Between Related Parties [Line Items]
Percentage of net revenue	3.50%
Zenabis | Net revenue in between 20 million and 25 millions | Cannabis | Bottom of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Net revenue	$ 20,000
Zenabis | Net revenue in between 20 million and 25 millions | Cannabis | Top of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Net revenue	$ 25,000
Zenabis | Net revenue in between 25 million and 30 millions | Cannabis
Disclosure Of Transactions Between Related Parties [Line Items]
Percentage of net revenue	3.00%
Zenabis | Net revenue in between 25 million and 30 millions | Cannabis | Bottom of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Net revenue	$ 25,000
Zenabis | Net revenue in between 25 million and 30 millions | Cannabis | Top of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Net revenue	$ 30,000
Zenabis | Net revenue in between 30 million and 37.5 millions | Cannabis
Disclosure Of Transactions Between Related Parties [Line Items]
Percentage of net revenue	2.50%
Zenabis | Net revenue in between 30 million and 37.5 millions | Cannabis | Bottom of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Net revenue	$ 30,000
Zenabis | Net revenue in between 30 million and 37.5 millions | Cannabis | Top of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Net revenue	$ 37,500
Zenabis | Net revenue more than 37.5 million | Cannabis
Disclosure Of Transactions Between Related Parties [Line Items]
Percentage of net revenue	2.00%
Net revenue	$ 37,500

Goodwill - Summary of Reconcili

Goodwill - Summary of Reconciliation of Changes in Goodwill (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Reconciliation Of Changes In Goodwill [Abstract]
Beginning Balance	$ 11,440
Acquisitions through business combinations		$ 107,053
Disposition of Bridge Farm (note 5)	(11,345)
Foreign currency translation	$ (95)	4,692
Impairment		(100,305)
Ending Balance		$ 11,440

Goodwill - Additional Informati

Goodwill - Additional Information (Details) $ in Thousands	Dec. 31, 2019CAD ($)
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]
Goodwill impairment	$ (11,440)
Accumulated impairment [member]
Disclosure Of Reconciliation Of Changes In Goodwill [Line Items]
Goodwill impairment	$ 100,300

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Subclassifications Of Assets Liabilities And Equities [Abstract]
Trade payables	$ 4,849	$ 20,228
Accrued and other liabilities	18,459	37,882
Accounts payable and accrued liabilities	$ 23,308	$ 58,110

Debt - Summary of Debt (Details

Debt - Summary of Debt (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Feb. 28, 2018
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt		$ 177,913	$ 54,636	$ 7,000
Current portion of long-term debt		177,913
Syndicated Credit Agreement | Syndicated Facility
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	Prime + 2.5%
Maturity	Aug 27, 2021
Principal	$ 74,000
Debt		82,910
Syndicated Credit Agreement | Operating Facility
Disclosure Of Detailed Information About Borrowings [Line Items]
Interest rate	Prime + 2.5%
Maturity	Aug 27, 2021
Principal	$ 5,330
Term Debt Facility
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal		115,000
Debt		95,003
Term Debt Facility | First Tranche
Disclosure Of Detailed Information About Borrowings [Line Items]
Maturity	Jul 27, 2023
Principal	$ 115,000
Debt		$ 95,003
Interest rate	9.75%

Debt - Summary of Syndicated Cr

Debt - Summary of Syndicated Credit Agreement (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Feb. 28, 2018
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt	$ 177,913	$ 54,636	$ 7,000
Syndicated Credit Agreement | Syndicated Facility
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal value of debt	84,000
Transaction costs	(1,313)
Accretion	223
Debt	$ 82,910

Debt - Additional Information (

Debt - Additional Information (Details) $ in Thousands	Jun. 05, 2020CAD ($)	Sep. 30, 2020CAD ($)	Dec. 31, 2018CAD ($)	Dec. 31, 2020CAD ($)	Dec. 31, 2019CAD ($)Financial_covenant
Disclosure Of Detailed Information About Borrowings [Line Items]
Repayment of principal				$ 84,000	$ 32,871
Equity component of convertible notes			$ 3,232
Term Debt Facility
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal amount					$ 115,000
Number of financial covenants | Financial_covenant					3
Borrowings extinguished	$ 73,200
Term Debt Facility | Bridge Farm Purchaser
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal amount	45,000
Term Debt Facility | Bottom of Range
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal amount					$ 75,000
Syndicated Facility
Disclosure Of Detailed Information About Borrowings [Line Items]
Minimum cash balance covenant	2,500
Capital required to be raised	10,000
Principal repayments per quarter		$ 2,100
Quarterly principal repayments of borrowings commencement date		Sep. 30, 2020
Syndicated Facility | Syndicated Credit Agreement
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal repayments per quarter		$ 2,100
Principal amount				74,000
Repayment of principal				$ 71,900
Borrowings maturity date				2021-08
Syndicated Facility | Syndicated Credit Agreement | Principal Due in August 2021
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal amount	65,600
Secured Convertible Note
Disclosure Of Detailed Information About Borrowings [Line Items]
Equity component of convertible notes	$ 73,200

Debt - Summary of Term Debt Fac

Debt - Summary of Term Debt Facility (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Feb. 28, 2018
Disclosure Of Detailed Information About Borrowings [Line Items]
Debt	$ 177,913	$ 54,636	$ 7,000
Term Debt Facility
Disclosure Of Detailed Information About Borrowings [Line Items]
Principal value of debt	115,000
Transaction costs	(9,461)
Accretion	3,397
Fair value assigned to warrants, at issuance	(13,933)
Debt	$ 95,003

Convertible Notes - Schedule of

Convertible Notes - Schedule of Secured Convertible Note (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020CAD ($)
Convertible Notes [Abstract]
Secured Convertible Note - fair value on issuance	$ 54,693
Change in fair value recognized in profit or loss	(5,075)
Converted to common shares	$ (49,618)

Convertible Notes - Additional

Convertible Notes - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands, $ in Millions

Oct. 22, 2020USD ($)$ / shares

Sep. 30, 2020CAD ($)

Jun. 05, 2020CAD ($)$ / sharesshares

Jun. 05, 2020USD ($)$ / sharesshares

Aug. 14, 2019CAD ($)$ / shares

Jul. 31, 2019CAD ($)

May 31, 2019CAD ($)

Dec. 31, 2020CAD ($)$ / sharesshares

Dec. 31, 2020$ / shares

Dec. 31, 2020USD ($)shares

Dec. 31, 2018CAD ($)

Dec. 31, 2020CAD ($)

Dec. 31, 2019CAD ($)shares

Dec. 31, 2018CAD ($)Tranche$ / sharesshares

Dec. 31, 2018USD ($)Tranche$ / sharesshares

Jun. 05, 2020$ / shares

Dec. 31, 2019USD ($)shares

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Term debt facility amount

$ 73,200

Secured convertible note converted to common shares

$ 73,200

$ 73,200

$ 73,227

Conversion price per common share | $ / shares

$ 1

Indebtedness under unsecured convertible notes

$ 3

Principal balance of secured convertible note convertible to common shares

$ 10

Conversion price | $ / shares

$ 0.1624

Weighted average price of common shares eight consecutive trading days volume, percentage

92.00%

Percentage of outstanding common shares

9.99%

Weighted average conversion price | $ / shares

$ 0.2468

Issuance of common shares | shares

296,700,000

Unsecured senior subordinated convertible notes convertible to common shares

$ 18

Purchase warrants to acquire common shares | shares

14,500,000

14,500,000

Initial exercise price of common share | $ / shares

0.9338

Proceeds from closure of private placement

$ 27,764

$ 18,070

$ 90,373

Issue of convertible notes

$ 3,232

Convertible debt converted into shares

$ 6,900

Conversion of debt conversion price | $ / shares

$ 13.84

Percentage of debt converted into shares

80.00%

Number of closed tranches of private placement | Tranche

3

3

Private placement of note, percentage

12.00%

12.00%

Proceeds from private placement of notes

$ 28,900

Number of each convertible into units consisting of common shares | shares

1.6

1.6

Number of each convertible into units consisting of common share purchase warrant | shares

0.8

0.8

Convertible notes maturing period

12 months

12 months

Convertible notes allocated to equity

$ 3,200

Convertible notes, principal amount

21,200

$ 2.5

Convertible notes, principal amount repaid to unit holders

$ 1,000

$ 2.4

Convertible Notes

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Interest rate

12.00%

12.00%

12.00%

Issue of convertible notes

$ 3,232

Interest rate payable, percent

12.00%

12.00%

12.00%

Directors and Officers

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Issue of convertible notes

$ 7,000

Agent Warrants

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Purchase warrants to acquire common shares | shares

1,080,000

1,080,000

Initial exercise price of common share | $ / shares

$ 1

Ordinary Shares

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Equity units issued | shares

6,200,000

6,200,000

Warrants

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Equity units issued | shares

3,600,000

3,600,000

Top of Range

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Purchase warrants to acquire common shares amount

$ 17,500

Exercise price per warrant | $ / shares

$ 1

Indebtedness under unsecured convertible notes

$ 3,000

3,000

Common share purchase warrant holding period

12 months

12 months

Secured Convertible Note Warrants | Top of Range

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Purchase warrants to acquire common shares amount

$ 17,500

Exercise price per warrant | $ / shares

$ 1.20

Secured Convertible Note

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Maturity

June 5, 2022

June 5, 2022

Issue of convertible notes

$ 73,200

Unsecured Convertible Notes

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Secured convertible note converted to common shares

$ 18

Maturity

June 5, 2022

June 5, 2022

Conversion price | $ / shares

$ 0.1624

Percentage of outstanding common shares

9.99%

9.99%

Weighted average conversion price | $ / shares

$ 0.2348

Issuance of common shares | shares

76,700,000

Weighted average price of common shares five consecutive trading days lowest volume, percentage

88.00%

88.00%

8% Senior Unsecured Convertible Notes

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Interest rate

8.00%

Proceeds from closure of private placement

$ 92,600

Issue of convertible notes

$ 600

$ 93,192

Interest rate payable, percent

8.00%

8% Senior Unsecured Convertible Notes | Directors and Officers

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Issue of convertible notes

$ 100

CAD Offering

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Proceeds from private placement of notes

$ 22,200

USD Offering

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Proceeds from private placement of notes

$ 5

CAD Denominated Convertible Notes

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Offering convertible price per unit | $ / shares

$ 3.91

USD Denominated Convertible Notes

Disclosure Of Detailed Information Of Convertible Notes [Line Items]

Offering convertible price per unit | $ / shares

$ 3.13

Convertible Notes - Schedule _2

Convertible Notes - Schedule of Change in Principal Balance of Secured Convertible Note (Details) - CAD ($) $ in Thousands	Jun. 05, 2020	Dec. 31, 2020	Dec. 31, 2020
Convertible Notes [Abstract]
Issued			$ 73,227
Converted to common shares	$ (73,200)	$ (73,200)	$ (73,227)

Convertible Notes - Schedule _3

Convertible Notes - Schedule of Unsecured Convertible Note (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020CAD ($)
Convertible Notes [Abstract]
Unsecured Convertible Notes - fair value on issuance	$ 16,113
Change in fair value recognized in profit or loss	(2,066)
Converted to common shares	(13,943)
Unrealized foreign exchange loss	$ (104)

Convertible Notes - Schedule _4

Convertible Notes - Schedule of Change in Principal Balance of Unsecured Convertible Note (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Convertible Notes [Abstract]
Issued	$ 18,000
Converted to common shares	$ (18,000)

Convertible Notes - Summary of

Convertible Notes - Summary of Senior Convertible Notes (Details) - CAD ($) $ in Thousands	1 Months Ended	10 Months Ended	12 Months Ended
	Jul. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Disclosure Of Detailed Information Of Convertible Notes [Line Items]
Equity component of convertible notes		$ 3,232
8% Senior Unsecured Convertible Notes
Disclosure Of Detailed Information Of Convertible Notes [Line Items]
Equity component of convertible notes	$ 600		$ 93,192
Transaction costs			(2,819)
Fair value attributable to conversion feature			(40,494)
Balance attributable to debt portion upon issuance			49,879
Accretion of note obligation			1,223
Amortization of note issue costs			93
Accrued interest			1,903
Conversion to common shares			$ (53,098)

Convertible Notes - Summary o_2

Convertible Notes - Summary of Convertible Notes (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019CAD ($)
Convertible Notes [Abstract]
Balance, beginning of year	$ 25,449
Unrealized foreign exchange gain	(209)
Accrued interest	(152)
Accretion	2,443
Amortization of note issue costs	745
Conversion to common shares	(18,139)
Conversion to warrants	(5,947)
Repayments	$ (4,190)

Derivative Warrant Liabilitie_2

Derivative Warrant Liabilities - Summary of Derivative Warrant Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020CAD ($)
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Change in fair value recognized in profit or loss	$ 12,995
Converted to common shares	(35,521)
Unrealized foreign exchange loss	22
Balance, end of year	428
Secured Convertible Note Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	6,683
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	3,961
Agent Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	504
Series A and Series B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Fair value on issuance	$ 11,784

Derivative Warrant Liabilitie_3

Derivative Warrant Liabilities - Secured Convertible Note Warrants - Additional Information (Details) $ / shares in Units, $ in Millions, $ in Millions	Sep. 30, 2020CAD ($)	Jun. 05, 2020CAD ($)$ / shares	Jun. 05, 2020USD ($)	Dec. 31, 2020CAD ($)shares$ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Indebtedness under unsecured convertible notes | $			$ 3
Issuance of common shares				296,700,000
Warrants outstanding				2,080,000
Top of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Indebtedness under unsecured convertible notes | $	$ 3	$ 3
Secured Convertible Note Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants description		The Secured Convertible Note Warrants were issued on June 5, 2020 and expired 36 months from the date of issuance.	The Secured Convertible Note Warrants were issued on June 5, 2020 and expired 36 months from the date of issuance.
Warrants expiration period		36 months	36 months
Warrants exercised				35,000,000
Weighted average exercise price of warrants | $ / shares				$ 0.1766
Issuance of common shares				35,000,000
Gross proceeds from exercise of warrants | $				$ 8
Warrants outstanding
Secured Convertible Note Warrants | Bottom of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Weighted average price of common shares | $ / shares		$ 2

Derivative Warrant Liabilitie_4

Derivative Warrant Liabilities - Unsecured Convertible Note Warrants - Additional Information (Details) $ / shares in Units, $ in Millions	Jun. 05, 2020$ / shares	Dec. 31, 2020shares	Dec. 31, 2020CAD ($)shares$ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Issuance of common shares		296,700,000
Warrants outstanding		2,080,000	2,080,000
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants description	The Unsecured Convertible Notes Warrants were issued on June 5, 2020, are immediately exercisable, and expire 42 months from the date that the underlying common shares become freely tradeable, which was July 16, 2020.
Warrants expiration period	42 months
Weighted average exercise price of warrants | $ / shares	$ 0.1766		$ 0.1766
Warrants exercised			14,000,000
Weighted average exercise price of warrants | $ / shares	0.1766		$ 0.1766
Issuance of common shares			14,000,000
Gross proceeds from exercise of warrants | $			$ 3.2
Warrants outstanding		500,000	500,000
Unsecured Convertible Notes Warrants | Bottom of Range
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Weighted average price of common shares | $ / shares	$ 2.8014

Derivative Warrant Liabilitie_5

Derivative Warrant Liabilities - Agent Warrants - Additional Information (Details)	Mar. 17, 2021$ / shares	Mar. 17, 2021USD ($)shares	Oct. 22, 2020	Jun. 05, 2020	Dec. 31, 2020shares	Dec. 31, 2020shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Beneficial ownership percentage of outstanding common shares			9.99%
Issuance of common shares					296,700,000
Agent Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants description				The Agent Warrants were issued on June 5, 2020, are immediately exercisable, and expire on June 5, 2025.
Warrants expiration date				Jun. 5, 2025
Beneficial ownership percentage of outstanding common shares				4.99%
Warrants exercised		540,000				0
Weighted average exercise price of warrants | $ / shares	$ 1
Issuance of common shares		356,949
Gross proceeds from exercise of warrants | $		$ 0

Derivative Warrant Liabilitie_6

Derivative Warrant Liabilities - Series A and Series B Warrants - Additional Information (Details) $ / shares in Units, $ in Millions	Aug. 20, 2020shares	Aug. 19, 2020shares	Aug. 18, 2020$ / sharesshares	Dec. 31, 2020shares$ / shares	Dec. 31, 2020CAD ($)shares$ / shares	Dec. 31, 2020shares$ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants term						5 years
Issuance of common shares				296,700,000
Warrants outstanding				2,080,000	2,080,000	2,080,000
Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of warrants issued			40,100,000
Warrants exercise price | $ / shares			$ 0.75	$ 0.1766	$ 0.1766	$ 0.1766
Warrants exercised					39,600,000
Weighted average exercise price of warrants | $ / shares					$ 0.1766
Issuance of common shares					39,600,000
Gross proceeds from exercise of warrants | $					$ 9.1
Warrants outstanding				500,000	500,000	500,000
Series B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Number of warrants issued			14,300,000
Warrants exercise price | $ / shares			$ 0.0001
Warrants exercised	5,100,000	9,200,000
Series A and Series B Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants term			5 years

Derivative Warrant Liabilitie_7

Derivative Warrant Liabilities - Summary of Outstanding Derivative Warrants (Details)	12 Months Ended
	Dec. 31, 2020shares$ / shares
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Warrants outstanding	2,080,000
Weighted average contractual life	3 years
Series A Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 0.1766
Warrants outstanding	500,000
Weighted average contractual life	4 years 7 months 6 days
Unsecured Convertible Notes Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 0.1766
Warrants outstanding	500,000
Weighted average contractual life	3 years
Agent Warrants
Disclosure Of Detailed Information About Derivative Warrant Liability [Line Items]
Exercise price | $ / shares	$ 1
Warrants outstanding	1,080,000
Weighted average contractual life	4 years 4 months 24 days

Lease Obligations - Summary of

Lease Obligations - Summary of Lease Obligations (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Lease Obligations [Line Items]
Acquisitions			$ 47,007
Lease payments	$ (34)	$ (420)	(292)
Dispositions		(10,457)
Current portion		409	722
Long-term		1,031	16,227
IFRS 16
Disclosure Of Lease Obligations [Line Items]
Balance, beginning of year		16,949	214
Adoption of IFRS 16			1,119
Acquisitions			15,179
Liabilities incurred		763	674
Lease payments		(937)	(778)
Dispositions		(735)	(468)
Interest expense		416	444
Foreign currency translation		(122)	565
Balance, end of year	$ 214	1,440	16,949
Current portion		409	722
Long-term		1,031	$ 16,227
IFRS 16 | Bridge Farm
Disclosure Of Lease Obligations [Line Items]
Dispositions		$ (14,894)

Lease Obligations - Summary o_2

Lease Obligations - Summary of Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2020CAD ($)
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	$ 1,607
Amounts representing finance charges	(167)
Net minimum lease payments	1,440
Less Than One Year
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	490
One to Three Years
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	895
Three to Five Years
Disclosure Of Maturity Analysis Of Finance Lease Payments Receivable [Line Items]
Minimum lease payments	$ 222

Contingent Consideration - Reco

Contingent Consideration - Reconciliation of Contingent Consideration (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Contingent Liabilities [Abstract]
Balance, beginning of year	$ 32,501
Acquisition of Bridge Farm		$ 15,991
Change in fair value recognized in profit or loss	2,252	18,645
Earn-out payments		(1,170)
Unrealized foreign exchange loss	1,058	(1,779)
Foreign currency translation	(899)	814
Disposition of Bridge Farm (note 5)	$ (34,912)
Balance, end of year		$ 32,501

Contingent Consideration - Addi

Contingent Consideration - Additional Information (Details) $ in Millions	Jun. 05, 2020CAD ($)
Bridge Farm
Disclosure Of Contingent Liabilities [Line Items]
Fair value of incremental shares	$ 34.6
Fair value of earn out shares	0.3
Contingent Consideration | Bridge Farm Purchaser
Disclosure Of Contingent Liabilities [Line Items]
Liabilities assumed in disposition of business	$ 34.9

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense (Recovery) (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Income Taxes [Line Items]
Loss before taxes	$ (56,526)	$ (206,317)	$ (146,307)
Income Tax Expense Recovery
Disclosure Of Income Taxes [Line Items]
Loss before taxes	$ (56,526)	$ (206,317)	$ (146,307)
Statutory income tax rates	27.00%	24.00%	26.50%
Expected income tax recovery	$ (15,262)	$ (49,516)	$ (38,771)
Non-deductible share-based compensation	1,860	1,970	10,474
Non-deductible finance expense	2,304	2,130	15,981
Other non-deductible expenses		348	2,621
Change in tax rates		1,528	3,305
Deferred tax benefits not recognized	$ 11,098	$ 43,540	2,781
Income tax (recovery) expense			$ (3,609)

Income Taxes - Summary of Defer

Income Taxes - Summary of Deferred Tax Assets (Liabilities) (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	$ 3,365	$ (3,365)	$ 0
Deferred Tax Assets and Liabilities
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)		(3,490)
Inventory
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	8,388	1,881
Deferred Biological Tax Assets
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)	$ (8,388)	(7,170)
Intangible Assets
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)		(7,355)
Non Capital Losses
Deferred Tax Assets And Liabilities [Line Items]
Net deferred tax asset (liability)		$ 12,769

Income Taxes -Summary of Unreco

Income Taxes -Summary of Unrecognized Deductible Temporary Differences (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Temporary Difference Unused Tax Losses And Unused Tax Credits [Abstract]
Property, plant and equipment	$ 36,782
Intangible assets	536
Share issue costs	11,112	$ 16,779
Financial obligations and other	1,054	1,726
Inventory and biological assets	34,781
Non-capital losses	171,205	54,472
Unrecognized deductible temporary differences	$ 255,470	$ 72,977

Income Taxes - Summary of Movem

Income Taxes - Summary of Movement in Deferred Income Tax Liability (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Deferred Tax Assets And Liabilities [Line Items]
Balance, beginning of year	$ 3,365	$ 0
Recognized in profit and loss		(3,609)
Recognized in other comprehensive income	(25)	27
Recognized in discontinued operations (note 5)	(225)	(1,017)
Balance, end of year	(3,365)	3,365
Bridge Farm
Deferred Tax Assets And Liabilities [Line Items]
Disposition of Bridge Farm (note 5)	$ (3,115)
Pathway Rx
Deferred Tax Assets And Liabilities [Line Items]
Acquisition		3,609
Bridge Farm
Deferred Tax Assets And Liabilities [Line Items]
Acquisition		$ 4,355

Income Taxes -Additional Inform

Income Taxes -Additional Information (Details) - CAD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Major Components Of Tax Expense Income [Abstract]
Non-capital losses available for future periods	$ 171.2	$ 99.1

Share Capital and Warrants - Ad

Share Capital and Warrants - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Thousands	Jan. 20, 2021USD ($)$ / sharesshares	Jan. 13, 2021USD ($)$ / sharesshares	Jan. 11, 2021USD ($)	Dec. 04, 2020USD ($)	Aug. 20, 2020shares	Aug. 19, 2020shares	Aug. 18, 2020USD ($)$ / sharesshares	Aug. 13, 2020USD ($)	Aug. 01, 2019	Dec. 31, 2020USD ($)$ / sharesshares	Apr. 30, 2019CAD ($)shares	Dec. 31, 2020CAD ($)shares	Dec. 04, 2020USD ($)$ / sharesshares	Mar. 17, 2021USD ($)$ / sharesshares	Dec. 31, 2020CAD ($)shares	Dec. 31, 2019CAD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Dec. 31, 2020$ / shares	Dec. 31, 2019$ / shares	Jul. 22, 2019	Dec. 31, 2018CAD ($)	Feb. 28, 2018CAD ($)
Share Capital And Warrants [Line Items]
Price per unit/common share | $ / shares																		$ 0
Share split ratio																				1.6
Description of offering															On August 18, 2020, the Company issued 25.8 million Series A Units (the “Series A Units”), each consisting of one common share and one Series A Warrant (collectively, the “Series A Warrants”) (note 17d) to purchase one common share and 14.3 million Series B Units (the “Series B Units”), each consisting of one pre-funded Series B Warrant (the “Series B Warrants”) to purchase one common share and one Series A Warrant to purchase one common share (note 17d).
Gross proceeds from offering | $							$ 20,000,000
Term of warrants															5 years
Issuance of common shares												296,700,000
Number of shares issued										156.3			153.5
Weighted average exercise price | $ / shares										$ 0.4795			$ 0.3250
Gross proceeds from offering of ATM program | $										$ 75,000,000			$ 49,900,000
Carrying Amount warrants | $												$ 269,695			$ 269,695	$ 221,198					$ (7,908)	$ 13,710
Warrants
Share Capital And Warrants [Line Items]
Warrants description															During the year ended December 31, 2020, the warrants issued upon conversion of the CAD and USD denominated convertible notes expired, and the 40% Warrants and 60% Warrants issued as part of the term debt financing were surrendered and cancelled.
Warrants exercised																4,551,082	4,551,082
Warrants expired											662				3,232,434	662	662
Carrying Amount warrants | $											$ 3,900	$ 6,138			$ 6,138	$ 27,831					$ 3,108
Major Ordinary Share Transactions
Share Capital And Warrants [Line Items]
Number of shares issued	237.7	72.4												117.6
Weighted average exercise price | $ / shares	$ 0.6325	$ 0.6903												$ 0.6379
Gross proceeds from offering of ATM program | $	$ 150,300,000	$ 50,000,000												$ 75,000,000
Top of Range
Share Capital And Warrants [Line Items]
Aggregate offering price | $				$ 150,000,000				$ 50,000,000
Top of Range | Major Ordinary Share Transactions
Share Capital And Warrants [Line Items]
Aggregate offering price | $	$ 400,000,000		$ 50,000,000
Series A Units
Share Capital And Warrants [Line Items]
Price per unit/common share | $ / shares							$ 0.50
Number of units issued							25,800,000
Series B Units
Share Capital And Warrants [Line Items]
Price per unit/common share | $ / shares							$ 0.50
Number of units issued							14,300,000
Reduction of price per unit from price per unit sold | $ / shares							$ 0.0001
60% Warrants
Share Capital And Warrants [Line Items]
Percentage of warrants									60.00%						60.00%
40% Warrants
Share Capital And Warrants [Line Items]
Percentage of warrants									40.00%						40.00%
Series A Warrants
Share Capital And Warrants [Line Items]
Warrant exercise price | $ / shares							0.75
Series B Warrants
Share Capital And Warrants [Line Items]
Warrant exercise price | $ / shares							$ 0.0001
Warrants exercised					5,100,000	9,200,000
Issuance of common shares					5,100,000	9,200,000
Exercise Price of $3.91 | Warrants
Share Capital And Warrants [Line Items]
Warrant exercise price | $ / shares																$ 3.91
Warrants exercised																4,211,242	4,211,242
Gross proceeds from warrants | $																$ 16,500
CAD Denominated Convertible Notes | Warrants
Share Capital And Warrants [Line Items]
Warrant exercise price | $ / shares																$ 4.38
Warrants exercised																307,840	307,840
Gross proceeds from warrants | $																$ 1,300
USD Denominated Convertible Notes | Warrants
Share Capital And Warrants [Line Items]
Warrant exercise price | $ / shares																			$ 3.75
Warrants exercised																32,000	32,000
Gross proceeds from warrants | $																	$ 120,000

Share Capital and Warrants - Su

Share Capital and Warrants - Summary of Issued and Outstanding (Details) - CAD ($) $ in Thousands	1 Months Ended	2 Months Ended	10 Months Ended	12 Months Ended
	Dec. 31, 2020	Dec. 04, 2020	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Classes Of Share Capital [Line Items]
Share issuances, shares	156.3	153.5
Beginning balance			$ 13,710	$ 221,198	$ (7,908)
Shares issued to related parties			16,474		69,293
Share issuance costs			(310)	(5,593)	(12,770)
Business acquisitions					47,007
Dispositions				(10,457)
Convertible debt - conversions				63,002	117,025
Derivative warrants exercised				55,912
Warrants exercised			2,182		17,950
Employee warrants exercised			2,033		1,371
Ending balance	$ 269,695		$ (7,908)	$ 269,695	$ 221,198
Share Capital
Disclosure Of Classes Of Share Capital [Line Items]
Balance, beginning of year, shares				107,180,423	68,648,984
Initial public offering, shares					11,000,000
Shares issued for assets, shares					797,952
Share issuances, shares				337,696,867	394,926
Shares issued to related parties, shares					3,730,963
Business acquisitions, shares					2,696,800
Disposition of Bridge Farm, shares				(2,716,271)
Convertible debt - conversions, shares				373,371,318	13,108,676
Derivative warrants exercised, shares				102,836,429
Warrants exercised, shares					4,551,082
Shares issued for services, shares					164,080
RSUs exercised, shares				475,367	57,960
Employee warrants exercised, shares					2,029,000
Balance, end of year, shares	918,844,133		68,648,984	918,844,133	107,180,423
Beginning balance			$ 25,769	$ 509,654	$ 65,133
Initial public offering, carrying amount					189,518
Shares issued for assets, carrying amount					6,537
Share issuances, carrying amount				176,931	2,323
Shares issued to related parties			16,474		63,460
Share issuance costs			(310)	(5,593)	(12,770)
Business acquisitions					39,849
Dispositions				(38,447)
Convertible debt - conversions				63,002	113,526
Derivative warrants exercised				55,912
Warrants exercised			2,182		21,882
Shares issued for services, carrying amount					2,320
RSUs exercised, carrying amount				587	195
Employee warrants exercised			3,980	535	17,681
Ending balance	$ 762,046		$ 65,133	$ 762,046	$ 509,654

Share Capital and Warrants - _2

Share Capital and Warrants - Summary of Common Share Purchase Warrants (Details) - CAD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2019	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Common Share Purchase Warrants [Line Items]
Beginning balance		$ 221,198	$ (7,908)
Ending balance		$ 269,695	$ 221,198
Warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Beginning balance, Number of Warrants		6,165,324	4,211,904
Warrants issued to related parties, Number of Warrants			480,000
Warrants issued on conversion of convertible notes, Number of Warrants			3,572,274
Warrants exercised, Number of Warrants			(4,551,082)
Warrants issued, Number of Warrants		544,000
Warrants expired, Number of Warrants	(662)	(3,232,434)	(662)
Warrants cancelled, Number of Warrants		(2,452,890)
Ending balance, Number of Warrants		1,024,000	6,165,324
Beginning balance		$ 27,831	$ 3,108
Warrants issued to related parties, Carrying Amount			5,833
Warrants issued on conversion of convertible notes, Carrying Amount			6,731
Warrants exercised, Carrying Amount			(3,931)
Warrants Issued, Carrying Amount		306
Warrants expired, Carrying Amount		(5,908)	(1)
Warrants cancelled, Carrying Amount		(16,091)
Ending balance	$ 3,900	$ 6,138	$ 27,831
Warrants | 40% Warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants reclassified from derivative liability, Number of Warrants			957,225
Warrants reclassified from derivative liability, Carrying Amount			$ 4,122
Warrants | 60% Warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrants reclassified from derivative liability, Number of Warrants			1,495,665
Warrants reclassified from derivative liability, Carrying Amount			$ 11,969

Share Capital and Warrants - _3

Share Capital and Warrants - Summary of Common Share Purchase Warrants (Parenthetical) (Details)	Aug. 01, 2019$ / shares	Dec. 31, 2020	Dec. 31, 2019$ / sharesshares	Dec. 31, 2019$ / shares
Warrants | CAD Denominated Convertible Notes
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrant exercise price			$ 4.38
Warrants issued on conversion of convertible notes | shares			3,095,386
Warrants | USD Denominated Convertible Notes
Disclosure Of Common Share Purchase Warrants [Line Items]
Warrant exercise price				$ 3.75
Warrants issued on conversion of convertible notes | shares			476,888
Director
Disclosure Of Common Share Purchase Warrants [Line Items]
Share purchase warrants | shares			480,000
Warrant exercise price			$ 15.94
40% Warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Percentage of warrants	40.00%	40.00%
Exercise price of warrants	$ 21.63
60% Warrants
Disclosure Of Common Share Purchase Warrants [Line Items]
Percentage of warrants	60.00%	60.00%
Exercise price of warrants	$ 20.76

Share Capital And Warrants - _4

Share Capital And Warrants - Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Number of warrants	2,080,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	3 years
Warrants
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 9.91	$ 11.97
Warrants outstanding and exercisable, Number of warrants	1,024,000	6,165,324
Warrants outstanding and exercisable, Weighted average contractual life (years)	5 years 3 months 18 days	1 year 7 months 6 days
Warrants | Term debt financing (60%)
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares		$ 20.76
Warrants outstanding and exercisable, Number of warrants		1,495,665
Warrants outstanding and exercisable, Weighted average contractual life (years)		2 years 7 months 6 days
Warrants | Term debt financing (40%)
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares		$ 21.63
Warrants outstanding and exercisable, Number of warrants		957,225
Warrants outstanding and exercisable, Weighted average contractual life (years)		2 years 7 months 6 days
Warrants | Financial Services
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 4.60
Warrants outstanding and exercisable, Number of warrants	544,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	8 years 7 months 6 days
Warrants | Acquisition of Financial Obligation
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares	$ 15.94	$ 15.94
Warrants outstanding and exercisable, Number of warrants	480,000	480,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	1 year 6 months	2 years 6 months
Warrants | USD Denominated Convertible Notes
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares		$ 3.75
Warrants outstanding and exercisable, Number of warrants		444,888
Warrants outstanding and exercisable, Weighted average contractual life (years)		9 months 18 days
Warrants | CAD Denominated Convertible Notes
Disclosure Of Exercise Price Number And Weighted Average Contractual Life Of Outstanding Share Options [Line Items]
Warrants outstanding and exercisable, Weighted average exercise price | $ / shares		$ 4.38
Warrants outstanding and exercisable, Number of warrants		2,787,546
Warrants outstanding and exercisable, Weighted average contractual life (years)		8 months 12 days

Share-based Compensation - Comp

Share-based Compensation - Components of Share-based Compensation Expense (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	$ 7,410	$ 8,566	$ 38,698
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	5,029	1,539	23,918
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	1,860	(42)	11,023
Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		651	98
Restricted Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		4,069	220
Shares Issued for Services
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation	$ 521		2,320
Deferred Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Share-based compensation		$ 2,349	$ 1,119

Share-based Compensation - Blac

Share-based Compensation - Black-Scholes Option Pricing Model to Estimate the Fair Value of Units Granted (Details) - $ / shares	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Expected life of units (years)		10 years
Expected annualized volatility		143.00%
Bottom of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Risk-free interest rate	1.65%	0.28%	1.41%
Expected life of units (years)	6 months		2 years
Expected annualized volatility	80.00%		97.00%
Weighted average Black-Scholes value of each unit	$ 1.76	$ 1.13	$ 0.67
Top of Range
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Risk-free interest rate	2.05%	0.29%	1.88%
Expected life of units (years)	14 years		10 years
Expected annualized volatility	106.00%		116.00%
Weighted average Black-Scholes value of each unit	$ 3.81	$ 1.17	$ 23.55

Share-based Compensation - Addi

Share-based Compensation - Additional Information (Details) $ in Millions	Mar. 17, 2021USD ($)	Dec. 31, 2020shares	Dec. 31, 2019shares
Simple and Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period		3 years
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Maturity period		5 years
Granted			4,795,200
Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting period		3 years
Maturity period		10 years
Deferred Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Vesting term		DSUs are granted to directors and generally vest in equal quarterly instalments over a one year.
Vesting period		1 year
Granted		3,265,503	378,080
Restricted Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted		3,002,213	107,543
Restricted Share Units | Long-term Incentive Program
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Granted | $	11.9

Share-based Compensation - Summ

Share-based Compensation - Summary of Changes in Simple and Performance Warrants (Details)	12 Months Ended
	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | shares	9,815,000	6,129,866
Granted | shares		4,795,200
Forfeited | shares	(6,390,400)	(733,866)
Exercised | shares		(376,200)
Ending balance | shares	3,424,600	9,815,000
Weighted average exercise price, beginning balance | $ / shares	$ 4.01	$ 1.80
Weighted average exercise price, Granted | $ / shares		6.32
Weighted average exercise price, Forfeited | $ / shares	3.79	2.32
Weighted average exercise price, Exercised | $ / shares		0.85
Weighted average exercise price, ending balance | $ / shares	$ 4.41	$ 4.01
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance | shares	5,798,822	7,094,822
Granted | shares		723,200
Forfeited | shares	(4,126,822)	(366,400)
Exercised | shares		(1,652,800)
Ending balance | shares	1,672,000	5,798,822
Weighted average exercise price, beginning balance | $ / shares	$ 2.66	$ 2.04
Weighted average exercise price, Granted | $ / shares		12.23
Weighted average exercise price, Forfeited | $ / shares	2.04	1.21
Weighted average exercise price, Exercised | $ / shares		0.63
Weighted average exercise price, ending balance | $ / shares	$ 4.19	$ 2.66

Share-based Compensation - Su_2

Share-based Compensation - Summarizes Outstanding Simple and Performance Warrants (Details)	12 Months Ended
	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares	Dec. 31, 2018shares$ / shares
Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	3,424,600	9,815,000	6,129,866
Weighted average exercise price, Warrants outstanding | $ / shares	$ 4.41	$ 4.01	$ 1.80
Weighted average contractual life, Warrants outstanding (years)	4 years 4 months 2 days	5 years 7 months 9 days
Number of warrants, Warrants exercisable | shares	2,155,800	5,132,600
Weighted average exercise price, Warrants exercisable | $ / shares	$ 2.27	$ 1.29
Weighted average contractual life, Warrants exercisable (years)	3 years 9 months 3 days	6 years
Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	1,672,000	5,798,822	7,094,822
Weighted average exercise price, Warrants outstanding | $ / shares	$ 4.19	$ 2.66	$ 2.04
Number of warrants, Warrants exercisable | shares	1,053,867	4,456,422
Weighted average exercise price, Warrants exercisable | $ / shares	$ 1.98	$ 1.02
$0.63 - $0.94 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	1,009,400	4,019,000
Weighted average exercise price, Warrants outstanding | $ / shares	$ 0.74	$ 0.68
Weighted average contractual life, Warrants outstanding (years)	3 years 6 months 14 days	5 years 7 months 13 days
Number of warrants, Warrants exercisable | shares	1,009,400	3,635,000
Weighted average exercise price, Warrants exercisable | $ / shares	$ 0.74	$ 0.68
Weighted average contractual life, Warrants exercisable (years)	3 years 6 months 14 days	5 years 7 months 9 days
$0.63 - $0.94 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	498,667	3,700,690
Weighted average exercise price, Warrants outstanding | $ / shares	$ 0.70	$ 0.64
Number of warrants, Warrants exercisable | shares	370,667	3,546,022
Weighted average exercise price, Warrants exercisable | $ / shares	$ 0.72	$ 0.64
$1.25 - $1.88 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	400,000	560,000
Weighted average exercise price, Warrants outstanding | $ / shares	$ 1.56	$ 1.50
Weighted average contractual life, Warrants outstanding (years)	3 years 7 months 2 days	10 years 2 months 4 days
Number of warrants, Warrants exercisable | shares	400,000	560,000
Weighted average exercise price, Warrants exercisable | $ / shares	$ 1.56	$ 1.50
Weighted average contractual life, Warrants exercisable (years)	3 years 7 months 2 days	10 years 2 months 4 days
$1.25 - $1.88 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	282,133	646,933
Weighted average exercise price, Warrants outstanding | $ / shares	$ 1.42	$ 1.52
Number of warrants, Warrants exercisable | shares	247,467	381,334
Weighted average exercise price, Warrants exercisable | $ / shares	$ 1.40	$ 1.48
$2.97 - $4.53 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	527,200	1,232,000
Weighted average exercise price, Warrants outstanding | $ / shares	$ 3.05	$ 3.18
Weighted average contractual life, Warrants outstanding (years)	3 years 7 months 20 days	5 years 7 months 13 days
Number of warrants, Warrants exercisable | shares	455,200	848,000
Weighted average exercise price, Warrants exercisable | $ / shares	$ 3.01	$ 3.10
Weighted average contractual life, Warrants exercisable (years)	3 years 6 months 14 days	4 years 11 months 12 days
$2.97 - $4.53 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	624,000	788,000
Weighted average exercise price, Warrants outstanding | $ / shares	$ 3.13	$ 3.09
Number of warrants, Warrants exercisable | shares	397,333	490,666
Weighted average exercise price, Warrants exercisable | $ / shares	$ 3.10	$ 3.08
$6.25 - $9.38 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	1,318,400	3,462,400
Weighted average exercise price, Warrants outstanding | $ / shares	$ 6.33	$ 6.37
Weighted average contractual life, Warrants outstanding (years)	5 years 2 months 4 days	4 years 6 months
Number of warrants, Warrants exercisable | shares	275,200	80,000
Weighted average exercise price, Warrants exercisable | $ / shares	$ 6.61	$ 6.25
Weighted average contractual life, Warrants exercisable (years)	5 years 1 month 6 days	4 years 5 months 8 days
$6.25 - $9.38 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	150,933	362,933
Weighted average exercise price, Warrants outstanding | $ / shares	$ 7.32	$ 6.97
Number of warrants, Warrants exercisable | shares	38,400	38,400
Weighted average exercise price, Warrants exercisable | $ / shares	$ 6.25	$ 6.25
$12.50 - $37.50 | Simple Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	169,600	541,600
Weighted average exercise price, Warrants outstanding | $ / shares	$ 22.28	$ 18.08
Weighted average contractual life, Warrants outstanding (years)	6 years 5 months 26 days	7 years 10 months 13 days
Number of warrants, Warrants exercisable | shares	16,000	9,600
Weighted average exercise price, Warrants exercisable | $ / shares	$ 20.60	$ 21.88
Weighted average contractual life, Warrants exercisable (years)	4 years 6 months	9 years 18 days
$12.50 - $37.50 | Performance Warrants
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Number of warrants, Warrants outstanding | shares	116,267	300,266
Weighted average exercise price, Warrants outstanding | $ / shares	$ 27.52	$ 23.72

Share-based Compensation - Su_3

Share-based Compensation - Summary of Changes in Stock Options (Details)	12 Months Ended
	Dec. 31, 2020shares$ / shares	Dec. 31, 2019shares$ / shares
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Balance at December 31, 2020	2,080,000
Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Balance at December 31, 2019	623,850
Granted	481,600	623,850
Forfeited	(384,850)
Balance at December 31, 2020	720,600	623,850
Weighted average exercise price, beginning balance | $ / shares	$ 4.33
Weighted average exercise price, Granted | $ / shares	1.16	$ 4.33
Weighted average exercise price, Forfeited | $ / shares	4.96
Weighted average exercise price, ending balance | $ / shares	$ 1.82	$ 4.33

Share-based Compensation - Su_4

Share-based Compensation - Summary of Outstanding Stock Options (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	2,080,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	3 years
Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	720,600	623,850
Warrants outstanding and exercisable, Weighted average contractual life (years)	9 years 2 months 4 days	7 years 11 months 19 days
Number of options, Stock options exercisable	159,017	22,500
Weighted average contractual life, Stock options exercisable (years)	9 years 25 days	4 years 11 months 19 days
$1.15 | Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	400,000
Warrants outstanding and exercisable, Weighted average contractual life (years)	9 years 4 months 28 days
$1.19 | Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	81,600
Warrants outstanding and exercisable, Weighted average contractual life (years)	9 years 5 months 26 days
Number of options, Stock options exercisable	81,600
Weighted average contractual life, Stock options exercisable (years)	9 years 5 months 26 days
$3.15 | Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants	239,000	373,850
Warrants outstanding and exercisable, Weighted average contractual life (years)	8 years 8 months 4 days	9 years 2 months 15 days
Number of options, Stock options exercisable	77,417	22,500
Weighted average contractual life, Stock options exercisable (years)	8 years 7 months 17 days	4 years 11 months 19 days
$5.93 | Stock Options
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Warrants outstanding and exercisable, Number of warrants		250,000
Warrants outstanding and exercisable, Weighted average contractual life (years)		6 years 4 months 13 days

Share-based Compensation - Su_5

Share-based Compensation - Summary of Changes in RSUs and DSUs (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Restricted Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	48,883
Granted	3,002,213	107,543
Forfeited	(43,813)	(700)
Exercised	(1,350,367)	(57,960)
Ending balance	1,656,916	48,883
Deferred Share Units
Disclosure Of Terms And Conditions Of Sharebased Payment Arrangement [Line Items]
Beginning balance	367,924
Granted	3,265,503	378,080
Forfeited	(310,164)	(7,617)
Settled		(2,539)
Ending balance	3,323,263	367,924

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue from Contracts with Customers (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 73,321	$ 66,927
Cannabis | Provincial Boards
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	55,315	13,386
Cannabis | Medical
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	32	24
Cannabis | Licensed Producers
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 17,974	$ 53,517

Revenue - Disaggregation of R_2

Revenue - Disaggregation of Revenue from Contracts with Customers (Parenthetical) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020CAD ($)Customer	Dec. 31, 2019CAD ($)Customer
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Number of major customers | Customer	4	4
Sales	$ 73,321	$ 66,927
Major Customer
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Sales	$ 43,900	$ 40,700

Revenue - Disaggregation of R_3

Revenue - Disaggregation of Revenue from Contracts with Customers by Form (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 73,321	$ 66,927
Dried Flower
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	51,424	58,246
Vapes
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	18,447	504
Oil
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	3,145	$ 8,177
Edibles
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	263
Concentrates
Disclosure Of Disaggregation Of Revenue From Contracts With Customers [Line Items]
Gross revenue	$ 42

Revenue - Summary of Receivable

Revenue - Summary of Receivables from Contracts with Customers (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Trade Receivables
Revenue [Line Items]
Receivables, included in trade receivables (note 7)	$ 15,786	$ 20,281	$ 209

Revenue - Additional Informatio

Revenue - Additional Information (Details) - CAD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue [Abstract]
Maximum period to settle receivables from contracts with customers	30 days
Impairment loss (reversal) on receivables from contracts with customers	$ (0.5)	$ 0.6

Other Operating Expenses - Summ

Other Operating Expenses - Summary of General and Administrative Expense (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Expense By Nature [Abstract]
Salaries and wages	$ 3,847	$ 11,634	$ 15,262
Consulting fees	1,647	2,193	6,896
Office and general	1,738	9,843	9,533
Professional fees	877	4,658	3,559
Director fees	30	365	188
Other	170	3,336	3,496
General and administrative expense	$ 8,309	$ 32,029	$ 38,934

Other Operating Expenses - Su_2

Other Operating Expenses - Summary of Sales and Marketing Expense (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Expense By Nature [Abstract]
Marketing	$ 1,733	$ 4,839	$ 3,093
Events		393	2,961
Research	24	57	199
Media	623	448	1,815
Sales and marketing expense	$ 2,380	$ 5,737	$ 8,068

Government Subsidies - Addition

Government Subsidies - Additional Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020CAD ($)
Disclosure Of Government Subsidies [Line Items]
Income from government subsidy	$ 4,128
Canadian Emergency Wage Subsidy
Disclosure Of Government Subsidies [Line Items]
Percentage of eligible employer wage subsidy	75.00%
Wage subsidy initial period	84 days
Initial wage subsidy starting date	Mar. 15, 2020
Initial wage subsidy end date	Jul. 4, 2020
Wage subsidy initial extended end date	Nov. 21, 2020
Wage subsidy additional extended end date	2021-06
Subsidy received periods description	The Company became eligible for the CEWS based on decreases in revenue and has received the subsidy for certain periods
Income from government subsidy	$ 4,000
Explanation of unfulfilled conditions description	There are no unfulfilled conditions or contingencies attached to the CEWS.
Canadian Emergency Rent Subsidy
Disclosure Of Government Subsidies [Line Items]
Subsidy received periods description	The Company became eligible for CERS based on decreases in revenue and has received the subsidy for certain periods
Income from government subsidy	$ 100
Explanation of unfulfilled conditions description	There are no unfulfilled conditions or contingencies attached to the CERS

Finance Costs - Summary of Fina

Finance Costs - Summary of Finance Costs (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Cash finance expense
Interest on Syndicated Credit Agreement		$ 4,546	$ 1,746
Interest on Credit Facilities	$ 437		1,818
Interest on Term Debt Facility		2,936	3,478
Interest on Senior Convertible Notes			375
Interest on Convertible Notes	421		2,574
Interest on other debt	1,659		1,526
Other finance costs	399	286	2,909
Interest expense	2,916	7,768	14,426
Non-cash finance expense (income)
Accretion	594	1,622	5,511
Amortization of debt issue costs	172	1,782	1,586
Change in fair value of convertible notes (note 16)		(7,141)
Change in fair value of derivative warrant liabilities (note 17)		12,995
Interest on Senior Convertible Notes			1,903
Loss on derivative liabilities			1,649
Loss on extinguishment of debt			488
Other	151	3	(67)
Non-cash finance expense (income)	917	9,261	11,070
Less: interest capitalized relating to CIP (note 10)	(2,036)		(1,280)
Interest income		(215)
Finance costs	$ 1,797	$ 16,814	$ 24,216

Loss On Financial Obligations -

Loss On Financial Obligations - Additional Information (Details) $ / shares in Units, $ in Thousands	Sep. 29, 2019CAD ($)	Aug. 06, 2019CAD ($)	Aug. 06, 2019$ / shares	Jul. 17, 2019CAD ($)$ / sharesshares	Aug. 16, 2018CAD ($)ft²	Dec. 31, 2018CAD ($)ft²shares	Dec. 31, 2020	Dec. 31, 2019CAD ($)
Financial Obligations [Line Items]
Loss on financial obligation						$ 18,485		$ 60,308
Former Executive Chairman
Financial Obligations [Line Items]
Shares issued | shares				50,963
Aggregate consideration of common shares | shares				3,680,000
Share purchase warrants | shares				480,000
Warrant exercise price | $ / shares				$ 15.94
Warrants exercise period				3 years
Cash to be paid for indirect acquisition of investment and royalty agreement				$ 9,500
Loss on financial obligation		$ 59,600
Initial public offering price | $ / shares			$ 13
Cash payment for the indirect acquisition of the investment and royalty agreement	$ 9,500
Investment and Royalty Agreement
Financial Obligations [Line Items]
Advance amount under investment and royalty agreement						$ 10,900
Amount converted to common shares | shares						7,149,035
Difference of estimated fair value and price per share in credit agreement charged to finance expense					$ 8,500
Area of land used for agriculture | ft²					25,000	44,403
Description of royalty payments agreement							Purchaser was entitled to quarterly royalty payments calculated based on the Company’s revenue from the facilities subject to the amended agreement for each fiscal quarter multiplied by 6.5
Present value of royalty payments						$ 18,500
Discount rate of present value calculation of royalty payments						18.00%
Term of valuation for royalty payments						10 years
Discount rate of estimate value calculation of royalty payments						18.00%
Top of Range | Investment and Royalty Agreement
Financial Obligations [Line Items]
Equity financing to be received under investment and royalty agreement					$ 11,000

Loss On Financial Obligations_2

Loss On Financial Obligations - Summary of Valuation of Royalty Payments (Details) - Investment and Royalty Agreement	12 Months Ended
	Dec. 31, 2018CAD ($)ft²g	Aug. 16, 2018ft²
Financial Obligations [Line Items]
Growing space related to royalty | ft²	44,403	25,000
Average yield	45
Total cannabis production	12,000,000
Average price | $	$ 5,500

Supplemental Cash Flow Disclo_3

Supplemental Cash Flow Disclosures - Summary of Changes in Non-cash Working Capital (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Cash provided by (used in):
Accounts receivable	$ (2,469)	$ (2,037)	$ (19,625)
Biological assets	(2,102)	13,789	19,328
Inventory	(923)	(12,315)	(57,977)
Prepaid expenses and deposits	1,072	2,280	(7,213)
Accounts payable and accrued liabilities	14,421	(20,793)	27,819
Convertible notes			(152)
Lease obligations	107
Changes in non cash working capital	10,106	(19,076)	(37,820)
Changes in non-cash working capital relating to:
Operating	1,217	(5,259)	(41,626)
Investing	10,282	(11,319)	1,659
Financing	(1,393)	(2,498)	2,147
Changes in non cash working capital	10,106	(19,076)	(37,820)
Cash interest paid	$ 919	$ 6,094	$ 13,753

Supplemental Cash Flow Disclo_4

Supplemental Cash Flow Disclosures - Summary of Reconciliation of Long Term Debt to Cash Flows Arising from Financing Activities (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Supplemental Cash Flow Disclosure [Abstract]
Beginning balance	$ 7,000	$ 177,913	$ 54,636
Proceeds from Credit Facilities	32,159		82,687
Repayment of credit facilities		(84,000)	(32,871)
Syndicated Credit Agreement costs		(493)
Proceeds from term debt facility, net of costs			105,539
Proceeds from other debt instruments	8,546
Repayment of other debt instruments			(56,173)
Promissory note issued to repurchase shares	6,931
Debt acquired through acquisitions			33,618
Extinguishment of debt issue costs		(59,649)	488
Term Debt Facility disposed of as part of Bridge Farm consideration		(38,346)
Accretion		2,665	3,030
Amortization of debt issue costs		$ 1,910	892
Reclassification to derivative liability			(13,933)
Ending balance	$ 54,636		$ 177,913

Loss Per Share - Summary of Los

Loss Per Share - Summary of Loss Per Share (Details) - CAD ($) $ / shares in Units, $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Weighted average shares outstanding (000s)
Basic and dilutive	69,203	218,645	85,750
Continuing operations
Net loss attributable to Sundial Growers Inc.	$ (56,526)	$ (206,056)	$ (142,533)
Per share - basic and diluted	$ (0.82)	$ (0.95)	$ (1.67)
Discontinued operations
Net loss from discontinued operations		$ (33,627)	$ (128,931)
Per share - basic and diluted		$ (0.15)	$ (1.50)
Net loss attributable to Sundial Growers Inc.	$ (56,526)	$ (239,683)	$ (271,464)
Per share - basic and diluted	$ (0.82)	$ (1.10)	$ (3.17)

Loss Per Share - Summary of L_2

Loss Per Share - Summary of Loss Per Share (Parenthetical) (Details) - shares shares in Millions	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Warrants exercisable		1	6.2
Simple warrants exercisable	2.2	2.2	5.1
Performance warrants exercisable	2	1.1	4.5

Financial Instruments - Summary

Financial Instruments - Summary of Fair Value Measurements of Long-term Debt, Derivative Warrant Liabilities and Contingent Consideration (Details) - Recurring Measurements - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Derivative Warrant Liabilities
Disclosure Of Financial Instruments [Line Items]
Financial liabilities	$ 428
Contingent Consideration
Disclosure Of Financial Instruments [Line Items]
Financial liabilities		$ 32,501
Level 3 | Derivative Warrant Liabilities
Disclosure Of Financial Instruments [Line Items]
Financial liabilities	$ 428
Level 3 | Contingent Consideration
Disclosure Of Financial Instruments [Line Items]
Financial liabilities		$ 32,501

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2020CAD ($)
Disclosure Of Financial Instruments [Line Items]
Percentage of change in material assumptions	10.00%
Derivative Warrant Liabilities
Disclosure Of Financial Instruments [Line Items]
Change in fair value liabilities	$ 0.1

Financial Instruments - Summa_2

Financial Instruments - Summary of Impairment Losses on Accounts Receivable Recognized in Profit or Loss (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Financial Instruments [Abstract]
Impairment loss (reversal) on trade receivables	$ (506)	$ 582
Impairment loss (reversal) on other receivables	(126)	170
Impairment loss (reversal) on accounts receivable	$ (632)	$ 752

Financial Instruments - Summa_3

Financial Instruments - Summary of Movement in Allowance for Impairment in Respect of Accounts Receivable (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Financial Instruments [Abstract]
Balance, beginning of year	$ 752
Net remeasurement of impairment loss allowance	(632)	$ 752
Balance, end of year	$ 120	$ 752

Financial Instruments - Summa_4

Financial Instruments - Summary of Company's Foreign Currency Balances Subject to Exchange Risk (Details) $ in Thousands	Dec. 31, 2020CAD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019CAD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018CAD ($)	Feb. 28, 2018CAD ($)
Disclosure Of Nature And Extent Of Risks Arising From Financial Instruments [Line Items]
Cash and cash equivalents	$ 60,376,000		$ 45,337,000		$ 14,121,000	$ 7,678,000
Foreign Currency Risk | USD
Disclosure Of Nature And Extent Of Risks Arising From Financial Instruments [Line Items]
Cash and cash equivalents		$ 1		$ 22,088
Accounts payable and accrued liabilities		(206)		(2,150)
Net foreign exchange exposure	$ (261,000)	(205)	$ 25,895,000	19,938
Translation to CAD	1.2732		1.2988
CAD equivalent at period end exchange rate	$ (261,000)	$ (205)	$ 25,895,000	$ 19,938

Financial Instruments - Schedul

Financial Instruments - Schedule of Net Foreign Exchange Exposure at End of Year After-tax Earnings Decreased or Increased by Approximately the Following Amounts (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Financial Instruments [Abstract]
Foreign exchange exposure sensitivity	$ (26)
Impact on profit (loss)		$ 2,590

Financial Instruments - Timing

Financial Instruments - Timing of Expected Cash Outflows Relating to Financial Liabilities (Details) - CAD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	$ 23,308	$ 58,110
Liquidity Risk Management
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	23,308
Lease obligations	1,440
Balance, end of period	24,748
Liquidity Risk Management | Less Than One Year
Disclosure Of Financial Instruments [Line Items]
Accounts payable and accrued liabilities	23,308
Lease obligations	409
Balance, end of period	23,717
Liquidity Risk Management | One to Three Years
Disclosure Of Financial Instruments [Line Items]
Lease obligations	818
Balance, end of period	818
Liquidity Risk Management | Three to Five Years
Disclosure Of Financial Instruments [Line Items]
Lease obligations	213
Balance, end of period	$ 213

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - Employees - Shareholder loan agreement $ in Thousands	12 Months Ended
	Dec. 31, 2020CAD ($)EMP	Dec. 31, 2019CAD ($)EMP
Disclosure Of Transactions Between Related Parties [Line Items]
Number of employees on loan agreement | EMP	2	2
Loans and receivables available	$ 100	$ 200
Repayment to one of the employees	$ 61
Bottom of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Interest rate	0.00%
Top of Range
Disclosure Of Transactions Between Related Parties [Line Items]
Interest rate	1.50%

Related Party Transactions - Su

Related Party Transactions - Summary of Related Party Transactions and Balances (Details) - CAD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Transactions Between Related Parties [Line Items]
Transactions	$ 3,606	$ 7,012
Balance outstanding	(510)	(662)
Marketing, brand research and development services
Disclosure Of Transactions Between Related Parties [Line Items]
Transactions	1,144	3,117
Balance outstanding		(265)
Legal services
Disclosure Of Transactions Between Related Parties [Line Items]
Transactions	2,462	3,895
Balance outstanding	$ (510)	$ (397)

Related Party Transactions - Co

Related Party Transactions - Compensation of Key Management Personnel (Details) - CAD ($) $ in Thousands	10 Months Ended	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Transactions Between Related Parties [Abstract]
Salaries and short-term benefits	$ 1,237	$ 1,944	$ 3,295
Share-based compensation	2,414	7,629	23,715
Key management personnel compensation	$ 3,651	$ 9,573	$ 27,010

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - CAD ($) $ in Millions	Dec. 31, 2020	Dec. 31, 2019
Disclosure Of Commitments And Contingencies [Abstract]
Accrued financial penalties payable	$ 1.5	$ 1.5

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) $ / shares in Units, $ / shares in Units, $ in Millions, $ in Millions

Mar. 15, 2021USD ($)

Feb. 23, 2021CAD ($)$ / sharesshares

Feb. 22, 2021USD ($)$ / sharesshares

Feb. 12, 2021$ / shares

Feb. 10, 2021USD ($)$ / sharesshares

Feb. 04, 2021USD ($)$ / sharesshares

Feb. 02, 2021USD ($)$ / sharesshares

Dec. 11, 2020

Aug. 20, 2020shares

Aug. 19, 2020shares

Aug. 18, 2020USD ($)$ / sharesshares

Dec. 31, 2020USD ($)$ / shares

Dec. 31, 2020$ / sharesshares

Dec. 04, 2020USD ($)

Dec. 31, 2020$ / shares

Feb. 16, 2021CAD ($)

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Price per unit | $ / shares

$ 0

$ 0

$ 0

Gross proceeds from offering | $

$ 20

Term of warrants

5 years

Issuance of common shares | shares

296,700,000

Gross proceeds from issuance of common shares | $

$ 75

$ 49.9

NASDAQ

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Additional period allowed to regain compliance with listing qualifications

180 days

Regain compliance with listing qualifications initial period date

Feb. 1, 2021

Regain compliance with listing qualifications initial end date

Feb. 12, 2021

Series A Units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Number of units issued | shares

25,800,000

Price per unit | $ / shares

$ 0.50

Series B Units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Number of units issued | shares

14,300,000

Price per unit | $ / shares

$ 0.50

Series A Warrants

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Warrant exercise price | $ / shares

0.75

Series B Warrants

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Warrant exercise price | $ / shares

$ 0.0001

Warrants exercised | shares

5,100,000

9,200,000

Issuance of common shares | shares

5,100,000

9,200,000

January 2021 Units Offering | Series A Units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Number of units issued | shares

100,000,000

Description of offering units

series A units (the “Series A Units”), each consisting of one common share and one-half series A warrant (collectively, the “Series A Warrants”) to purchase one common share

Sale price per unit | $ / shares

$ 0.75

January 2021 Units Offering | Series B Units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Number of units issued | shares

33,300,000

Description of offering units

series B units (the “Series B Units”), each consisting of one pre-funded series B warrant (the “Series B Warrants”) to purchase one common share and one-half Series A Warrant to purchase one common share

Sale price per unit | $ / shares

$ 0.75

January 2021 Units Offering | Series A and series B units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Gross proceeds from offering | $

$ 100

January 2021 Units Offering | Top of Range | Series A and series B units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Price per unit | $ / shares

$ 0.0001

January 2021 Units Offering | Series A and Series B Warrants

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Term of warrants

5 years

January 2021 Units Offering | Series A Warrants

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Warrant exercise price | $ / shares

0.80

Warrants exercised | shares

63,300,000

3,300,000

Issuance of common shares | shares

63,300,000

3,300,000

Weighted average warrant exercise price | $ / shares

$ 0.80

$ 0.80

Gross proceeds from warrants | $

$ 50.7

$ 2.7

January 2021 Units Offering | Series B Warrants

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Warrant exercise price | $ / shares

$ 0.0001

Warrants exercised | shares

33,300,000

Issuance of common shares | shares

33,300,000

February 2021 Units Offering

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Term of warrants

5 years

February 2021 Units Offering | Series A Units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Number of units issued | shares

60,500,000

Description of offering units

additional series A units (the “Additional Series A Units”), each consisting of one common share and one-half additional series A warrant (collectively, the “Additional Series A Warrants”) to purchase one common share

Sale price per unit | $ / shares

$ 1

February 2021 Units Offering | Series B Units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Number of units issued | shares

14,000,000

Description of offering units

additional series B units (the “Additional Series B Units”), each consisting of one pre-funded additional series B warrant (the “Additional Series B Warrants”) to purchase one common share and one-half Additional Series A Warrant to purchase one common share

Sale price per unit | $ / shares

$ 1

February 2021 Units Offering | Series A and series B units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Gross proceeds from offering | $

$ 74.5

February 2021 Units Offering | Top of Range | Series A and series B units

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Price per unit | $ / shares

$ 0.0001

February 2021 Units Offering | Series A Warrants

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Warrant exercise price | $ / shares

1.10

Warrants exercised | shares

35,000,000

2,300,000

Issuance of common shares | shares

35,000,000

2,300,000

Weighted average warrant exercise price | $ / shares

$ 1.10

$ 1.10

Gross proceeds from warrants | $

$ 38.5

$ 2.5

February 2021 Units Offering | Series B Warrants

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Warrant exercise price | $ / shares

$ 0.0001

Warrants exercised | shares

14,000,000

Issuance of common shares | shares

14,000,000

Registered Offerings | Warrants

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Term of warrants

42 months

Warrant exercise price | $ / shares

$ 1.50

Number of common stock shares issuable upon conversion of warrants | shares

1

Number of warrants issued | shares

98,300,000

Minimum Bid Price Requirement | NASDAQ

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Regain compliance with listing qualifications common stock minimum bid price | $ / shares

$ 1

Number of consecutive business period to maintain minimum bid closing price

10 days

Strategic Investment | Indiva

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Announced strategic value investment | $

$ 22

Strategic Investment | Indiva | Brokered Private Placement

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Issuance of common shares | shares

25,000,000

Common shares issued price per share | $ / shares

$ 0.44

Gross proceeds from issuance of common shares | $

$ 11

Cash out flow for non-revolving loan issuance | $

$ 11

Joint Venture | SunStream Bancorp Inc.

Disclosure Of Nonadjusting Events After Reporting Period [Line Items]

Percentage of joint venture ownership

50.00%

Initial commitment amount | $

$ 100